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The last decades a very impressive progress has been made 
in diagnostic as well as surgical techniques. As a consequence the 
need for a safe and stable long-standing anaesthesia during these 
procedures increases. Inhalation anaesthetics are very useful for this 
purpose. Halothane has being used for several decades in veterinary 
medicine and is still a valuable compound in many clinical settings.  
 
However, halothane is not an ideal anaesthetic drug. This is 
not surprising as an ideal volatile anaesthetic compound has to fulfil 
many criteria: minimal or no depressing effects on vital functions such 
as respiration and circulation, rapid onset of action, beneficial 
interaction with premedication and anaesthesia-inducing drugs, not to 
mention low health hazard for the anaesthetists, low flammability and 
the lack of need for expensive vaporizers.  
 
The last decades several new volatile anaesthetics have been 
developed such as isoflurane, desflurane and sevoflurane in order to 
obtain drugs with more beneficial and less side effects than the 
previous ones. Some of these drugs like isoflurane have been studied 
extensively in dogs, in experimental as well as clinical settings. The 
results of such studies indicate that new drugs may be superior for 
some but not all aspects leading to nuanced conclusions. 
 
Sevoflurane has been studied widely in humans. The findings 
are interesting in order to have an idea of the profile of this almost 
unknown drug in veterinary medicine. In humans its lack of airway 
pungency and mainly its low blood-gas solubility induce a fast 
induction and recovery from anaesthesia. Sevoflurane has little 
influence on cerebral perfusion and intracranial pressure. Depression 
of cardiac output is only reported at higher concentrations. Both 
characteristics make it the agent of choice in neurological and cardiac 
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patients.  However one should be careful by extrapolating these 
results to canine medicine. Therefore several studies were undertaken 
in dogs in order to investigate some clinical implications and 
applications of sevoflurane. 
 
In the first part of this thesis (chapter 1 and 2) 
physicochemical and pharmacological properties of sevoflurane are 
extensively reviewed and compared with other inhalation 
anaesthetics. 
 
In the second part own studies on sevoflurane in dogs are 
described. These studies deal with several pharmacological and 
clinical aspects of sevoflurane anaesthesia: recovery times and 
haemodynamics in comparison to other anaesthetics (chapter 3); 
influence of ventilation mode (chapter 4) and thoracoscopy (chapter 5) 
on cardiopulmonary parameters; vascular access port implantation 
(chapter 6) in order to study the influence of sufentanil long-acting 
premedication on haemodynamics (chapter 7) and analgesic effects 
(chapter 8) of sevoflurane. 
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1/ To compare the recovery times and clinical haemodynamic 
parameters of sevoflurane, isoflurane and halothane anaesthesia in 
mongrel dogs. 
 
2/ To investigate the influence of ventilation mode (spontaneous 
ventilation, IPPV and PEEP) on cardiopulmonary parameters in 
sevoflurane anaesthetized dogs. 
 
3/ To determine the effects of intrathoracic pressure elevation on 
cardio-respiratory parameters during sevoflurane anaesthesia with 
continuous two-lung ventilation for thoracoscopy in dogs. 
 
4/ To describe the vascular access port implantation for blood 
sampling and continuous blood pressure measurement in dogs. 
  
5/ To examine the haemodynamic influences of a long-acting 
formulation of sufentanil administered at different time intervals in 
sevoflurane anaesthetized dogs. 
 
6/ To evaluate antinociceptive and sedative effects of premedication 
with a long-acting formulation of sufentanil during and after 
sevoflurane anaesthesia in dogs. 
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SEVOFLURANE:      PHYSICO-CHEMICAL PROPERTIES  
                                   
                                  AND MAC 
 
I. Polis1, F. Gasthuys2, L. Van Ham1 
 
1 Department of Small Animal Medicine and Clinical Biology 
2 Department of Surgery and Anaesthesia of Domestic Animals 
  Ghent University, Faculty of Veterinary Medicine, Salisburylaan 133, 
  B-9820 Merelbeke, Belgium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from:  
I. Polis, F. Gasthuys, L. Van Ham (1999). Sevoflurane: een nieuw 
inhalatieanestheticum voor hond en kat. Deel 1 Vlaams 
Diergeneeskundig Tijdschrift 68: 261-266. 
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INTRODUCTION 
 
Recently two new inhalant anaesthetic agents were 
commercialised in Europe, sevoflurane and desflurane. Both agents fit 
the mould of several other new anaesthetic agents and adjuvants. 
They permit greater control over the course of anaesthesia and more 
rapid recovery from anaesthesia than do their predecessors. In this 
review a survey was put together on the properties of sevoflurane in 
comparison with other recently developed inhalant anaesthetic agents 
(desflurane, isoflurane, halothane, enflurane). Furthermore, the 
possible usefulness of sevoflurane in anaesthesia of companion 
animals, in particular in dogs and cats was highlighted. The influences 
of sevoflurane on several body systems will be described in the 
second chapter.  
 
HISTORY OF INHALANT ANAESTHETIC AGENTS (Table 1) 
 
The earliest recorded attempts to induce anaesthesia appear 
to have been performed in humans. The ancients used opiates, 
alcohol, asphyxia, and even rather primitive techniques as 
compression of the carotid arteries to alleviate pain during surgical 
intervention.  
 
In 1800, Sir Humphrey Davy suggested that nitrous oxide 
might have anaesthetic properties. Shortly thereafter in 1824, H. H. 
Hickman demonstrated that pain associated with surgery in dogs 
could be alleviated by inhalation of a mixture of nitrous oxide and 
carbon dioxide (Thurmon et al., 1996). 
 
 It was not until 1842 that ether was used for human 
anaesthesia. Jackson was the first clinician to employ ether 
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extensively in animals in 1853 (Jackson, 1853). Although chloroform 
was discovered by Liebig in 1831, it only was used in 1847 for general 
anaesthesia in animals by Flourens (Dadd, 1854). Diethyl ether and 
chloroform had marked side effects including arrhythmogenic effects, 
cardiovascular and respiratory depression and liver toxicity. In 
addition, some practical objections were the flammability and 
explosiveness of ether (Hall and Clarke, 1991). 
 
 Waters was the first to clinically use cyclopropane in human 
anaesthesia in 1933. Gregory developed the use of cyclopropane for 
experimental animal anaesthesia. From the fifties on, it was routinely 
used in several animal species in Great Britain. Practical problems 
rose again with its high flammability and explosiveness (Hall and 
Clarke, 1991). Since 1941 trilene (trichloro-ethyleen) has been widely 
used. Trilene had good analgesic effects; it was non-flammable, nor 
irritating. Nevertheless, its anaesthetic properties and muscle 
relaxation were insufficient (Vickers et al., 1978). 
 
 Fluroxene (2,2,2,trifluoroethyl-ether) was developed by 
Shukyse in 1951. This anaesthetic agent gave a rapid induction of 
anaesthesia with a dose related cardiopulmonary depression. 
However, it was extremely flammable and toxic after repeated use 
especially in animals (Hall and Clarke, 1991). 
 
 Already in 1940 methoxyflurane (2,2-dichloro-1,1-
difluoroethylmethylether) was synthesized, although it was only 
commercialised in 1958. Methoxyflurane was a potent, non-flammable 
anaesthetic agent with good analgesic properties (Artusio et al., 
1960). Its high blood-gas solubility was accompanied by a prolonged 
induction and recovery time. The recorded post-anaesthetic renal 
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failure was due to fluoride ion release during metabolisation of 
methoxyflurane (Mazze et al., 1971).  
 
 
Table 1. Historical overview of volatile anaesthetic agents. 
 
 
AGENTS 
 
YEAR* 
 
ADVANTAGES 
 
DISADVANTAGES 
    
 
Nitrous oxide 1800 analgetic properties 
low blood-gas solubility 
 
low analgetic potency in 
animals 
    
 
Ether 
 
1842 potent anaesthetic agent inflammable, irritating 
high blood-gas solubility 
 
    
Chloroform 1847 potent anaesthetic agent hepatic and renal toxicity 
arhytmogenicity 
 
    
Cyclopropaan 1933 low blood-gas solubility Inflammable 
Explosive 
 
    
Trichloroethyleen 
(trilene) 
1941 good analgesia 
non-irritating 
weak anaesthetic agent 
toxic breakdown in soda-lime 
 
    
Halothane 1956 potent anaesthetic agent 
low toxicity 
 
unstable in light 
    
Methoxyflurane 1958 potent anaesthetic agent  
analgetic properties 
high blood-gas solubility 
metabolised to fluorine 
 
    
Enflurane 1958 potent anaesthetic agent  
low blood-gas solubility 
 
epileptic properties 
    
Isoflurane 1971 potent anaesthetic agent  
low metabolisation 
degree 
low blood-gas solubility 
 
airway pungency 
    
Desflurane 1987 low metabolisation 
degree 
extremely low blood-gas 
solubility 
 
specialised vaporiser 
technology  
airway pungency 
    
Sevoflurane 1990 potent anaesthetic agent 
low metabolisation 
degree 
low blood-gas solubility 
 
renal toxicity? 
 
* Year routinely used in human practice. 
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 Halothane was introduced in veterinary anaesthesia in 1956, 
after its development for human anaesthesia by Sweking in 1951 
(Suckling, 1957). Halothane is non-explosive and relatively stable. It 
gives a relatively fast induction of and recovery from anaesthesia and 
is less toxic than previously used inhalant anaesthetic agents. As with 
all volatile anaesthetic agents a dose related cardiopulmonary 
depression occurs (Short, 1987). In 1958 enflurane was introduced in 
human anaesthesia as a potent and slightly irritating volatile 
anaesthetic agent. Induction and recovery from anaesthesia are 
uneventful due to the low blood-gas solubility. Yet, higher enflurane 
concentrations have epileptic properties in dogs, cats and horses 
(Stevens et al., 1983, Oshima et al., 1985). In the early seventies 
isoflurane was developed by Terrell (Wade and Stevens, 1981). 
Isoflurane has a low blood-gas solubility resulting in short induction 
and recovery times.  
 
 In the continued search for less reactive, more potent and 
non-inflammable volatile anaesthetic agents focus on halogenation of 
these compounds has predominated. Chlorine and bromine especially 
convert many compounds of low anaesthetic potency into more potent 
drugs. Fluorination although improving stability, produces less potent 
compounds than addition of chlorine or bromine (Targ et al., 1989b). 
The lighter the halogens, the lower the anaesthetic potency of the 
compounds.  
  
Up to now the search for developing new volatile anaesthetic 
agents with a higher safety margin, minimal cardiovascular depression 
and permitting a rapid and precise control of alveolar anaesthetic 
concentration, is continued. This resulted in the recent development of 
sevoflurane and desflurane, two anaesthetics permitting a flexible 
control of anaesthesia maintenance and inducing a rapid recovery. 
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Research on sevoflurane and desflurane develops parallel to one 
other.  
  
Desflurane was recently commercialised in Europe. It has the 
lowest blood-gas solubility of all contemporary volatile anaesthetic 
agents. Besides its relatively low anaesthetic potency (high 
concentrations needed) and its airway irritating property; its high 
vapour pressure (specialized vaporizer technology required) is also a 
disadvantage for its practical use (Eger, 1993; Young and Apfelbaum, 
1995). 
  
Sevoflurane was developed in the seventies (Wallin et al., 
1975) and since 1980 it is extensively examined in human and 
veterinary anaesthesia, especially on an experimental basis in the 
beginning. Since 1990 it can be used in clinical human anaesthesia. 
And finally in 1996 sevoflurane was registered for human anaesthesia 
in Belgium.  
 
MOLECULAR STRUCTURE AND PHYSICAL PROPERTIES OF 
SEVOFLURANE (Table 2a +b) 
 
The chemical structure of inhalation anaesthetics and their 
physical properties are important determinants of their actions and 
safety of administration. All contemporary volatile anaesthetic agents 
are organic compounds except nitrous oxide (N2O). Sevoflurane is a 
methyl-propyl-ether with 7 fluorine atoms and a molecular weight of 
200.1 (Aida et al., 1994). The chemical structure of sevoflurane 
(CFH2-O-CH(CF3)2) is responsible for its kinetic properties.  
  
Fluorination of the carbon group resulted in a low blood-gas 
partition coefficient (0.68), which is considerably lower compared to 
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halothane, enflurane and isoflurane (Eger, 1994). The low blood-gas 
solubility produces the following properties: 1/ more rapid increase in 
alveolar anaesthetic concentration during induction of anaesthesia, 2/ 
more precise control of alveolar anaesthetic concentration during 
maintenance of anaesthesia and 3/ more rapid decrease in alveolar 
anaesthetic concentration during elimination. The human tissue-blood 
partition coefficients of sevoflurane in the brain (1.70), fat (48.0), 
kidneys (1.20), liver (1.80) and muscles (3.10) are intermediate 
between isoflurane en halothane (Steffey, 1996). A low brain-blood 
partition coefficient is advantageous for a rapid control and adjustment 
of anaesthetic depth; whereas a low fat-blood partition coefficient is of 
primordial importance for a rapid recovery from anaesthesia (Jones, 
1990).  
 
The solubility characteristics of sevoflurane in rubber and 
plastic are lower compared to isoflurane and halothane (Targ et al., 
1989a). Consequently, the anaesthetic circuit extracts less agent 
during anaesthetic administration and redistributes less agent to 
rebreathed gases during elimination. This can be important since 
losses of volatile anaesthetic by circuit absorption may compromise 
measurements of anaesthetic uptake (Eger et al., 1998).  
 
The boiling point and vapour pressure of sevoflurane are 
comparable with those from halothane, isoflurane and enflurane. 
Hence, conventional precision vaporisers without specific technical 
requirements can be used. On the contrary, the boiling point and 
vapour pressure of desflurane are completely different from the other 
volatile anaesthetic agents requiring specialised vaporizer technology 
for desflurane. Furthermore, sevoflurane doesn’t contain thymol or 
any other preservative, in contrast with the less stable halothane. 
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Thymol is much less volatile than the inhalant anaesthetic agents and 
over time collects within the vaporisers leading to malfunctioning. 
 
 
 
Table 2 a : Physico-chemical properties of recent volatile anaesthetic agents.  Modified from   
                   Steffey E.P. in Lumb & Jones’  Veterinary Anesthesia Chapt.11 (1996). 
 
      
AGENT TRADENAME COLOUR 
CODE 
CHEMICAL 
STRUCTURE 
BLOOD-GAS 
PARTITION 
COEFFICIENT 
At 37°C 
RUBBER-GAS  
PARTITION  
COEFFICIENT 
at roomtemp. 
      
      
halothane Fluothaneâ red Br  F 
¦  ¦ 
H-C-C-F 
¦  ¦ 
Cl  F 
2.54 120 
      
      
Enflurane Ethraneâ orange Cl  F        F 
¦  ¦        ¦ 
H-C-C-O-C-H 
¦  ¦        ¦ 
F   F        F 
2.00 74 
      
      
Isoflurane Foreneâ purple F  Cl      F 
¦  ¦       ¦ 
F-C-C-O-C-H 
¦  ¦       ¦ 
F  H       F 
1.46 62 
      
      
desflurane Supraneâ blue F  H       F 
¦  ¦       ¦ 
F-C-C-O-C--H 
¦  ¦       ¦ 
F   F       F 
0.42 / 
      
      
sevoflurane Sevoraneâ yellow           F 
           ¦ 
 H     F- C-F 
       ¦          ¦ 
F-C--O-C-H 
       ¦          ¦ 
   H       F-C-F 
           ¦ 
           F 
0.68 14.0 
      
      
Nitrous 
Oxide 
/ blue       N 
O    ¦ 
      N 
0.47 1.2 
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Table 2 b : Physico-chemical properties of recent volatile anaesthetic agents.  Modified from  
                   Steffey E.P. in Lumb & Jones’  Veterinary Anesthesia Chapt.11 (1996). 
     
     
AGENT TRADENAME BOILING 
POINT 
VAPOUR  
PRESSURE 
at 20°C 
at 24°C 
% 
 METABOLISATION 
     
     
halothane Fluothaneâ 50.2 °C 243 mmHg 
288 mmHg 
20-25 
     
     
Enflurane Ethraneâ 57 °C 172 mmHg 
207 mmHg 
2.4 
     
     
Isoflurane Foreneâ 49 °C 240 mmHg 
286 mmHg 
0.17 
 
 
    
     
desflurane Supraneâ 23.5 °C 664 mmHg 
/ 
0.02 
     
     
sevoflurane Sevoraneâ 59 °C 160 mmHg 
197 mmHg 
3.0 
     
     
Nitrous 
Oxide 
/ -89 °C / 
/ 
0.004 
     
 
 
ANAESTHETIC PROPERTIES OF SEVOFLURANE 
 
* Inhalation Induction (Figure 1) 
The aim in administering an inhalation anaesthetic agent to a 
patient is to achieve an adequate partial pressure of anaesthetic in the 
brain to cause a desired level of central nervous system depression. 
The rate of change of anaesthetic depth is of obvious clinical 
importance and is directly dependent upon the rate of change in 
anaesthetic tensions in the various media in which it is taken up 
before reaching the brain. Inhalation anaesthetics move down a series 
of partial pressure gradients from regions of higher tension to those of 
lower tension until equilibrium is established over the several 
compartments. The anaesthetic agent travels from vaporizer to 
breathing circuit, from circuit to lungs, from lungs to arterial blood, and 
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finally, from arterial blood to body tissues (see figure1). Of these the 
alveolar partial pressure (PA) of the anaesthetic agent is most crucial. 
The brain has a high blood supply and the anaesthetic in arterial blood 
rapidly equilibrates with brain tissue. 
 The rate of increase in alveolar anaesthetic concentration (FA) 
toward the concentration inspired (FI) during induction relates 
inversely to solubility of the potent agent in blood (Yasuda et al., 
1991a; Yasuda et al., 1991b). Sevoflurane induces a rapid increase in 
FA/FI ratio due to its low blood-gas solubility (Eger, 1994). A more 
rapid increase in FA/FI suggests the potential for a more rapid 
induction of anaesthesia. Administering N2O in conjunction with the 
volatile anaesthetic agent can influence the alveolar anaesthetic 
concentration. Very early in the administration of N2O the rate of rise 
of the alveolar concentration of the concurrently administered 
inhalation anaesthetic is increased. This is commonly referred to as 
the “second gas” effect, and this phenomenon can be applied clinically 
to speed anaesthetic induction (Eger, 1963). Yet, the benefits 
provided by N2O appear minimal in dogs when low solubility inhalation 
agents such as  isoflurane and sevoflurane are used for mask 
induction (Mutoh et al., 2001c). In dogs the FA/FI ratio of sevoflurane 
(0.75 ± 0.06) is greater compared to isoflurane and halothane (resp. 
0.60 ± 0.05 and 0.25 ± 0.02); resulting in a smooth and rapid induction 
of inhalation anaesthesia (Kazama and Ikeda, 1988).  
 Mask- or inhalation induction technique is routinely used in 
human paediatric anaesthesia and is also applicable in veterinary 
anaesthesia. An important problem with inhalation induction is the 
resistance of the animals against proper placement of the facemask 
leading to inhalation of an inadequate concentration of volatile 
anaesthetic agent. A second problem is the possible occurring airway 
irritation induced by the anaesthetic agent. This pungency results in 
hypersalivation, apnoea, coughing, breath-holding, laryngo- and 
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bronchial spasms and increased airway secretions. These undesirable 
responses result from irritation of the mucosa of the nasal passages, 
pharynx and larynx, which may impair smooth induction of 
anaesthesia and lead to airway obstruction and associated hypoxia 
and hypercapnia in dogs, cats and humans. Mutoh et al. (1995) 
described that inhalation induction with 2.5 MAC isoflurane in dogs 
was accompanied with relatively more struggling compared to 
induction with 2.5 MAC sevoflurane. Upper-airway administration of 
sevoflurane, halothane and isoflurane with concentrations used for 
mask induction induced milder reflex inhibition of breathing with 
sevoflurane. Lack of respiratory reflexes attributable to stimulation of 
the nasal passages may contribute to speed of onset and promote a 
smoother induction with sevoflurane (Mutoh et al., 2001a; Mutoh et 
al., 2001b). 
 The pungency of sevoflurane parallels that of halothane; this 
makes them the less pungent volatile anaesthetic agents. Both 
inhalant anaesthetics can be applied for mask induction in human and 
small animal anaesthesia (Sarner et al., 1995; Lerman et al., 1996; 
Blair et al., 2000). The differences in induction speed and airway 
irritability have not been confirmed in cats. Hikasa et al. (1996) did not 
see any difference in induction speed between halothane, isoflurane 
and sevoflurane. Possible explanations for these different findings 
could be the administered premedication and the slow and gradual 
induction technique applied. Sevoflurane mask induction is suitable in 
feline practice because of its good quality of induction in most cats 
and dogs (Johnson et al., 1998; Tzannes et al., 2000; Mutoh et al., 
2001c; Lerche et al., 2002). Desflurane on the other hand is not 
recommended for inhalation induction in paediatric anaesthesia due to 
its high pungency with laryngeal spasms, coughing and increased 
airway secretions (Eger, 1994).  
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    Fig.1: The flow pattern of inhaled anaesthetic agents during  
               anaesthetic induction and recovery. 
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         Fa       ARTERIAL BLOOD            VENOUS BLOOD Fv 
 
 
            B - T 
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   CLINICAL EFFECT 
 
 
   FD: delivered anaesthetic concentration by the vaporizer 
   FA: alveolar anaesthetic concentration 
   FI: inspiratory anaesthetic concentration 
   FE: expiratory anaesthetic concentration 
   Fa: arterial anaesthetic concentration 
   Fv: venous anaesthetic concentration 
   B – G: blood – gas solubility 
   B – T: blood – tissue solubility 
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* Maintenance of anaesthesia 
 
Maintenance of a constant level of anaesthesia with an 
inhalant anaesthetic agent may be equated to the maintenance of a 
constant alveolar anaesthetic concentration. A precise control of 
anaesthetic depth on basis of vaporizer settings is desirable in clinical 
practice. The difference between the concentration of anaesthetic 
agent delivered (FD) from a vaporizer and the FA may be used to 
define the degree of control of the anaesthetic level obtained with an 
inhalant agent during maintenance of anaesthesia (Eger, 1994). A 
ratio of FD/FA that approaches 1.0 indicates precise control, and 
deviations from 1.0 less control. The FD/FA ratio depends on the 
anaesthetic agent, the anaesthetic system (rebreathing degree) and 
the fresh gas flow. Anaesthetic uptake and rebreathing determine the 
proximity of FD/FA to 1.0: a smaller uptake (lower solubility and greater 
tissue equilibration) and diminished rebreathing (i.e., a higher inflow 
rate, a higher fresh gas flow rate) provide a value closer to 1.0. 
Furthermore, cardiac output and alveolar ventilation have an important 
influence on the FD/FA ratio of a volatile anaesthetic agent.  
 
The low blood-gas solubility of sevoflurane even in 
combination with an economical flow rate of 1-2 L/min permits to 
estimate the alveolar anaesthetic concentration from the delivered 
concentration by the vaporizer.  
 
The use of an agent-specific analyser facilitates a precision 
over the control of maintenance of anaesthesia, regardless of 
solubility by measuring inspiratory and end tidal anaesthetic gases.  
 
 * Recovery from anaesthesia 
Recovery from inhalation anaesthesia depends on solubility 
and concentration of the volatile agent, duration of anaesthesia and 
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metabolisation percentage (Lerman et al., 1996). The lower solubility 
of sevoflurane permits a more rapid decrease in FA at the end of 
anaesthesia. Its low fat solubility assures a rapid elimination 
regardless of anaesthesia duration. 
  
In humans a positive correlation (r = 0.517) was found for 
isoflurane between total anaesthetic exposure or dose (MAC-hours, 
see further) and recovery time. After sevoflurane anaesthesia MAC-
awake (the average of the bracketing alveolar anaesthetic 
concentration that allows and prevents the response to verbal 
command during recovery from anaesthesia; Stoelting et al., 1970) 
was independent of anaesthetic duration in adults (Campbell et al., 
1995). Hikasa et al. (1996) showed that recovery times in cats were 
significantly shorter after 90 minutes of sevoflurane anaesthesia 
compared to halothane anaesthesia, but only slightly shorter 
compared to isoflurane anaesthesia. 
  
Inhalation anaesthetic agents are not chemically inert. They 
undergo varying degrees of metabolism primarily in the liver, but also 
to a lesser degree in the lung, kidney and intestinal tract (Rehder et 
al., 1967; Holaday et al., 1970). Especially methoxyflurane and to a 
lesser extent halothane have longer recovery times caused by their 
extended metabolisation (Carpenter et al., 1986). 
  
More recent volatile anaesthetic agents have shorter 
emergence times greatly due to their low extent of biotransformation 
(see table 2). Important elimination routes from the body are the 
lungs, and of minor clinical importance through faeces, urine, 
transpiration, percutaneous loss and eventually through the surgical 
site (Stoelting and Eger, 1969; Fassoulaki et al., 1991; Lockhart et al., 
1991).   
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Nevertheless, in comparison with isoflurane and desflurane, 
sevoflurane still has a relatively high metabolisation percentage, yet it 
has a rapid recovery. This is probably related to the low fat solubility of 
sevoflurane resulting in low deposition of the anaesthetic agent in 
body fat tissue. Body fat tissue functions as depot for the volatile 
anaesthetic agent during elimination. 
  
The pharmacokinetic profile of sevoflurane resulting in rapid 
emergence times is especially useful after ambulatory anaesthesia in 
human anaesthesia. Time intervals from stopping the delivery of the 
anaesthetic to specific emergence and recovery parameters (e.g., 
time to extubation, opening of the eyes, emergence, orientation, 
response to commands, etc.) are shorter when compared to 
anaesthesia using volatile agents with higher blood-gas solubilities 
(e.g. isoflurane, enflurane) (Frink et al., 1992; Smith et al., 1992; 
Campbell et al., 1995; Eriksson et al., 1995; Philip et al., 1996; Aono 
et al., 1997; Ebert et al., 1998; Song et al., 1998 ; Robinson et al., 
1999). In comparison with halothane time interval between end of 
anaesthesia and response to commands is reduced with 33% after 
sevoflurane anaesthesia (Lerman et al., 1996). 
 
Fast recovery from sevoflurane, however, is likely to be 
accompanied by postoperative delirium, which is considered due to 
the early appearance of pain (Naito et al., 1991; Lerman et al., 1996; 
Aono et al., 1997). Especially in children who did not receive any 
analgesic or regional anaesthesia, the incidence of agitation and 
excitement during emergence from sevoflurane was greater than the 
incidence after halothane or propofol anaesthesia (Lerman et al., 
1996; Beskow and Westrin, 1999; Picard et al., 2000). The excitement 
was probably due to inadequate postoperative analgesia and a fast 
recovery of cognitive functions (Lerman, 1995). In animals early pain 
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perception will probably occur if inadequate postoperative analgesia is 
provided.  
 
MINIMUM ALVEOLAR CONCENTRATION (MAC) (Table 3) 
 
MAC is defined as the minimum alveolar concentration of a 
volatile anaesthetic agent that prevents a reaction on a standardised 
pain stimulus (a haemostatic forceps clamped on the tail or a 
standardised electric pulse) in 50% of a population (Merkel and Eger, 
1963; Laster et al., 1993). Thus MAC corresponds to the effective 
dose50 or ED50; half of the subjects are anaesthetized and half have 
not yet reached that level (De Jong and Eger, 1975, Quasha et al., 
1980). 
 
MAC-values are used to compare the anaesthetic potency of 
different volatile anaesthetic agents. The term potency refers to the 
quantity of an inhalant anaesthetic that must be administered to cause 
a desired effect (e.g. general anaesthesia). Equipotent doses are 
useful for comparing effects of inhalation anaesthetics on vital organs. 
  
MAC-values from volatile anaesthetic agents are inversely 
related to their oil-gas solubility (Lerman, 1993).  The anaesthetic 
potency of a volatile anaesthetic agent is also inversely related with 
the MAC-value. Sevoflurane has an intermediate anaesthetic potency 
and a low oil-gas solubility leading to a relatively high MAC-value. 
Halothane and isoflurane are relatively more potent volatile 
anaesthetic agents with a high oil-gas partition coefficient and a low 
MAC-value.  
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Table 3 : Minimal alveolar concentration (MAC) of volatile anaesthetic     
               agents in dogs, cats and humans. 
 
 
    
AGENT MAC-
VALUE* 
SPECIES REFERENCES 
    
    
Halothane 0.77 
0.89 
1.19 
 
man 
dog 
cat 
 
Saidman et al., 1967 
Kazama et al., 1988 
Drummond et al., 1983 
 
    
    
Enflurane 1.68 
2.06 
2.37 
 
man 
dog 
cat  
 
Gion et al., 1971 
Steffey and Howland, 1978 
Drummond et al., 1983 
 
    
    
Isoflurane 1.15 
1.39 
1.63 
 
man 
dog 
cat 
 
Stevens et al., 1975 
Steffey and Howland, 1977 
Steffey and Howland, 1977 
 
    
    
Desflurane 6.00/ 7.25 
7.20 
9.79 
 
man 
dog 
cat 
 
Rampil et al., 1991 
Doorley et al., 1988 
McMurphy et al., 1995 
 
    
    
Sevoflurane 1.71 
2.36 
2.58 
 
man 
dog 
cat 
 
Katoh and Ikeda, 1987 
Kazama et al., 1988 
Scheller et al., 1990 
 
 
 
In a single species the variability in MAC is generally small 
and is only minimally influenced by age, gender, body temperature, 
pregnancy, administered premedication, duration of anaesthesia and 
N2O administration (Saidman and Eger, 1964; Palahniuk et al., 1974; 
Steffey et al., 1977; Heard et al., 1986; Katoh et al., 1987; Glosten et 
al., 1990; Ewing et al., 1993; Katoh et al., 1994). In humans a marked 
decrease in sevoflurane MAC is observed with increasing age, except 
for a small rise in MAC between birth and the age of 6 months (Katoh 
et al., 1993a; Nakajima et al., 1993; Inomata et al., 1994). Nitrous 
oxide (60% end tidal) reduces the MAC-value of sevoflurane with 60% 
in adults and with 24% in young children (Lerman et al., 1994). Hence, 
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N2O is frequently used in combination with volatile anaesthetic agents 
since less volatile agent is needed and fewer side effects occur. To 
get important benefits of N2O, it is usually administered in high-
inspired concentrations. Nitrous oxide has less value in the 
anaesthetic management of animals because the anaesthetic potency 
of N2O is only half that found for humans (Eger et al., 1965; Steffey et 
al., 1974; DeYoung et al., 1980; Hornbein et al., 1982). MAC-values of 
several inhalant anaesthetic agents were determined in dogs and cats 
(see Table 3). The addition of 66% inspired nitrous oxide reduces the 
mean end tidal halothane concentration with 39%, with 26% for 
isoflurane and with 23% for sevoflurane in cats (McMurphy and 
Hodgson, 1995; Hikasa et al., 1996).  
 
Fentanyl, a potent and short acting narcotic analgetic agent, 
has a low hypnotic effect and reduces in a dose-dependent manner 
the MAC-awake of sevoflurane. In contrast, morfine is a less potent 
and longer acting opioid with less influence on the MAC-awake of 
sevoflurane (Katoh et al., 1993b). 
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SUMMARY 
 
In this chapter the influences of sevoflurane on the different 
vital systems are discussed. It shows that sevoflurane has little 
influence on brain perfusion and intracranial pressure. Cardiac output 
only decreases at high sevoflurane concentrations and coronary 
circulation is maintained. Sevoflurane induces a dose dependent 
respiratory depression and lacks airway pungency. Its low 
metabolisation percentage and minimal influence on total liver 
perfusion make it extremely useful for patients with liver dysfunction. 
Nevertheless, for animals with renal insufficiency some caution is 
adviced, since the compound A and fluoride issues merit further 
investigation. At this moment a possible renal toxicity has only been 
proved in rats. 
 
 Furthermore, the economic considerations on the use of 
sevoflurane in clinical practice are discussed. In the near future the 
use of sevoflurane will be affordable in veterinary practice.  
 
INTRODUCTION 
 
The chemical and physical properties of sevoflurane 
concerning induction, maintenance and recovery from anaesthesia 
were discussed in the first chapter. 
  
Furthermore, the knowledge of the influences on the different 
vital systems is of primary importance for using a new inhalant 
anaesthetic agent since this can lead to the prevention and treatment 
of potential side effects during anaesthesia. Therefore, the effects of 
sevoflurane on central nervous system, cardiovascular system, 
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respiratory system, in addition to hepatic and renal effects together 
with economic considerations are discussed. 
 
EFFECTS ON CENTRAL NERVOUS SYSTEM 
 
Cerebral perfusion (cerebral blood flow: CBF) is influenced by 
the so-called cerebral autoregulation mechanism (Brian, 1998). The 
cerebral autoregulation is a sensitive physiologic mechanism keeping 
CBF constant within a cerebral perfusion pressure between 50 and 
150 mm Hg protecting the brain against acute changes in arterial 
blood pressure.  
 
All traditional inhalant anaesthetic agents (halothane, 
isoflurane and enflurane) decrease cerebral vascular resistance 
leading to an increased intracranial pressure (Hörmann et al., 1997). 
The abolishment of cerebral autoregulation in a dose-dependent 
matter by inhalation anaesthetic agents can be a problem during 
intracranial surgery or in patients with head trauma. Between agents a 
great difference exists in influencing degree of cerebral perfusion and 
pressure (Ogawa et al., 1997). Halothane and enflurane influence 
cerebral autoregulation in humans by dilation of cerebral vessels and 
increase in CBF (Miletich et al., 1976). In healthy sevoflurane 
anaesthetized patients cerebral autoregulation remains well preserved 
unto 1.5 MAC (Summors et al., 1999). Moreover, even in patients with 
ischaemic cerebrovascular diseases autoregulation is not disturbed at 
0.88 MAC sevoflurane (Kitaguchi et al., 1993; Cho et al., 1996; Gupta 
et al., 1997). It can be concluded that in common with other volatile 
anaesthetic agents, sevoflurane has a ”weak” intrinsic, dose-
dependent cerebral vasodilatory effect (Bundgaard et al., 1998). 
However, this effect is less than that reported for halothane, isoflurane 
and desflurane at equipotent anaesthetic concentrations. Because of 
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this weak intrinsic vasodilatory action, sevoflurane is unlikely to cause 
a significant increase in intracranial pressure. Sevoflurane has 
therefore a haemodynamic profile favouring its use in neuro-
anaesthesia (Matta et al., 1999). 
 
In dogs the different inhalant anaesthetic agents have specific 
influences on cerebral perfusion. Halothane decreases cerebral 
vascular resistance leading to increased cerebral perfusion (Theye 
and Michenfelder, 1968). Isoflurane and enflurane induce a dose-
related decrease in cerebral vascular resistance (Cucchiara et al., 
1974; Michenfelder and Cucchiara, 1974; Artru, 1983; Scheller et al., 
1990). The same goes for the two recently developed inhalation 
anaesthetics, sevoflurane and desflurane: in dogs a dose-mediated 
decrease in cerebral vascular resistance occurred associated with an 
increased cerebral perfusion (Scheller et al., 1990; Lutz et al., 1990). 
Desflurane reduces cerebral vascular resistance with 67% between 
0.5 and 2 MAC; however, at higher concentrations between 1.5 and 2 
MAC a further increase of CBF is limited by occurring hypotension 
(Lutz et al., 1990). The same phenomenon is seen during isoflurane 
anaesthesia. In general, the degree of occurring cerebral 
vasodilatation during inhalation anaesthesia is as follows: desflurane > 
halothane > enflurane > isoflurane » sevoflurane (Todd and 
Drummond, 1984; Lutz et al., 1990; Takahashi et al., 1993).  
 
 Besides the direct influence of the volatile anaesthetic agent 
on CBF, the indirect role of carbon dioxide (CO2) on brain perfusion 
has to be taken into account. Carbon dioxide is a potent cerebral 
vasodilator. Hypercapnia exhausts the cerebral vasodilator response 
to changes in perfusion pressure reducing the autoregulatory capacity 
(Raichle and Stone, 1972). In contrast, hypocapnia increases cerebral 
vascular tone resulting in improved cerebral autoregulation (Paulson 
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et al., 1972). During inhalation anaesthesia hypercapnia (increase in 
PaCO2) often occurs due to hypoventilation leading to cerebral 
vasodilatation accompanied by increased CBF and intracranial 
pressure. During brain surgery a decreased brain perfusion is 
advisable and can be achieved by hyperventilation of the patients 
(Cold et al., 1998). The low arterial CO2 concentration induces 
cerebral vasoconstriction and a decreased CBF. In humans for every 
change in PaCO2 with 1 mm Hg CBF alters with 1-2 ml/100 g/min 
(Pickard et al., 1977). If PaCO2 decreases from 35-40 mm Hg to 20-25 
mm Hg CBF decreases with 40-50%. On the other hand, a further 
decrease in PaCO2 has no influence on CBF (Alexander et al., 1968). 
Cats have a mean cortical blood flow of 86 ml/100 g/min; a difference 
of 1.7 ml in CBF was observed after a change in PaCO
2 
with 1 mm Hg 
(Sato et al., 1984).  
 
In humans cerebrovascular reaction on changes in PaCO2 
remain unaffected during sevoflurane and desflurane anaesthesia 
leading to a beneficial decreased CBF and intracranial pressure with 
hypocapnia (Kitaguchi et al., 1993; Ornstein et al., 1993; Cho et al., 
1996; Nishiyama et al., 1997; Bundgaard et al., 1998; Mielck et al., 
1999). Another study showed that hypocapnia induced reduction of 
intracranial pressure was slightly more effective during the 
administration of isoflurane than sevoflurane (Nishiyama et al., 
1999a). Hypocapnia can also be used in dogs to achieve an effective 
decrease in CBF and intracranial pressure at 1 and 2 MAC isoflurane 
and sevoflurane (McPherson et al., 1989; Takahashi et al., 1993). 
However, when using halothane or enflurane even at low 
concentrations in dogs cerebral vasoconstriction induced by 
hypocapnia can be abolished (Artru 1983; Ogawa et al., 1997). On the 
other hand, in cats CBF can be reduced by hyperventilation with 
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hypocapnia during halothane and isoflurane anaesthesia (Drummond 
and Todd, 1985). In conclusion, cerebral pressure autoregulation and 
CO2 –responsiveness during brain surgery are best preserved in 
sevoflurane or isoflurane anaesthetized hyperventilated patients. 
 
In humans sevoflurane, isoflurane and desflurane induce a 
depression in electroencephalogram (EEG) activity without the 
occurrence of epileptiform activity (Eger et al., 1971; Rampil et al., 
1991; Kuroda et al., 1996;). Recently, periodic epileptiform discharges 
were observed on EEG during single-breath sevoflurane induction. 
The epileptiform EEG activity was of short duration and led to no 
untoward effects after anaesthesia in healthy patients (Vakkuri et al., 
2000). A study in cats showed that sevoflurane suppresses central 
nervous system background activities but has little effect on the 
reactive properties of the brain in light stages (2% sevoflurane), and 
facilitates them in relatively deep (5% sevoflurane) stages of 
anaesthesia. These data support the hypothesis that sevoflurane may 
have convulsive properties in cats similar to enflurane (Osawa et al., 
1994). With enflurane at high concentrations seizure activity was seen 
on EEG, especially during hypocapnia (Neigh et al., 1971). As in 
human anaesthesia enflurane induced seizure activity on EEG during 
auditory stimulation in dogs when used at concentrations above 1 
MAC (Scheller et al., 1990). Desflurane differs from the other 
anaesthetics in that the effect of higher concentrations of desflurane 
on EEG activity may be limited with time (Lutz et al., 1990). In healthy 
dogs no epileptiform activity was registered on EEG during 
sevoflurane and isoflurane anaesthesia and this during normocapnia, 
hypocapnia as well as during intense auditory stimulation (Scheller et 
al., 1990). 
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Sevoflurane has a haemodynamic profile favouring its use in 
neuro-anaesthesia due to its minimal influence on brain perfusion and 
CO2 – responsiveness, both in human and veterinary medicine 
(Baker, 1997). Furthermore, the fast and smooth recovery from 
anaesthesia after sevoflurane is useful for a rapid postoperative 
neurological evaluation of the patient. Special attention should 
therefore be given to postoperative analgesia as one of the main 
causes for postoperative excitation. 
 
EFFECTS ON CARDIOVASCULAR SYSTEM 
  
Like all other volatile anaesthetic agents sevoflurane induces 
a dose-dependent cardiovascular depression. The influence of 
sevoflurane on several cardiovascular parameters will be discussed: 
heart rate (HR), cardiac output (CO), myocardial contractility, coronary 
circulation and systemic blood pressure. Comparable to other volatile 
anaesthetics a relatively stable heart rate has been reported during 
sevoflurane anaesthesia in humans, even in children with congenital 
heart disease (Ebert et al., 1995; Malan et al., 1995; Rivenes et al., 
2001). A stable heart rate is favourable for myocardial oxygen 
consumption and for myocardial perfusion time. However, an increase 
in heart rate was reported during sevoflurane anaesthesia in dogs 
from 1.2 MAC on (Bernard et al., 1990; Mutoh et al., 1997). The 
increased heart rate was mainly due to baroreceptor-reflex induced by 
systemic hypotension. In dogs and humans sevoflurane has less 
negative influence on baroreceptor-reflex function than isoflurane 
(Tanaka and Nishikawa, 1999). No difference in compromising 
baroreceptor-reflex was observed between sevoflurane and isoflurane 
when increasing the MAC above 2 (Bernard et al., 1990). Arterial 
baroreflex function is an important neural control system for 
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maintaining cardiovascular stability. Halothane has less influence on 
heart rate in small animals, a slight increase was observed in dogs, 
while a small decrease occurred in cats. On the other hand, 
desflurane and isoflurane induced a non dose-dependent increase in 
heart rate in dogs (Grandy et al., 1989; Merin et al., 1991; Pagel et al., 
1991a; Clarke et al., 1996;).  
  
Sympathetic nerve stimulation (e.g. tachycardia, hypertension) 
as reported to occur in humans after desflurane induction, is not 
observed during sevoflurane mask induction (Ebert and Muzi, 1993; 
Moore et al., 1994; Weiskopf et al., 1994; Ebert et al., 1995; Muzi et 
al., 1996). The neurocirculatory excitation seen with rapid increases in 
desflurane did not occur with sevoflurane. The airway irritation 
associated with desflurane in humans may be involved in the marked 
activation of the neuro-endocrine axis (Ebert and Muzi, 1993; 
Weiskopf et al., 1994). 
 
 Volatile anaesthetic agents can  sensitise the myocardium to 
adrenaline-induced premature ventricular depolarisations presumably 
due to the depression of sinus node automaticity, the slowing of atrio-
ventricular nodal and His-Purkinje’s conduction, and the 
hyperpolarisation and shortening of the refractoriness of Purkinje’s 
fibre (Atlee, 1985). In humans and dogs sevoflurane does not change 
the sensitivity of the myocardium to the arrhythmogenic effect of 
exogenously administered adrenaline (Imamura and Ikeda, 1987; 
Hayashi et al., 1988; Navarro et al., 1994). The dose of adrenaline 
required with sevoflurane is higher than that required with halothane 
and enflurane, and similar to that with isoflurane in dogs (Imamura 
and Ikeda, 1987; Hayashi et al., 1988). This was also reported in cats, 
the effect of sevoflurane on the sensitisation of the feline myocardium 
to the arrhythmogenic effect of adrenaline was significantly less than 
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that of halothane and not different from isoflurane (Hikasa et al., 
1996).  
 
 In sevoflurane anaesthetized men myocardial depression 
mainly occurs due to the negative inotropic property of sevoflurane, 
although this is less pronounced compared to halothane (Malan et al., 
1995; Holzman et al., 1996; Rivenes et al., 2001). A dose-related 
decreased myocardial contractility was also observed in dogs during 
sevoflurane anaesthesia and was comparable with the depression 
seen with isoflurane and desflurane (Bernard et al., 1990; Pagel et al., 
1991b; Harkin et al., 1994; Pagel et al., 1994; Hettrick et al., 1996). 
Depression of myocardial contractility by sevoflurane may be due to a 
block of the transmembrane calcium influx and is accompanied by a 
decrease in stroke volume (Bernard et al., 1990; Hatakeyama et al., 
1993; Park et al., 1996). Cardiac output will only decrease from 2 
MAC on, because the initial decrease in stroke volume at lower 
sevoflurane concentrations is abolished by tachycardia (Bernard et al., 
1990; Lowe et al., 1996).  
 
 Global coronary circulation remains intact in sevoflurane 
anaesthetized dogs even during myocardial ischaemia. Nevertheless, 
a small decrease in coronary vascular resistance was observed in 
dogs (Bernard et al., 1990). This might lead to the so-called “coronary 
steal” effect. Coronary steal is defined as a marked redistribution of 
myocardial blood flow from ischaemic to normal zones; this can lead 
to exacerbation of myocardial ischaemia in patients with coronary 
artery disease (Warltier et al., 1980; Gross and Warltier, 1981). 
Isoflurane and to a lesser degree halothane, induce a coronary steal 
effect in dogs because of their coronary vasodilating properties 
(Buffington et al., 1987; Priebe, 1988). In contrast, sevoflurane lacks 
potent coronary vasodilating properties in dogs, which are necessary 
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to cause this effect (Kersten et al., 1994; Kitahata et al., 1999). Since 
sevoflurane is a less potent coronary vasodilator than isoflurane, it 
preserves coronary blood flow reserve and diminishes the potential for 
coronary steal (Larach and Schuler, 1991; Hirano et al., 1992; Ebert et 
al., 1997; Tomiyasu et al., 1999; Crystal et al., 2000).  
 
In humans, as in companion animals sevoflurane induces a 
dose-related hypotension partly due to decreased peripheral 
resistance and partly to a reduced stroke volume (Ebert et al., 1995; 
Malan et al., 1995; Lowe et al., 1996; Mutoh et al., 1997). Halothane, 
isoflurane, desflurane and enflurane also induce a dose-dependent 
decrease in arterial blood pressure in dogs and cats (Steffey and 
Howland, 1977; Steffey and Howland, 1978; Frink et al., 1992c, 
McMurphy and Hodgson, 1996). 
 
 In conclusion, cardiovascular influences of sevoflurane are 
similar to those of isoflurane, but favourable to those of halothane. 
Sevoflurane only decreases cardiac output during high concentrations 
and offers protection against catecholamine induced arrhythmias. 
Moreover, adequate coronary circulation is maintained offering 
potential benefits for anaesthetizing cardiac patients. 
 
EFFECTS ON RESPIRATORY SYSTEM 
  
Sevoflurane induces a dose-related respiratory depression in 
both humans and companion animals (Doi et al., 1986; Doi and Ikeda, 
1987; Tamura et al., 1991; Mutoh et al., 1997). The depression in 
ventilatory function is characterized by a decrease in tidal volume with 
increasing depth of anaesthesia and a moderate increase in PaCO2. 
The decrease in tidal volume is not adequately compensated for by an 
increase in respiration rate, which leads to hypoventilation. 
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Respiratory depression is mediated by central depression of the 
medullar respiratory neurons and by a decrease in diaphragmatic 
contractility (Doi et al., 1988; Ide et al., 1991; Ide et al., 1992). 
 
Isoflurane induces a similar respiratory depression in dogs. 
Tidal volume remains higher during enflurane anaesthesia compared 
to sevoflurane, but respiratory rate is more decreased (Mutoh et al., 
1997). During halothane anaesthesia in dogs respiratory rate is higher 
and tidal volume lower compared to sevoflurane (Mutoh et al., 1997). 
From 1.4 MAC on sevoflurane anaesthesia is accompanied by a more 
pronounced respiratory depression in humans compared to equipotent 
concentrations of halothane (Doi and Ikeda, 1987). Dose-related 
respiratory depression is also reported during desflurane anaesthesia 
both in humans, dogs and cats (Lockhart et al., 1991; Clarke et al., 
1996; McMurphy and Hodgson, 1996). 
 
Sevoflurane induces bronchodilation in dogs by inhibition of 
histamine- or acetylcholine-induced bronchial muscle contractions 
(Katoh and Ikeda, 1991). Isoflurane but mainly halothane abolished 
histamine-induced bronchoconstriction in a dose-dependent manner 
(Brown et al., 1993). In human anaesthesia sevoflurane may be a 
worthwhile alternative to the traditional choice of halothane as an 
adjunct to prevent and manage intraoperative bronchospasm (Rooke 
et al., 1997). Sevoflurane is as effective as isoflurane in attenuating 
bronchoconstriction associated with anaphylaxis in dogs and may be 
a useful alternative for the other volatile agents in the treatment of 
bronchospasm in asthma or anaphylaxis (Mitsuhata et al., 1994). 
 
Lack of pungency is an important characteristic for volatile 
anaesthetic agents used for mask induction. Airway reflexes such as 
apnoea, breath-holding, laryngospasm and hypersecretion as well as 
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excitement can occur during induction (Harvey, 1992). These 
undesirable responses are believed to be the result of irritation of the 
mucosa of the nasal passages, pharynx and larynx, which may impair 
smooth induction of anaesthesia and lead to airway obstruction and 
associated hypoxia and hypercapnia in dogs, cats and humans 
(Yurino and Kimura, 1993; Steffey, 1994; Mutoh et al., 1995). The 
degree of airway irritation varies with the type of inhalant (Doi and 
Ikeda, 1993). In contrast with isoflurane, sevoflurane and halothane 
cause less airway irritation, less stimulation of the cough reflex and 
less reflex inhibition of breathing in both dogs and humans (Inomata et 
al., 1994; Green, 1995; Kandasamy and Sivalingam, 2000; Klock et 
al., 2001; Mutoh et al., 2001a; Mutoh et al., 2001b; Mutoh et al., 
2001c). Rapid induction of anaesthesia (sevoflurane > isoflurane >> 
halothane) is of great importance in preventing excitation during mask 
induction. The risk for cardiopulmonary problems and overdosage 
increases during long inhalation inductions. Mask induction in healthy 
dogs is fast and accompanied by less excitation when using 
sevoflurane. However, isoflurane, enflurane and halothane are 
associated with longer induction times and more resistance from the 
animals on mask placement (Mutoh et al., 1995). Until now 
sevoflurane is a very suitable volatile anaesthetic for inhalation 
induction in humans and small animals (Doi and Ikeda, 1992; Doi and 
Ikeda, 1993).  
 
HEPATIC EFFECTS 
  
All volatile anaesthetic agents are primarily metabolised in the 
liver to a different extent. Normal liver functioning is necessary for 
metabolisation and elimination of most volatile anaesthetic. In 
contrast, metabolism of sevoflurane does not contribute to termination 
of clinical drug effect, unlike more extensively metabolised drugs as 
CHAPTER 2 
 
 
 48
halothane (Kharasch, 1995). Only a limited amount (3.3% in humans 
and 2.5% in dogs) of absorbed sevoflurane is metabolised in the liver 
by cytochrome P450 2E1 enzymes, in dogs metabolic pathways are not 
yet described (Table 1) (Martis et al., 1981; Shiraishi and Ikeda, 
1990). Sevoflurane is metabolised to hexa-fluoro-isopropanol and 
inorganic fluoride. Hexa-fluoro-isopropanol is conjugated with 
glucuronic acid and excreted in the urine as a non-toxic glucuronide 
conjugate (Figure 1) (Holaday and Smith, 1981; Martis et al., 1981; 
Kharasch et al., 1995b). Sevoflurane metabolites do not bind to liver 
proteins decreasing the risk for direct liver toxicity by formation of 
antibodies (Young and Apfelbaum, 1995). Furthermore, the production 
of free radicals or other reactive metabolites as during halothane 
metabolism was not observed (Kharasch, 1995). Free radicals are 
partially responsible for post-anaesthetic liver damage (Ray and 
Drummond, 1991; Frink and Brown, 1994). In addition, only four cases 
of liver dysfunction could be related to previous sevoflurane exposure 
in men (Shichinohe et al., 1992; Watanabe et al., 1993; Bruun et al., 
2001). 
 
 
Table 1 : Biotransformation of volatile anaesthetic agents in        
                  humans 
 
   
AGENT % METABOLISATION REFERENCE 
   
   
Halothane 20-25 Rehder et al., 1967. 
Cascorbi et al., 1970. 
   
   
Enflurane 2,4 Chase et al., 1971. 
   
   
Isoflurane 0,17 Holaday et al., 1975. 
   
   
Desflurane 0,02 Eger, 1994. 
   
   
Sevoflurane 3,3 Shiraishi and Ikeda, 1990. 
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Post-anaesthetic liver damage can also be caused by local 
hypoxaemia due to inadequate hepatic circulation. Total liver 
perfusion is assured by the hepatic arterial blood flow and the portal 
venous blood flow. During sevoflurane anaesthesia in dogs a 
decrease in hepatic arterial circulation was reported at 2 MAC. Arterial 
circulation remained constant at lower anaesthetic concentrations. On 
the other hand, portal venous circulation decreased at 1.5 and 2 MAC. 
In conclusion, total liver perfusion only decreased at high sevoflurane 
concentrations (2 MAC) (Frink et al., 1992c). During isoflurane 
anaesthesia in dogs hepatic arterial blood flow remained constant at 2 
MAC, while portal venous perfusion only decreased slightly. This 
resulted in a constant total liver perfusion even at higher anaesthetic 
levels of isoflurane (Bernard et al., 1992). Halothane and to a lesser 
extent enflurane induced a marked decrease in hepatic arterial and 
portal venous circulation in dogs (Frink et al., 1992c). 
 
 A recent study reported that isoflurane induced an increase in 
serum levels of liver enzymes more frequently than did sevoflurane 3 
to 14 days after anaesthesia (Nishiyama et al., 1999b). Standard 
hepatocellular enzymes were within normal range, while a clinically 
non-significant increase of indirect bilirubine was reported after 
sevoflurane anaesthesia in men (Frink et al., 1992a; Newman et al., 
1994; Ebert et al., 1998; Ebert and Arain, 2000; Suttner et al., 2000). 
Even in patients with minimal or no hepatic metabolic capacity, such 
as those with diminished enzyme activity or with intrinsic liver disease, 
recovery from sevoflurane anaesthesia should not be affected 
significantly (Kharasch et al., 1995b). Moreover, sevoflurane and 
isoflurane only give a decrease in total liver perfusion at higher 
concentrations, which are seldom necessary in clinical practice using 
balanced anaesthesia protocols. In conclusion, in patients with liver 
malfunctioning sevoflurane or isoflurane are preferably used, since 
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both volatile anaesthetic agents have a low metabolisation degree 
(sevoflurane: 3.3% and isoflurane: 0.17%) and are thought to be less 
hepatotoxic compared to halothane and enflurane. 
 
RENAL EFFECTS 
 
The introduction of sevoflurane into clinical human 
anaesthesia has been clouded by concerns about the potential risk of 
nephrotoxicity after its use. Two theoretical sources for the 
nephrotoxicity after sevoflurane are the plasma concentration of 
inorganic fluoride, an in vivo metabolite of sevoflurane and the so 
called ”compound A”, an in vitro degradation product of sevoflurane in 
the presence of soda lime and baralyme. The metabolism of 
sevoflurane involves enzymatic breakdown leading to the generation 
of fluoride ions. Fluoride ions are potentially toxic and can cause renal 
failure (Mazze, 1984). Because evidence of methoxyflurane renal 
dysfunction was not observed when peak fluoride concentrations were 
less than 50 µmol/l, this concentration was considered to be the 
threshold of fluoride nephrotoxicity (Cousins and Mazze, 1973). In 
clinical anaesthesia with sevoflurane some transient fluoride plasma 
concentrations of more than 50 µmol/l were measured in humans 
(Frink et al., 1992a; Kobayashi et al., 1992; Stickler et al., 1994; 
Munday et al., 1995). And yet, no clinically relevant kidney failure was 
reported in humans. Even in patients with pre-existing renal 
impairment no further deterioration occurred after sevoflurane 
anaesthesia (Melotte et al., 1994; Nuschler et al., 1994). For children 
and obese persons the use of sevoflurane did not increase the risk for 
potential renal toxicity, although, obesity was reported to increase the 
fluoride production (Frink et al., 1993; Levine et al., 1996).   
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 Fig. 1 : Metabolisation of sevoflurane (adapted from Frink et al., 1992a) 
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 Because of previous clinical results the initial “fluoride-rule” of 
methoxyflurane should not be applied to sevoflurane anaesthesia 
(Frink et al., 1992a; Kobayashi et al., 1992; Frink et al., 1994). Human 
kidney microsomes metabolise methoxyflurane and to a much lesser 
extent sevoflurane to inorganic fluoride. Sevoflurane is predominantly 
metabolised by cytochrome P450 2E1 in the liver. In contrast, no 
significant amounts of P450 2E1 have been found in human kidneys 
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(de Waziers et al., 1990; Kharasch et al., 1995c). Therefore, human 
renal fluoride concentrations after sevoflurane anaesthesia are 
considerably lower than serum fluoride concentrations. Hence, serum 
fluoride concentration after sevoflurane is probably of little importance 
for renal damage, even when the 50 µmol/l threshold is exceeded 
(Kharasch et al., 1995a). 
 
 In a study on biotransformation of sevoflurane in dogs (2.5 %) 
maximum serum fluoride concentrations were considerably lower than 
those associated with nephrotoxicity in rats; respectively 18.5 µmol/l 
and 20.0 µmol/l after 3 and 4% sevoflurane exposures (Martis et al., 
1981). These fluoride concentrations were not expected to induce 
renal damage. 
 
 Of more concern than fluoride production during sevoflurane 
metabolisation, is its interaction with CO2 absorbents, which generates 
several degradation products. In modern anaesthesia, low fresh gas 
flows (< 2 L/min) are common practice in order to reduce costs of 
volatile anaesthetics and to avoid environmental pollution as well as to 
preserve heat and humidify the inspired gas. Yet, all volatile 
anaesthetics can be degraded by the lime in the circle absorber 
system. Desflurane, enflurane and isoflurane react with dry 
absorbents forming CO (Fang et al., 1995). Sevoflurane on the other 
hand reacts with absorbents by formation of degradation products 
called compounds A-E (Cunningham et al., 1996). The amounts of 
compounds B, C, D and E were negligible whereby compounds C, D 
and E were only found in in vitro studies using closed containers filled 
with sevoflurane and sodalime (Wallin et al., 1975; Hanaki et al., 
1987). The most significant substance is compound A, a vinyl ether, 
which has dose-dependent nephrotoxic properties inducing tubular 
necrosis in rats. Clinically significant effects of this degradation in 
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humans are still controversial (Bito et al., 1997; Kharasch et al., 1997; 
Mazze and Jamison, 1997). Exposure of rats to high sevoflurane 
concentrations is also detrimental for liver, lungs and central nervous 
system (Gonsowski et al., 1994a). Compound A production and 
accumulation in a circle absorber system is dependent on sevoflurane 
concentration, the type of absorber material (baralyme or soda lime), 
the water content of the absorbent, absorbent temperature, freshness 
of the CO2-absorbent, CO2-production, fresh gas flow rates and type 
of anaesthetic machine (Bito and Ikeda, 1991; Liu et al., 1991; Frink et 
al., 1992b; Wong and Lerman, 1992; Ruzicka et al., 1994; Osawa and 
Shinomura, 1998; Bito et al., 1998; Goeters et al., 2001; Yamakage et 
al., 2001;). In the former absorbents, NaOH and KOH appear to 
enhance the production of compound A and CO by degrading volatile 
anaesthetics (Stabernack et al., 2000). New absorbents containing 
Ca(OH)2 or Li(OH)2 could eliminate any potential hazards from the 
toxic compounds by decreasing the production of compound A and 
CO (Higuchi et al., 2000; Yamakage et al., 2000). The new material is 
an effective carbon dioxide absorbent and is chemically unreactive 
with sevoflurane, enflurane, isoflurane and desflurane (Murray et al., 
1999; Mchaourab et al., 2001). 
 
 The lethal concentration in 50% (LC50) of compound A in rats 
equaled 331 ppm, 203 ppm and 127 ppm for a 3-h, 6-h and 12-h 
exposure period (Gonsowski et al., 1994a en b). In a recent study on 
low-flow sevoflurane anaesthesia in dogs concentrations of compound 
A in the anaesthetic circuit were less than values reported to produce 
renal toxicosis and death in rats (Muir and Gadawski, 1998). In all 
reported sevoflurane studies compound A concentration remained far 
below the toxic margin in humans (Frink et al., 1992b; Bito and Ikeda, 
1994; Frink et al., 1994; Bito and Ikeda, 1995; Kharasch et al., 1997; 
Kharasch and Jubert, 1999; Igarashi et al., 1999). Moreover, Rolly 
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and Versichelen (1998) found amounts of compound A of 6 to 9 ppm 
using soda-lime as CO2-absorbent. In a recent study using a high-flow 
(7.0 l/min) closed-circuit PhysioFlex apparatus (Dräger, Lübeck, 
Germany) with soda-lime and computer-controlled liquid injection of 
sevoflurane compound A concentrations were significantly lower (6 
ppm) than in conventional (14.3 ppm), valve-based machines during 
closed-circuit conditions. Lower absorbent temperatures, resulting 
from the high flow appear to account for the lower compound A 
formation (Versichelen et al., 2000). Furthermore, recent studies 
revealed that humans may be less susceptible to compound A renal 
toxicity than rats, since the beta-lyase pathway responsible for 
nephrotoxic metabolites of compound A is 10- to 30-fold less active in 
humans than in rats (Altuntas and Kharasch, 2001; Altuntas and 
Kharasch, 2002) 
 
 Renal functioning is mainly assessed by changes in serum 
creatinine or blood urea nitrogen (BUN). These conventional markers 
do not evaluate tubular function and are insensitive measures of 
glomerular filtration (Shemesh et al., 1985). They are usually within 
the normal range after “high-flow” (Frink et al., 1994; Higuchi et al., 
1994; Obata et al., 2000) and “low-flow” sevoflurane anaesthesia 
(Kharasch et al., 1997; Bito et al., 1997; Eger et al., 1997; Higuchi et 
al., 1998; Groudine et al., 1999; Obata et al., 2000). Even in patients 
with moderately impaired renal function low-flow sevoflurane 
anaesthesia had similar effects on renal function compared to 
isoflurane (Higuchi et al., 2001). In specific experimental studies 
several specific and sensitive biomarkers were used for evaluation of 
renal function. These biomarkers bind on enzymes released with 
kidney damage. Despite the sensitive tests no difference in renal 
enzyme excretion between sevoflurane and isoflurane was found (Bito 
et al., 1997; Kharasch et al., 1997; Kharasch et al., 2001).  Eger et al. 
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(1997; 1999) on the other hand, associated low flow (2 l/min during 8 
hours) sevoflurane in humans with a transient renal injury in the 
glomerulus, the proximale and distale tubuli, in contrast to desflurane 
anaesthesia where no renal damage was observed. However, the 
reliability of urinary biomarkers as indicator for clinical significant 
kidney injuries in humans is still controversial (Baines, 1994). 
 
 The Food and Drug Administration (FDA) approved the clinical 
use of sevoflurane regarding some precautions. A minimal flow of 2 
l/min for exposures greater than 1 hour should be respected in semi-
closed systems. Until more information on degradation (compound A) 
and metabolisation (fluoride) of sevoflurane is available, sevoflurane is 
not recommended for using in patients with impaired kidney function 
(Mazze and Jamison, 1995; 1997). 
 
ECONOMIC CONSIDERATIONS 
  
Do the benefits of sevoflurane compensate for the associated 
higher costs in comparison to halothane and isoflurane in clinical 
anaesthesia practice? Cost considerations are of increasing 
importance when choosing anaesthetic techniques and drugs. 
Different factors have an influence on the price of volatile 
anaesthetics. The immediate cost of an inhaled anaesthetic results 
from an interplay between 4 main factors: 1/ the cost per ml of liquid 
anaesthetic, 2/ the volume of vapour that results from each ml of 
liquid, 3/ the effective potency of the anaesthetic, 4/ the fresh gas flow.  
 
First of all, there is the price imposed by the manufacturer 
(Weiskopf and Eger, 1993). At this moment the price of 1 ml of 
sevoflurane is a decisive factor for its use in veterinary practice. This 
price is still considerably high in comparison with halothane and to a 
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lesser extent with isoflurane. The purchasing cost will probably be 
reduced in the near future, since sevoflurane is rapidly gaining ground 
in human anaesthesia at the expense of halothane and isoflurane. 
 
 Secondly, the amount of vapour produced from 1 ml liquid 
anaesthetic influences anaesthetic costs. The amount of vapour 
produced is a function of the specific gravity and molecular weight of 
the volatile anaesthetic, respectively 168 g and 1.467 g/ml for 
desflurane, 184.5 g and 1.50 g/ml for isoflurane and 200 g and 1.505 
g/ml for sevoflurane. The amount of produced vapour from 1 ml 
decreases with 7% as follows: desflurane > isoflurane > sevoflurane 
(Eger, 1994). 
 
Furthermore, there are the factors inherent to the used 
anaesthetic agent, as anaesthetic potency and blood-gas solubility of 
the volatile anaesthetic agent (Bach et al., 1997; Philip, 1997). A lower 
blood-gas solubility of an anaesthetic accords the same level of 
control at a lower fresh gas flow rate than is achieved at a higher fresh 
gas flow with a more soluble anaesthetic (Weiskopf and Eger, 1993). 
The anaesthetic potency of sevoflurane is smaller compared to 
halothane and isoflurane, but sevoflurane has a substantially lower 
blood-gas partition coefficient. Low blood-gas solubility permits a rapid 
and precise control of anaesthetic depth during anaesthesia induction 
and maintenance, even with a relatively low flow. Halothane and 
isoflurane need higher, less economic fresh gas flows to adjust 
anaesthetic depth. Finally, the delivered concentration of the 
anaesthetic by the vaporiser is responsible for the anaesthetic 
consumption and not the alveolar concentration. The difference 
between both is wasted. The low blood-gas solubility of sevoflurane 
decreases the difference between inspired and end tidal concentration 
leading to less waste and better control of anaesthesia. 
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As already mentioned, the applied fresh gas flow is also of 
great importance for anaesthetic cost savings.  The main waste with 
an inhalant anaesthetic is the one induced by unnecessarily high 
carrier gas flows (Rosenberg et al., 1994). The lower the fresh gas 
flow, the less volatile anaesthetic is wasted (Camu and Van De Velde, 
1997; Suttner and Boldt, 2000). In closed circuit only a fresh gas flow 
that supplies vapours required by the patient is used. This produces 
the least cost, but also the least control of anaesthetic depth. 
Nevertheless, the FDA suggested recently a minimal flow of 1 l/min for 
exposures up to 1 hour in semi-closed systems to reduce the potential 
risk for renal damage by accumulation of degradation products of 
sevoflurane (Mazze and Jamison, 1997; Gentz and Malan, 2001).  
 
 Another benefit of sevoflurane, especially in human 
anaesthesia is its fast recovery which could result in decreased 
hospitalisation costs. For veterinary anaesthesia, however, the capital 
costs include the expense of agent-specific vaporisers and of 
converting or purchasing gas analysers. To reduce expenses an 
enflurane vaporiser could be used for sevoflurane, since both 
anaesthetics have a similar vapour pressure, 172 mm Hg for 
enflurane and 160 mm Hg for sevoflurane (chapter 1 table 2). In 
addition, the anaesthetic potency of both anaesthetics is similar: MAC 
of enflurane in dogs is 2.06 and 2.36 for sevoflurane (chapter 1 table 
3). When using an enflurane vaporiser type Enfluratec 4 for 
sevoflurane administration the MAC-output is reduced with 21 % to 31 
% in comparison with a specific sevoflurane vaporiser (Abel and 
Eisenkraft, 1996). Nevertheless, the use of an enflurane vaporiser for 
sevoflurane is not recommendable, since the limited vaporiser output 
could lead to insufficient surgical anaesthetic depth. In short term 
second-hand sevoflurane vaporisers will be available for veterinary 
anaesthesia. 
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CONCLUSION 
  
Considering the multiple benefits of sevoflurane in veterinary 
anaesthesia, there will certainly be a future for sevoflurane in 
anaesthesia of dogs and cats. In patients with renal impairment some 
precautions are advised, since more experience and studies on the 
compound A and fluoride issues are necessary. Due to a rapid 
advance of sevoflurane in human anaesthesia price reductions are 
expected in the near future justifying the use of sevoflurane in modern 
veterinary practice. 
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In these chapters the clinical aspect of the anaesthetic 
protocol is emphasised. The majority of articles describe recovery 
times and cardiorespiratory influences of sevoflurane anaesthesia in 
studies with an experimental anaesthetic set-up. In contrast, the 
amount of information gathered under clinical circumstances with a 
standard anaesthetic protocol is rather limited. In most experimental 
studies on sevoflurane in dogs the anaesthetic protocol is reduced to 
the strict minimum to eliminate potential influences of other 
anaesthetic drugs. Therefore, premedication and induction with 
intravenous anaesthetic agents are excluded. Instead, anaesthesia is 
induced and maintained solely by the volatile anaesthetic agent 
(sevoflurane). In the present work the anaesthetic protocol included a 
standard premedication, since preanaesthetics drugs are of major 
importance under clinical circumstances. 
 
Premedication decreases stress before induction of 
anaesthesia, facilitates manipulations and contributes to a smooth 
induction and recovery from anaesthesia. Moreover, opioids are often 
included in premedication reducing the severity and duration of post-
operative pain. The so-called “pre-emptive analgesia” is of major 
importance for the patient. For these reasons premedication with a 
neurolept-analgesic mixture including droperidol and fentanyl can be 
justified. Influences of droperidol on recovery times and 
cardiorespiratory parameters are probably not neglectable because of 
its long-lasting action, and hence can not be ruled out. Fentanyl, on 
the other hand, has a rapid onset of effect (1-2 minutes and is short-
acting (20-30 minutes). Accordingly, no effects on recovery times and 
only initial influences on cardiorespiratory parameters could be 
expected. 
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Induction of anaesthesia is mainly achieved by intravenous 
anaesthetics because of their rapid onset of action and ease of 
administration. Propofol was preferred in the present study due to its 
unique pharmacokinetic properties and clinical advantages. It has a 
specific extrahepatic metabolism and is rapidly cleared from the body. 
After bolus injection, plasma concentrations decrease rapidly due to 
redistribution of the drug to the brain and other highly perfused 
tissues. It provides a rapid and smooth induction of anaesthesia and a 
fast excitement-free recovery with no hangover-effect. Although the 
elimination half-life of propofol is long (330 minutes in dogs), this is not 
clinically relevant and should not influence recovery times after 1 hour 
of inhalation anaesthesia. Influences on cardiopulmonary parameters 
under sevoflurane anaesthesia during spontaneous and controlled 
ventilation might be observed the first 30 minutes of the standardised 
anaesthetic period. This was not considered a problem since surgical 
preparation of the dogs was performed during the first hour of 
anaesthesia. 
 
Chapter 3 discusses the recovery times after clinical 
sevoflurane anaesthesia compared with more frequently used inhalant 
anaesthetic agents (isoflurane and halothane). The aim was to 
investigate the advantage of the low blood-gas solubility of 
sevoflurane compared to the other volatile anaesthetic agents for the 
recovery times in premedicated dogs. In chapter 4 cardio-pulmonary 
parameters of sevoflurane anaesthesia during spontaneous and 
controlled ventilation at different MAC values are described using a 
clinical anaesthetic protocol including premedication and intravenous 
induction. 
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SUMMARY 
 
In the present study the influence of 3 volatile agents 
{halothane, isoflurane and sevoflurane} in oxygen at 2 concentrations 
(1.5 and 2 MAC) in 6 dogs on non-invasive cardio-respiratory 
parameters (heart and respiratory rates, non-invasive blood pressures 
at 15, 30, 60 minutes and after extubation) and on the recovery times 
(appearance of the first eyelid reflex, emergence time) after clinical 
anaesthesia was studied (cross-over design). After premedication with 
fentanyl-droperidol (5 mg/kg and 0.25 mg/kg IM) and induction with 
propofol (5 mg/kg IV) six dogs were randomly anaesthetised for one 
hour for a standard neurologic stimulation test. 
 
A wide individual variation in respiration rate (induced by an 
initial hyperpnea) was observed in the 1.5 MAC protocols, without 
significant differences between the 3 different volatile agents. Heart 
rate was significantly lower during 1.5 and 2 MAC halothane when 
compared to isoflurane and sevoflurane. An increase from 1.5 to 2 
MAC induced significant decreases in diastolic (DAP) and mean 
arterial blood pressure in all groups without significant changes in the 
systolic arterial pressures. Only DAP in sevoflurane protocol was 
significantly lower at 1.5 and 2 MAC compared to halothane. Time had 
no significant influences on the non-invasive blood pressures in all 
protocols. Extubation induced a significant increase of all parameters 
in all protocols. Time for a first eyelid reflex was significantly longer 
after 2 MAC compared to the 1.5 MAC protocol. There was no 
significant difference between the 3 anaesthetic agents. Although 
emergence time was longest for halothane at both anaesthetic 
concentrations, no significant difference in emergence time was 
observed for the 3 volatile agents. 
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INTRODUCTION 
 
Sevoflurane (CFH2-O-CH(CF3)2) is a volatile anaesthetic 
agent developed in the early seventies (Wallin et al., 1975). This drug 
has specific characteristics including a low blood/gas partition 
coefficient (0.69) (Strum and Eger, 1987). The low solubility partly 
contributes to a rapid induction of and emergence from anaesthesia 
compared to other volatile anaesthetics such as halothane, enflurane 
and isoflurane (Smith et al., 1992; Lerman et al., 1996; Steffey, 1996; 
Aono et al., 1997; Ebert et al., 1998). Sevoflurane has a low pungency 
and produces little to no airway irritability compared to isoflurane but 
especially to desflurane. This positive effect results in little to no 
airway responses (coughing or laryngeal spasm), allowing a smooth 
mask induction in children and small animals (Doi and Ikeda, 1992; 
Doi and Ikeda, 1993; Inomata et al., 1994; Lerman et al., 1996; Muzi 
et al., 1996).  
 
A lot of research has been performed in man, in particular 
about the emergence time of sevoflurane compared to other fast 
acting anaesthetic agents such as isoflurane, desflurane and propofol 
(Smith et al., 1992; Ebert et al., 1998; Song et al., 1998). Only a 
limited number of reports on this subject are available in small 
animals. Johnson et al. (1998) reported the induction and recovery 
characteristics of sevoflurane, in comparison with isoflurane in adult 
unpremedicated experimental dogs using mask induction. However, 
mask induction without premedication is seldom used under clinical 
circumstances. In clinical trials sevoflurane was compared to 
halothane after propofol or thiopentone induction (Oliva et al., 2000). 
The present study was performed to determine the differences in 
emergence times and related parameters during and after a clinical 
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standard anaesthesia in spontaneously breathing adult dogs. 
Commonly used non-invasive cardio-respiratory parameters were also 
compared. The anaesthetic protocol included a standard neurolept-
analgesic premedication and propofol induction. 
 
MATERIALS AND METHODS 
 
The study was approved by the Ethical committee of the 
Faculty of Veterinary Medicine, Ghent University (filenumber: 97/12). 
Six adult male mongrel dogs weighing 18 to 35 kg from 3 to 7 years 
were used for the study. The dogs were dewormed and vaccinated at 
a regular basis. Clinical examination and a blood analysis (standard 
kidney and liver function tests) confirmed the health status of the 
animals before the study. No specific medication altering anaesthetic 
or analgesic requirements were administered at least 1 month before 
the experiments.  
 
Study Protocol 
The dogs were randomly assigned to 6 anaesthetic protocols 
of 1 hour (including halothane (Halo), isoflurane (Iso), and sevoflurane 
(Sevo), each at 1.5 and 2 MAC) using a cross over design. The 
minimum interval between 2 successive studies was 2 weeks. Food 
but not water was withheld for 12 hours before each experiment. Body 
weight, heart (HR) and respiratory (RR) rates were obtained in the 
unpremedicated dogs. 
 
Premedication and Induction of Anaesthesia 
The dogs were premedicated 30 minutes before induction of 
anaesthesia with fentanyl-droperidol IM (respectively 5 µg/kg and 0.25 
mg/kg of body weight BWT) (ThalamonalÒ, Janssen-Cilag, Berchem, 
Belgium). Induction of anaesthesia was performed using propofol (5 
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mg/kg of BWT) (RapinovetÒ, Mallinckrodt Veterinary, Stockholm, 
Sweden) intravenously over 15-20 seconds. After loss of the 
swallowing reflex the dogs were orally intubated (endo-tracheal tube 9 
or 12 mm ID, Rüsch, Germany).  
 
Maintenance of Anaesthesia 
A circle system (TitusÒ, Dräger, Lübeck, Germany) with an 
agent specific calibrated precision out of circuit vaporiser (Vapor 
19,3Ò, Dräger, Lübeck, Germany) was used throughout the study. 
The soda lime (Dräger Sorb 800Ò, Dräger, Lübeck, Germany) was 
renewed before each experiment and the whole system was air dried 
between the experiments. The anaesthetic circuit was flushed with 
100% oxygen for 5 minutes before the experiment and afterwards 
filled with the desired inspiratory anaesthetic concentration of the 
specific volatile agent using a fresh gas flow of 2 l/min oxygen. The 
intubated dogs were connected to an anaesthetic circuit and 
anaesthesia was continued for 1 hour. No intravenous infusions were 
administered during the trial. 
 
Measurements and Monitoring 
A multi anaesthetic gas analyser (Capnomac UltimaÒ, Datex 
Engstrom Instrumentarium Corp., Helsinki, Finland) was calibrated 
(Quick Cal TM calibration gasÒ, Datex Engstrom Instrumentation 
Corp., Helsinki, Finland) before each experiment. Inspiratory oxygen 
fraction (FiO²), end-tidal anaesthetic agent percentage (AA %), end-
tidal carbon dioxide percentage (CO²ET %) and RR were recorded 
continuously (sampling of 200 ml/min at Y-piece, sample scavenged). 
The vaporizer settings were adjusted throughout the experiment to 
maintain an end-tidal anaesthetic concentration of 1.5 and 2 MAC of 
each specific volatile agent. The used MAC values throughout the 
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study were 2.36 vol% for Sevo, 1.39 for Iso and 0.89 for Halo (Steffey 
and Howland, 1977; Steffey and Howland, 1978; Kazama et al., 
1988). HR and peripheral haemoglobin saturation (SpO² %) were 
monitored continuously using a pulse oxymeter (N-20PA Nellcor 
Puritan BennettÒ, Pleasanton, California, USA) with the probe placed 
on the tongue. 
 
Non-invasive systolic and diastolic arterial blood pressures 
(SAP, DAP) were obtained after 15, 30 and 60 minutes of anaesthesia 
using a Doppler flow detector. The indirect blood pressures were 
obtained by placing a paediatric cuff above a Doppler device 
(Ultrasonic Doppler Flow Detector, Model 811-BÒ, Parks Medical 
Electronics, Inc., Aloha, Oregon U.S.A.) around the radial area of the 
foreleg of the dogs. 
 
A standardised neurologic stimulation test was performed 
during the anaesthesia in each anaesthetized dog. Briefly, motor 
evoked potentials were recorded from the extensor carpi radialis 
muscle of the forelimb after magnetic stimulation of the radial nerve, 
and from the cranial tibial muscle of the hindlimb after magnetic 
stimulation of the sciatic nerve. Reference values were established for 
onset latencies and peak-to-peak amplitudes of these potentials. After 
1 hour of anaesthesia the dogs were allowed to recover while 
breathing ambient air in a quiet room without stimulation. The time 
period between the disconnection of the circuit and the reappearance 
of the first eyelid reflex was recorded. Emergence time was defined as 
the time from end of anaesthesia to extubation without external 
stimulus. HR, RR, SAP and DAP were recorded immediately after 
extubation. 
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Statistical analysis 
Mean arterial blood pressure (MAP) was calculated using the 
following equation: MAP = 0.33 (SAP-DAP) + DAP (Trim, 1994). 
 
Continuous dependent variables, i.e. HR, RR, MAP, SAP and 
DAP were checked for normality and, if necessary, transformed in 
order to obtain a normal distribution. A loge-transformation was 
necessary for RR. Statistical evaluation was done with repeated 
measures ANOVA (PROC MIXED, SAS 6.12, SAS Institute Inc.). 
Time was considered a repeated measure, treatment and dose fixed 
effects, and dog a random effect nested within treatment and dose.  
 
Dependent variables expressing a fraction, i.e. FiO², end-tidal 
anaesthetic agent percentage, and SpO² %, were evaluated with 
repeated measures ANOVA (GLIMMIX Macro, SAS 6.12, SAS 
Institute Inc.), using the same model as described for continuous 
dependent variables.  
 
The effect of treatment and dose on the time to a positive 
eyelid reflex and a positive swallowing reflex following discontinuation 
of anaesthesia was analysed with ANOVA (PROC MIXED, SAS 6.12; 
SAS Institute Inc.). A p-value < 0.05 was considered significant. The 
results of the different recorded and calculated parameters are 
expressed as mean values ± standard deviation. 
 
RESULTS 
 
 The magnetic motor evoked potentials protocol had no effect 
on the different parameters investigated during the different 
anaesthetic protocols. HR did not change significantly over time for 
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each individual volatile agent. There were no significant differences in 
HR between the 2 anaesthetic concentrations of each agent and 
between the Sevo and Iso protocols. HR during 1.5 and 2 MAC Halo 
was significantly lower compared to similar Sevo and Iso protocols 
(table 1A and 1B).  
 
A significant decrease in RR over time was present in the 1.5 
MAC protocols, whereby large individual variations were observed. 
Although much lower and stable RR’s were present in the 2 MAC 
protocols, no significant differences were observed between the 
different agents at 1.5 and 2 MAC concentrations. Extubation induced 
a significant increase in RR in all protocols (table 1A and 1B). 
 
No specific differences were observed for DAP over time for 
each agent. DAP in 1.5 MAC protocols was significantly different from 
2 MAC protocols for all agents (p = 0.04). DAP of the 1.5 and 2 MAC 
Sevo was significantly lower than Halo (p = 0.01), but not significantly 
different from the Iso protocol. Extubation induced a significant 
increase in DAP in all protocols (table 1A and 1B). Although no 
specific differences were observed for SAP over time between the 
different agents and between the different anaesthetic concentrations, 
the lowest SAP was recorded at 2 MAC Sevo. Extubation induced a 
significant increase in SAP in all protocols (table 1A and 1B). No 
specific differences were present for calculated MAP over time of the 
different agents; the lowest MAP was recorded during Sevo 
anaesthesia. The MAP at 1.5 MAC was significantly higher than MAP 
in 2 MAC protocols for all agents. Extubation induced a significant 
increase in MAP in all protocols (table 1A and 1B).  
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 Table 1 a : Cardiorespiratory parameters measured in 6 mongrel dogs during and after 
 1.5 MAC isoflurane (Iso), sevoflurane (Sevo) and halothane (Halo) anaesthesia   
                                    
                                    
VARIABLE ANAEST.   1.5 MAC ANAESTHETIC CONCENTRATION       
  AGENT                  
    15' 30' 60' after extubation 
                           
            
  Iso 83.8 ± 27.4* 88.0 ± 19.1* 90.8 ± 14.4* 102.0 ± 23.8 * 
HR Sevo 88.0 ± 17.7* 88.8 ± 14.4* 101.0 ± 10.7* 95.5 ± 20.4 * 
Beats/min Halo 74.5 ± 30.3 68.8 ± 17.8 74.3 ± 18.4 102.3 ± 29.8   
                    
RR Iso 30.7 ± 33.6| 22.5 ± 25.3| 12.3 ± 8.9 | 27.5 ± 13.2   
Breaths/min Sevo 26.7 ± 31.8| 13.8 ± 15.0| 16.5 ± 21.6| 35.0 ± 42.3   
 Halo 26.7 ± 26.4| 19.8 ± 20.2| 15.7 ± 11.0| 26.7 ± 26.7   
                     
DAP Iso 61.3 ± 16.7| 62.7 ± 16.5| 62.5 ± 17.8| 92.7 ± 22.3   
Mm Hg Sevo 55.8 ± 10.4|,* 52.5 ± 11.6|,* 57.5 ± 11.5|,* 85.5 ± 15.3 * 
  Halo 62.0 ± 11.2 | 64.0 ± 13.6| 66.2 ± 13.7| 79.7 ± 11.3   
                     
SAP Iso 119.7 ± 23.1| 116.7 ± 20.1| 114.7 ± 25.2| 170.3 ± 25.6   
Mm Hg Sevo 110.0 ± 17.1| 106.7 ± 19.8| 109.0 ± 17.7| 157.0 ± 28.6   
  Halo 121.2 ± 23.6| 120.2 ± 22.9| 126.0 ± 20.7 | 155.3 ± 28.4   
                     
MAP Iso 80.5 ± 18.6| 80.3 ± 17.2| 79.7 ± 19.4| 118.2 ± 22.3   
Mm Hg Sevo 73.8 ± 11.9| 70.5 ± 13.6| 74.5 ± 12.8| 109.0 ± 19.2   
  Halo 81.5 ± 15.1| 82.3 ± 16.3| 85.7 ± 15.8| 104.5 ± 16.2   
                     
FiO ² Iso 0.90 ± 0.019 | 0.91 ± 0.015 | 0.91 ± 0.021 | No Data     
  Sevo 0.87 ± 0.055 |,* 0.88 ± 0.012 |,* 0.89 ± 0.012 |,*  As not applicable 
  Halo 0.90 ± 0.015 | 0.90 ± 0.012 | 0.90 ± 0.014 |      
                     
SpO ² Iso 96.3 ± 1.2  97.2 ± 2.2  97.0 ± 2.4       
%  Sevo 96.7 ± 1.6  97.2 ± 1.9  96.7 ± 1.2       
  Halo 96.7 ± 1.9  96.5 ± 2.5  97.3 ± 1.6       
                     
CO² ET Iso 4.7 ± 1.6* 5.6 ± 0.6*,° 5.9 ± 0.8*,°      
%  Sevo 4.8 ± 1.7* 6.1 ± 0.5*,° 6.2 ± 1.0*,°      
  Halo 4.1 ± 1.3  4.5 ± 0.8  4.6 ± 0.5       
                                    
                                    
 | significantly different from time after extubation P = 0.05           
 ° significantly different from time 15' P = 0.05              
 * significantly different from halothane P = 0.05             
 Data are expressed as mean ± SD               
 Abbreviations variables: see text               
                                    
 
 
 
CHAPTER 3 
 
 
 89
 Table 1 b : cardiorespiratory parameters measured in 6 mongrel dogs during and after 2 MAC       
 isoflurane (Iso), sevoflurane (Sevo) and halothane (Halo) anaesthesia         
                                    
                                    
VARIABLE ANAEST.    2 MAC ANAESTHETIC CONCENTRATION       
  AGENT                  
    15' 30' 60' after extubation 
                             
              
  Iso 87.3 ± 23.7 * 92.5 ± 15.8* 98.8 ± 11.4* 98.0 ± 28.6 * 
HR Sevo 91.3 ± 13.5 * 94.3 ± 6.7* 99.3 ± 12.2* 96.0 ± 21.5 * 
beats/min. Halo 70.0 ± 23.7  70.3 ± 15.2 79.0 ± 9.6  93.0 ± 18.8   
                     
RR Iso 11.7 ± 8.2 | 11.7 ± 7.3 | 8.2 ± 4.6 | 49.3 ± 28.7   
breaths/min. Sevo 7.5 ± 3.5 | 7.2 ± 4.0 | 6.2 ± 4.6 | 25.7 ± 5.4   
  Halo 12.8 ± 2.7 | 12.0 ± 3.6 | 12.8 ± 4.9 | 27.3 ± 8.5   
                     
DAP Iso 55.3 ± 12.6 #,| 49.2 ± 10.7#,| 52.7 ± 17.8#,| 78.5 ± 13.6 # 
mm Hg Sevo 46.0 ± 11.1 #,|,* 41.7 ± 12.4#,|,* 37.7 ± 12.8#,|,* 75.7 ± 7.6 # 
  Halo 60.3 ± 12.0 #,| 60.5 ± 14.8#,| 62.3 ± 14.4#,| 77.0 ± 22.5 # 
                     
SAP Iso 107.2 ± 21.6 | 98.3 ± 23.8| 103.3 ± 28.2| 155.8 ± 25.9   
mm Hg Sevo 92.5 ± 18.3 | 88.7 ± 26.7| 83.0 ± 24.1| 145.3 ± 17.4   
  Halo 114.5 ± 21.8 | 113.0 ± 26.4| 119.0 ± 26.3| 154.5 ± 44.9   
                     
MAP Iso 72.5 ± 15.2 #,| 65.8 ± 14.4#,| 69.3 ± 21.1#,| 103.8 ± 17.3 # 
mm Hg Sevo 61.3 ± 13.2 #,| 57.2 ± 16.9#,| 52.5 ± 16.4#,| 98.8 ± 8.4 # 
  Halo 78.3 ± 15.1 #,| 77.8 ± 18.1#,| 80.5 ± 18.3#,| 102.5 ± 28.6 # 
                     
FiO ² Iso 0.88 ± 0.012 | 0.88 ± 0.012 | 0.89 ± 0.012 | No Data    
  Sevo 0.90 ± 0.036 *,| 0.89 ± 0.028 *,| 0.89 ± 0.020 *,|   As not applicable 
  Halo 0.91 ± 0.016 | 0.91 ± 0.019 | 0.91 ± 0.024 |      
                     
SpO ² Iso 96.5 ± 2.0  95.2 ± 1.9  96.5 ± 1.9       
%  Sevo 90.8 ± 13.7  96.0 ± 2.7  97.2 ± 1.9       
  Halo 96.8 ± 1.2  96.8 ± 0.7  97.0 ± 1.5       
                     
CO² ET Iso 5.7 ± 0.8 * 6.0 ± 0.8*,° 6.6 ± 0.8*,°      
%  Sevo 6.2 ± 0.5 * 6.8 ± 0.4*,° 5.8 ± 2.9*,°      
  Halo 5.1 ± 0.8  5.2 ± 0.8  5.3 ± 0.8       
                                    
                                    
 # significantly different from 1.5 MAC P = 0.05             
 | significantly different from time after extubation P = 0.05           
 ° significantly different from time 15' p = 0.05              
 * significantly different from halothane P = 0.05             
 Data are expressed as mean ± SD               
 Abbreviations variables: see text               
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There were no significant changes in SpO² % during the 
anaesthesia period between the different anaesthetic agents and the 
different MAC protocols. FiO² during Sevo was significantly lower than 
during the halothane protocol (table 1A and 1B). CO²ET % was 
significantly lower during the Halo protocol compared to Sevo and Iso 
at both MAC values. At 15 minutes after induction CO²ET % was 
significantly lower compared to 30 and 60 minutes in the Iso and Sevo 
protocols (table 1A and 1B). 
 
The time recorded for the reappearance of the first eyelid 
reflex was not significantly different between all agents (table 2). Halo 
anaesthesia was characterized with longer recovery times at both 
anaesthetic concentrations, except for time to positive eyelid reflex at 
2 MAC; whereas Iso 1.5 MAC induced the shortest reappearance 
period of the eyelid reflex, but it was not statistically significant. A 
significant longer reappearance time (p = 0.04) was present in all 2 
MAC protocols (Sevo > Halo > Iso). 
 
                          
 Table 2 : recovery times in seconds (s) after 60 minutes anaesthesia using 1.5 and  
 2 MAC Isoflurane (Iso), sevoflurane (Sevo) and halothane (Halo) in 6 mongrel dogs 
                          
                          
VARIABLE ANAESTHETIC AGENT ANAESTHETIC CONCENTRATION 
                  
      1.5 MAC 2 MAC 
                          
                  
Time to first positive Iso 188.3 ± 63.9  237.0* ± 107.4   
Eyelid reflex (s) Sevo 201.8 ± 72.9  389.8* ± 281.0   
  Halo 241.5 ± 137.3  290.2* ± 196.1   
                
Time to extubation (s) Iso 682.2 ± 540.7  797.0 ± 482.9   
  Sevo 631.7 ± 479.7  946.0 ± 515.5   
  Halo 820.5 ± 462.0  1168.7 ± 319.9   
                          
* significantly different from 1.5 MAC (P = 0.05)                     
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Sevo 1.5 MAC induced a faster extubation time but not in the 
2 MAC protocol (table 2). At both MAC protocols the longest 
extubation time was after Halo anaesthesia; but this difference was 
not significant. Overall, no significant differences were calculated 
between the different agents and the different MAC protocols. 
 
DISCUSSION 
 
In experimental studies there are quite a lot of differences in 
cardio-respiratory parameters and emergence times between 
isoflurane, sevoflurane and halothane (Bernard et al., 1990; Merin et 
al., 1991; Pagel et al., 1991; Ebert et al., 1998). However clinically 
those differences are not always clear (Oliva et al., 2000; Tacke et al., 
2000). To simulate clinical anaesthesia, the dogs in this study were 
premedicated and induction was done with an intravenous anaesthetic 
agent. But premedication and induction certainly influence the cardio-
respiratory and recovery parameters. The dogs received a neurolept-
analgesic mixture, fentanyl and droperidol, as premedicant agent. 
Droperidol is a butyrophenone tranquilizer causing sedation with 
decreased motor activity and tranquilization similar to acepromazine 
(Thurmon et al., 1996). Furthermore it gives a high incidence of post-
operative sedation, which can influence the recovery profile 
(Bissonnette et al., 1999). Fentanyl is an opioid agonist with a short 
duration of action; the peak effect lasts less than 30 minutes. 
Droperidol has a long duration of action that extends beyond the 
analgesic effects of fentanyl (Moore and Dundee, 1961). The drug 
combination of droperidol and fentanyl induces an intense analgesic 
effect of relatively short duration. In dogs, this mixture produces 
sedation, analgesia, immobilization, respiratory depression and/or 
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panting, a1-adrenergic blockade, a decrease in blood pressure and 
bradycardia (Thurmon et al., 1996).  
 
In the present study anaesthesia was induced with propofol, a 
short acting induction agent, with rapid metabolisation (Shafer et al., 
1988). Since propofol has a fast redistribution from highly perfused 
tissues (e.g. brain) into less-well perfused tissues, plasma levels of 
propofol decline rapidly (Shafer, 1993). And because of its high 
metabolic clearance rate, which is approximately ten times faster than 
that of thiopentone, we can assume that the emergence time is 
minimally influenced by propofol (Shafer, 1993; Smith et al., 1994). 
For those reasons we chose propofol as induction agent. Oliva et al. 
(2000) compared sevoflurane with halothane recovery after propofol 
and thiopentone induction. Shorter extubation times after propofol 
induction with both inhalant anaesthetics were reported.  But induction 
technique will have progressively less influence on post-anaesthetic 
recovery as the duration of anaesthesia increases, mainly because 
the washout period of an anaesthetic agent is determined by the 
duration of anaesthesia and its oil/gas partition coefficient (Stoelting 
and Eger, 1969).  
 
Equipotent doses using minimum alveolar concentration 
multiples were used in this study to allow a comparison not only of the 
recovery time, but also of clinically useful non-invasively measured 
cardio-respiratory parameters in dogs. Monitoring is essential during 
clinical anaesthesia in dogs. We preferred non-invasive techniques 
including anaesthetic gas analysis, capnography, pulse oxymetry and 
non-invasive blood pressure measurements. Although the Doppler 
blood pressure technique is less accurate than invasive techniques, it 
is certainly acceptable under clinical circumstances (Stepien, 2000). 
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In the present study heart rate during halothane anaesthesia 
was significantly lower than during isoflurane and sevoflurane 
anaesthesia at both anaesthetic concentrations. There was no 
significant difference in heart rate between isoflurane and sevoflurane 
anaesthesia. In non-premedicated dogs sevoflurane induces a rise in 
heart rate from 1.2 MAC on (Bernard et al., 1990; Mutoh et al., 1997). 
Activation of the baroreceptor-reflex, induced by a decreased arterial 
blood pressure, was reported to be mainly responsible for this rise in 
heart rate. Isoflurane also gives an increased heart rate in non-
premedicated dogs (Merin et al., 1991). In contrast, halothane has 
little influence on heart rate in dogs (Pagel et al., 1991). These 
findings might be an indication for a less depressant effect to 
baroreceptor-reflex function with Sevo and Iso compared to Halo 
(Bernard et al., 1990; Pagel et al., 1991). 
 
All volatile anaesthetic agents cause a dose-related 
respiratory depression in dogs (Doi et al., 1986; Mutoh et al., 1997). 
This decrease in respiratory rate results in hypoventilation with 
increasing CO²ET %. The respiratory depression is also characterized 
by a decrease in tidal volume for all anaesthetic agents (Doi et al., 
1986; Mutoh et al., 1997). In our study respiration rate decreased in all 
anaesthetic protocols whereby 2 MAC induced a lower respiration rate 
compared to 1.5 MAC. However, there was a clear difference between 
the protocols; halothane anaesthesia was accompanied by higher 
respiration rates compared to isoflurane and sevoflurane. This finding 
was also reflected in a lower CO²ET % during halothane anaesthesia. 
It is also consistent with literature since halothane was reported to 
induce a smaller decrease in respiration rate (Mutoh et al., 1997). 
During the initial 15 minutes of anaesthesia at 1.5 MAC with all 
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agents, there was a large individual variation in respiration rate. This 
variation was probably due to the premedication with fentanyl-
droperidol, which can cause panting in dogs. This initial tachypnoea 
can be a problem for achieving a stable anaesthesia at a low 
anaesthetic concentration. Panting did not occur at 2 MAC, probably 
because a deeper anaesthetic stage was reached faster. 
 
Volatile anaesthetic agents induce a dose-related decrease in 
arterial blood pressure (Steffey and Howland, 1977; Frink et al., 
1992). This decrease in blood pressure is partly caused by a 
decreased peripheral vascular resistance and partly by a decrease in 
stroke volume (Malan et al., 1995; Lowe et al., 1996; Mutoh et al., 
1997). MAP and DAP at 1.5 MAC were significantly higher than MAP 
and DAP in 2 MAC protocols for all agents. SAP was also higher at 
1.5 MAC, but the difference was not significant. At both anaesthetic 
concentrations the MAP, SAP and DAP were lowest for sevoflurane. 
Only DAP from sevoflurane at both anaesthetic concentrations was 
significantly lower compared to DAP from isoflurane and halothane. 
This can be attributed to a decrease in peripheral vascular resistance 
as mentioned in literature (Mutoh et al., 1997). In contrast, the 
hypotension induced by halothane anaesthesia occurs mainly 
because of direct myocardial depression (Paddleford, 1999; Stowe et 
al., 1991). Oliva et al. (2000) found also a decrease in arterial blood 
pressure during sevoflurane anaesthesia compared to base line 
values. In our study blood pressure is lower during sevoflurane 
anaesthesia compared to halothane and isoflurane. Because of this 
greater decrease in arterial blood pressure with sevoflurane, heart 
rate in compensation was probably higher than during halothane 
anaesthesia, due to the baroreceptor-reflex (Pagel et al., 1991).  
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The FiO² during sevoflurane anaesthesia was significantly 
lower compared to halothane and isoflurane anaesthesia. This can 
easily be explained by the lower anaesthetic potency of sevoflurane. 
The MAC from sevoflurane 2.36 vol% is considerably higher than the 
MAC from halothane and isoflurane (resp. 0.89 and 1.39) (Steffey et 
al., 1977; Kazama et al., 1988). To reach the same anaesthetic depth 
a higher concentration of sevoflurane is necessary and the FiO² will 
be lower. SpO² % was constant during the anaesthesia period with all 
agents and with both MAC values. This could be expected considering 
the high, inspired oxygen fractions.  
 
Recovery from inhalation anaesthesia is underlies several 
influences. Anaesthetic recovery is mostly influenced by the blood/gas 
partition coefficient of the anaesthetic agent. A low blood/gas partition 
coefficient allows more rapid drug elimination and results in a shorter 
emergence time. The blood/gas partition coefficient of halothane and 
isoflurane in man is respectively 2.54 and 1.46. The blood/gas 
solubility of sevoflurane (0.68) is much lower and similar to that for 
nitrous oxide (0.47) (Strum and Eger, 1987; Steffey, 1996). This 
indicates that the anaesthetic recovery of sevoflurane would be more 
rapid than that with the other two inhalant anaesthetics. Based on 
blood/gas solubility the length of the emergence time would increase 
in this order: sevoflurane < isoflurane < halothane.  
 
Of minor importance is the oil/gas partition coefficient. It has 
an influence on potency and washout speed of volatile agents. The 
oil/gas partition coefficient is 47 for sevoflurane, 91 for isoflurane and 
224 for halothane (Steward et al., 1973; Wallin et al., 1975; Strum and 
Eger, 1987). The higher the oil/gas partition coefficient, the greater the 
potency of the anaesthetic agent. With a smaller oil/gas partition 
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coefficient, there is less transfer and storage of anaesthetic into the 
lipid tissue. The washout speed of the inhalation anaesthetic will be 
much higher in contrast with anaesthetics with a higher oil/gas 
partition coefficient (Steffey, 1996). 
 
Low metabolism can facilitate anaesthetic recovery but only in 
a limited way. The metabolisation percentages in man for halothane, 
isoflurane and sevoflurane are respectively 20-25%, 0.17% and 3% 
(Cascorbi et al., 1970; Holaday et al., 1975; Eger, 1994). The smaller 
the metabolisation percentage of an inhalation anaesthetic agent, the 
faster the anaesthetic recovery will be (Carpenter et al., 1987).  
 
Other factors such as alveolar ventilation, cardiac output and 
duration of anaesthesia have also an influence on recovery from 
inhalation anaesthesia (Stoelting and Eger, 1969; Carpenter et al., 
1987). Even the rebreathing circuit itself can reduce the rate of 
recovery, because at the end of anaesthesia it is still containing some 
anaesthetic agent in the rubber parts of the system. To prevent this 
negative influence on recovery times, we disconnected the patient 
from the anaesthetic system at the end of the anaesthesia period.  
  
Factors also influencing inhalation anaesthetic elimination 
from the body are percutaneous loss and intertissue diffusion of 
agents. However, these influences are of little clinical importance 
(Lockhart et al., 1991; Carpenter et al., 1987).  
 
Possible parameters for evaluation of anaesthesia recovery in 
dogs are eyelid and swallowing reflexes and, time to sternal 
recumbency. As was expected in our study the time for a first positive 
eyelid reflex was significantly shorter at the lower anaesthetic dosage 
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of the three anaesthetic agents. Surprisingly at both anaesthetic 
concentrations the time for a first positive eyelid reflex was the 
shortest with isoflurane. On the other hand at 1.5 MAC the time to a 
first positive eyelid reflex was longest for halothane and at 2 MAC it 
was longest for sevoflurane. But the differences between the three 
anaesthetic agents were not significant, since wide individual 
variations were present between individuals per anaesthetic agent. As 
mentioned above this is easily explained by the greater blood/gas and 
oil/gas solubility of halothane. The washout of anaesthetic from alveoli 
of more soluble anaesthetics is more gradually in time, than the 
washout from less soluble anaesthetics (Eger, 1992). For sevoflurane 
at 2 MAC the time for a first positive eyelid reflex was longer than for 
the other anaesthetic agents. This could be attributed to a decrease in 
cardiac output and a decrease in ventilation (Steffey, 1996). The 
respiration rate for sevoflurane at 2 MAC was the lowest and heart 
rate higher than with halothane. This higher heart rate might be 
attributed to the low arterial blood pressure and a low cardiac output 
at this stage of anaesthesia, and together with the low respiration rate 
this could explain why the time for a first positive eyelid reflex is 
longest for sevoflurane at 2 MAC. During halothane anaesthesia at 2 
MAC the respiration rate was higher and heart rate much lower, 
together with a higher arterial blood pressure than during sevoflurane 
anaesthesia. This can be an explanation for a shorter time to a 
positive eyelid reflex with halothane at 2 MAC, although the blood/ gas 
solubility of halothane is much higher than for sevoflurane. 
Furthermore, it is more difficult to show the kinetic advantages of less 
soluble anaesthetics, as sevoflurane, after anaesthetic exposures of 
less than 1 hour compared to anaesthetic exposures of more than 1 
hour (Eger and Johnson, 1987). After short-duration anaesthetic 
exposures a minimal difference in recovery will exist between any of 
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the volatile anaesthetics because there will be little time to saturate 
tissue groups. It also has been reported in rodents that the differences 
in times to recovery endpoints between anaesthetics are smaller when 
low concentrations of the anaesthetics are used (Eger and Johnson, 
1987). In addition there are the residual effects of droperidol and 
fentanyl, exerting an effect on cognitive functioning. This might nullify 
any kinetic advantage of the less-soluble anaesthetic sevoflurane over 
isoflurane and halothane. 
 
There were no statistically significant differences in 
emergence times between the 3 anaesthetic agents, although the 
emergence time was the longest for halothane at both anaesthetic 
concentrations. Like for the eyelid reflex this can be explained by the 
high blood/ gas and oil/gas solubility of halothane in combination with 
its higher metabolisation percentage (20-25%) (Cascorbi et al., 1970). 
At 1.5 MAC the emergence time was the shortest for sevoflurane, but 
at 2 MAC isoflurane had a shorter emergence time, although the 
difference was not significant and very small. In conclusion, clinically 
there is little difference in emergence times between halothane, 
isoflurane, and sevoflurane in premedicated dogs after 1 hour of 
inhalation anaesthesia. 
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SUMMARY 
 
The purpose of this study was to investigate the 
cardiopulmonary influences of sevoflurane (Sevo) in oxygen at 2 
anaesthetic concentrations (1.5 and 2 MAC) during spontaneous and 
controlled ventilation in dogs. After premedication with fentanyl-
droperidol (5 µg/kg and 0.25 mg/kg IM) and induction with propofol (6 
mg/kg IV) 6 dogs were anaesthetized for 3 hours. Three types of 
ventilation were compared: spontaneous ventilation (SpV), intermittent 
positive pressure ventilation (IPPV), and positive end expiratory 
pressure ventilation (PEEP, 5 cm H²O).  
 
Heart rate, haemoglobin oxygen saturation, arterial blood 
pressures, right atrial and pulmonary arterial pressure, pulmonary 
capillary wedge pressure and cardiac output were measured. End 
tidal CO² percentage, inspiratory oxygen fraction, respiration rate and 
tidal volume were recorded using a multi gas analyzer and a 
respirometer. Acid-base and blood gas analyses were performed. 
Cardiac index, stroke volume, stroke index, systemic and pulmonary 
vascular resistance, left and right ventricular stroke work index were 
calculated. 
 
Increasing the anaesthetic concentration during sevoflurane 
anaesthesia with spontaneous ventilation induced a marked 
cardiopulmonary depression; on the other hand, HR increased 
significantly, but the increases were clinically not relevant. 
 
The influences of artificial respiration on cardiopulmonary 
parameters during 1.5 MAC sevoflurane anaesthesia were minimal. In 
contrast, PEEP ventilation during 2 MAC concentration had more 
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pronounced negative influences, especially on right cardiac 
parameters. In conclusion, at 1.5 MAC, a surgical anaesthesia level, 
sevoflurane can be used safely in healthy dogs during spontaneous 
and controlled ventilation (IPPV and PEEP of 5 cm H²O). 
 
INTRODUCTION 
 
Sevoflurane (CFH²-O-CH(CF³)²) is a recently developed 
volatile anaesthetic agent currently used in human anaesthesia. 
Sevoflurane has a low blood-gas partition coefficient of 0.69 (Strum 
and Eger, 1987). This low blood-gas solubility contributes to a more 
rapid induction of, and emergence from anaesthesia compared to 
halothane, enflurane, and isoflurane (Smith et al., 1992; Lerman et al., 
1996; Aono et al., 1997; Ebert et al., 1998). The low blood-gas 
solubility also permits an easier control in anaesthetic depth. The 
minimum alveolar concentration (MAC) value of sevoflurane in dogs is 
2.36 % (Kazama and Ikeda, 1988). 
 
A lot of research has been performed in man, but only a 
limited number of reports on cardiopulmonary parameters during 
sevoflurane anaesthesia are available in small animals (Bernard et al., 
1990; Oliva et al., 2000; Tacke et al., 2000). Mutoh et al. (1997) 
reported the cardiopulmonary effects of sevoflurane, in comparison to 
halothane, enflurane, and isoflurane in adult unpremedicated dogs 
using mask induction. However, mask induction without premedication 
is seldom used under clinical circumstances. The principal goal of the 
present study was to evaluate the effects of spontaneous and 
controlled ventilation (IPPV and PEEP) on cardiopulmonary 
parameters in sevoflurane anaesthetized premedicated dogs. 
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MATERIALS AND METHODS 
 
Instrumentation and measurements 
The study was approved by the Ethical Committee of the 
Faculty of Veterinary Medicine, Ghent University (filenumber: 97/12). 
Six, ASA I male mongrel dogs weighing 29 ± 7.30 kg (mean ± 
standard deviation) from 3 to 7 years were used for the study. The 
dogs were vaccinated and dewormed at a regular base. Clinical 
examination and a blood analysis confirmed the health status of the 
animals before the study.  No specific medication altering anaesthetic 
or analgesic requirements were administered at least 1 month before 
the experiments.  
 
Food, but not water was withheld for 12 hours before each 
experiment. The dogs were premedicated 30 minutes before induction 
with fentanyl-droperidol IM (respectively 5 µg/kg and 0,25 mg/kg of 
body weight BWT) (ThalamonalÒ, Janssen-Cilag, Berchem, Belgium). 
Induction of anaesthesia was performed using propofol (6 mg/kg of 
BWT) (RapinovetÒ, Mallinckrodt Veterinary, Stockholm, Sweden) 
intravenously over 15-20 seconds. After loss of swallow reflex the 
dogs were orally intubated (endotracheal tube 9 to 12 mm ID, Rüsch, 
Germany).  
 
A circle system (TitusÒ, Dräger, Lübeck, Germany) with a 
precision out of circuit vaporiser (quick lock system) (Vapor 19,3Ò, 
Dräger, Lübeck, Germany) was used throughout the study. The soda 
lime (Dräger Sorb 800Ò, Dräger, Lübeck, Germany) was renewed 
before each experiment. The whole system was air dried between the 
experiments. The anaesthetic circuit was flushed with 100% oxygen 
for 5 minutes before the experiment and afterwards filled with 
sevoflurane 1.5 MAC (1.5 ´ 2.36 % (Kazama and Ikeda, 1988)) using 
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a fresh gas flow of 2 L/min oxygen. No intravenous infusions were 
administered during the trial. 
 
Monitoring included a calibrated (Quick CalÔ  Calibration Gas, 
Datex-Ohmeda Corp., Helsinki, Finland) multi anaesthetic gas 
analyser (Capnomac UltimaÒ, Datex Engstrom Instrumentation Corp., 
Helsinki, Finland) for determination of the following parameters: 
inspiratory anaesthetic agent concentration (FiAA %), inspiratory 
oxygen fraction (FiO²), end tidal CO² concentration (ET CO² %) and 
respiratory rate (RR). Samples were taken at the Y-part (Straight 
Adapter®, Datex-Engstrom Instrumentarium Corp., Helsinki, Finland) 
with a rate of 200 mL/min and were scavenged. Tidal volume (TV) 
was monitored with a respirometer (VolumeterÒ, Dräger, Lübeck, 
Germany). TV and RR were adjusted if necessary during the 
experiment to keep a normal PaCO2 level between 35 and 45 mm Hg 
(Hartsfield, 1996). The vaporizer settings were adjusted throughout 
the experiment to maintain an end-tidal anaesthetic concentration of 
1.5 and 2 MAC sevoflurane by monitoring the inspiratory sevoflurane 
concentration. Heart rate (HR) and peripheral haemoglobin saturation 
(SpO²%) were monitored continuously using a pulse oximeter (N-
20PA Portable Pulse OximeterÒ, Nellcor Puritan Bennett Inc., 
Pleasanton, CA, U.S.A.) with the probe placed on the tongue. 
 
During the first hour of anaesthesia the dogs were instrumented 
for the experiment. A thermodilution catheter (Swan-GanzÒ catheter, 
7.5 french, American Edwards Laboratories, Santa Ana, U.S.A.) was 
placed in the left jugular vein of the dog through an introducer 
(Percutaneous Sheath Introducer SetÒ, Arrow, Reading, U.S.A.). The 
thermodilution catheter was advanced into the pulmonary artery using 
the characteristic pressure waveforms on the display of the pressure 
monitor (Hellige Servomed SMV 104Ò, Germany). The proximal port 
of the thermodilution catheter was positioned in the right atrium. The 
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distal port and thermistor were positioned in the pulmonary artery in a 
way that by inflating the balloon of the catheter wedge position was 
achieved. Mean (MPAP), systolic (SPAP), diastolic (DPAP) pulmonary 
artery pressure, right atrial pressure (RAP) and pulmonary capillary 
wedge pressure (PCWP) were measured by connecting the 
thermodilution catheter to the pressure transducer (Monitoring-setÒ, 
Vascumed N.V., Ghent, Belgium) using an extension tube 
(LectrocathÒ, 150 cm, cap. 1.60 mL, Vygon, Ecouen, France) filled 
with heparinised saline (5 I.U. heparin per ml). The pressure 
transducer was placed at the level of the heart of the dog.  
 
The thermodilution catheter was connected to the cardiac ouput 
computer (COM-1Ò, American Edwards Laboratories, Santa Ana, 
U.S.A.) and a closed injectate delivery system (CO-setÒ+, Model 93-
610, Baxter Healthcare Corporation, Edwards Critical –Care Division, 
Irvine, U.S.A.). Several cardiac output (CO) determinations were 
performed using 5 ml of a saline 0.9% solution at room temperature 
injected into the right atrium. The mean value from three results close 
to each other was used as actual value. Blood temperature of the dog 
and injection temperature of the saline solution were measured using 
the cardiac output computer. 
  
A catheter (VasocanÒBraunüle, 22 gauge, B.Braun, 
Melsungen, Germany) was surgically placed into the right femoral 
artery. The catheter was connected to the pressure transducer 
(Monitoring-setÒ, Vascumed N.V., Ghent, Belgium) by means of 
extension tubing filled with heparinised saline. The pressure 
transducer was placed at the level of the heart of the dog. The mean 
(MAP), systolic (SAP) and diastolic arterial blood pressure (DAP) were 
measured using a calibrated blood pressure monitor (Hellige 
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Servomed SMV 104Ò, Germany). Arterial blood was collected in 
heparinized 2 ml syringes and stored on ice for measurement of blood 
gas tensions and acid-base balance (PCV, pH, pCO², pO², plasma 
bicarbonate concentration (HCO³-), and standard base excess (SBE)) 
with a blood gas analyzer calibrated at 37°C (ABL5Ò, Radiometer 
Copenhagen, Denmark).  
 
Experimental Design 
The dogs were anaesthetised during the instrumentation 
period at a concentration of 1.5 MAC sevoflurane breathing 
spontaneously (SpV) before the first measurements were done. These 
measurements were used as baseline values. Afterwards the 
concentration of sevoflurane was increased to 2 MAC and a 
stabilisation period of 20 minutes was respected before the next 
measurements. Then the dogs were ventilated using IPPV (Ventilog 3, 
Dräger, Lübeck, Germany), the anaesthetic concentration was 
reduced back to 1.5 MAC and afterwards increased to 2 MAC. 
Between each alteration in anaesthetic concentration or ventilation 
pattern, 20 minutes of stabilisation time was respected before new 
measurements were done. At the end the dogs were ventilated with a 
PEEP of 5 cm H²O and a concentration of 1.5 MAC and 2 MAC. Again 
20 minutes of stabilisation time was respected before each 
measurement. The entire experimental protocol was finished after 180 
minutes (Table1).  
 
After the experiment, catheters were removed and 
postoperative analgesia (buprenorphine 10 µg/kg IM q 6h 
(TemgesicÒ, Schering-Plough, Hull, England) was administered 
before transferring the dogs to the recovery room. The dogs received 
amoxycillin clavulanate (8.75 mg/kg/day SC, SynuloxÒReady-To-Use, 
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Pfizer Animal Health) during 5 days to prevent wound infection. 
Anaesthesia and recovery were uneventful.   
 
      
 Table 1: Time Schedule.   
      
      
TIME SEVO CONCENTRATION ACTION 
(minutes) VENTILATION PATTERN   
      
      
T0 1.5 MAC SpV induction  
      
    instrumentation 
      
T60   measurement 1 
      
      
  2 MAC SpV   
      
T80   measurement 2 
      
      
  1.5 MAC IPPV   
      
T100   measurement 3 
      
      
  2 MAC IPPV   
      
T120   measurement 4 
      
      
  1.5 MAC PEEP   
      
T140   measurement 5 
      
      
  2 MAC PEEP   
      
T160   measurement 6 
      
 
 
 
 
 
Calculations 
Calculated values were determined as follows: (Gross et al., 1990) 
Body surface area (BSA; m²) 
 BSA = Body Weight (g) ²/³ x 10.1 
   104 
 
CHAPTER 4 
 
 
 112
   Cardiac index (CI; L/min/m²) 
  CI = CO 
          BSA 
  
Stroke volume (SV; mL/beat) 
  SV = CO x 1000 
            HR 
 Stroke index (SI; mL/beat/m²) 
  SI = SV 
          BSA 
  
Systemic vascular resistance (SVR; dynes.sec/cm5) 
  SVR = MAP – RAP x 80 
          CO 
 Pulmonary vascular resistance (PVR; dynes.sec/ cm5) 
  PVR = MPAP – PCWP x 80 
             CO 
Left ventricular stroke work index (LVSWI; g.m/m²) 
  LVSWI = 1.36 (MAP – PCWP) x SI 
           100 
 Right ventricular stroke work index (RVSWI; g.m/m²) 
  RVSWI = 1.36 (MPAP – RAP) x SI 
         100  
 
Statistical analysis 
The results of the different recorded parameters are 
expressed as mean ± standard deviation. Statistical analysis for each 
parameter was done with repeated measures analysis of variance. 
Continuous dependent variables were analysed with Proc Mixed (SAS 
v8, SAS Institute Inc., SAS Campus Drive, Cary, NC, USA). 
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Dependent variables expressing a proportion were analysed with 
Glimmix Macro (SAS v8) using a logit link function and a binomial 
error term. Time (i.e. treatment) was considered a repeated measure, 
and dogs a random effect. An autoregressive covariance structure of 
order 1 was included in the analyses to take correlations between 
measurements at different time point intervals into account. 
 
RESULTS    
   
  Cardiovascular effects induced by SpV and CV (IPPV and 
PEEP) in 1.5 and 2 MAC sevoflurane anaesthesia: 
 
At 1.5 MAC HR increased significantly during IPPV and PEEP 
compared to SpV (p = 0.01 and p = 0.004). The increase during CV 
was non-significant at 2 MAC. The HR during SpV at 2 MAC was 
significantly higher compared to 1.5 MAC (p = 0.01). (Fig.1). 
 
   
 Fig. 1.  The influences  of  SpV  and  CV on  HR,  MAP,  CI  and  SI  in     
                       Sevoflurane and  2  MAC)  anaesthetized  dogs.    significantly     
                                 different  from  1.5 MAC  significantly different from SpV.     
                      Values are expressed as mean ± standard deviation 
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MAP, SAP, and DAP increased significantly during the IPPV 
1.5 MAC Sevo protocol compared to SpV (p = 0.01). On the other 
hand, 2 MAC IPPV and PEEP induced a non-significant decrease of 
these parameters. Blood pressures were significantly lower at 2 MAC 
Sevo CV compared to 1.5 MAC Sevo (p = 0.0001) (Fig.1). 
 
In the 1.5 MAC protocol only RAP during IPPV was 
significantly lower compared to PEEP (p = 0.02). RAP during 2 MAC 
PEEP was significantly higher than SpV and IPPV (p = 0.05 and p = 
0.03). RAP of 2 MAC CV was significantly higher compared to 1.5 
MAC.  
 
MPAP in the 1.5 MAC protocol increased significantly during 
IPPV and PEEP compared to SpV (IPPV was also significantly 
different from PEEP) (p = 0.001). The MPAP of 2 MAC Sevo also 
increased during CV; but the differences were only significant for 
PEEP compared to SpV and IPPV (p = 0.001). The MPAP of the 1.5 
MAC SpV was significantly lower than 2 MAC (p = 0.02). SPAP and 
DPAP during 1.5 MAC increased when CV was applied; PEEP was 
significantly different from SpV for both parameters (p = 0.01) and 
from IPPV for DPAP (p = 0.01). The increase of SPAP and DPAP was 
non-significant in the 2 MAC protocol. 2 MAC during SpV induced a 
significant increase in SPAP and DPAP compared to 1.5 MAC (p = 
0.04).  
 
At 1.5 MAC PCWP increased significantly during CV, this 
increase was significant during PEEP compared to SpV (p = 0.007) 
and for PEEP compared to IPPV (p = 0.007). At 2 MAC only the 
increase in PCWP during PEEP compared to IPPV was significant (p 
= 0.02). 2 MAC during SpV and IPPV induced a significant increase in 
PCWP compared to 1.5 MAC (p = 0.0009 and p = 0.03). 
 
CHAPTER 4 
 
 
 115
   
 Fig. 2 : The influences of  SpV and CV on LVSWI, RVSWI, SVR and PVR  
              in sevoflurane (1.5 and  2  MAC)  anaesthetized  dogs.        
              significantly  different  from  1.5 MAC ;   significantly different    
              from SpV. Values are expressed as mean ± standard deviation 
 
  
  
 
CV induced no significant changes in CO and CI, SV, SI and 
LVSWI in both MAC protocols. 2 MAC anaesthesia induced signicant 
lower values compared to 1.5 MAC for these parameters. (Fig. 1 and 
2). CV induced a non-significant rise in RVSWI and SVR during the 
1.5 MAC protocol. On the contrary at 2 MAC there was a slight 
decrease in RVSWI and SVR during CV compared to SpV. During 2 
MAC CV there was a significant decrease in RVSWI and SVR 
compared to 1.5 MAC (p = 0.006). (Fig. 2). CV induced a non-
significant increase in PVR in both MAC protocols; only PEEP was 
significantly different from SpV (p = 0.04). (Fig. 2). 
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  Table 2 : Influences of SpV and CV on cardiovascular parameters in sevoflurane  
                  (1.5 and 2 MAC) anaesthetized dogs.       
                                
VAR VENT  SEVO CONCENTRATION VAR VENT  SEVO CONCENTRATION 
    1,5 MAC 2 MAC     1,5 MAC 2 MAC 
                            
HR  SpV 102 ± 14 113 ± 10.8 * CO  SpV 2.5 ± 0.6 2.2 ± 0.5 * 
beats IPPV 114 ± 10.8 ° 116 ± 11.6  L/min IPPV 2.5 ± 0.7 2 ± 0.5 * 
per min. PEEP 119 ± 14.1 ° 121 ± 14.5    PEEP 2.5 ± 0.7 1.9 ± 0.7 * 
                            
MAP  SpV 65 ± 8.1 59 ± 15.6  CI SpV 2.62 ± 0.43 2.31 ± 0.38 * 
mm Hg IPPV 79 ± 11.2 ° 55 ± 11.7 * L/min/m² IPPV 2.64 ± 0.5 2.18 ± 0.51 * 
  PEEP 73 ± 9.5 49 ± 13.7*   PEEP 2.67 ± 0.59 2.02 ± 0.62 * 
                            
SAP  SpV 92 ± 11 84 ± 19.5  SV SpV 24.91 ± 7.83 19.69 ± 6.22 * 
mm Hg IPPV 112 ± 18 ° 78 ± 21.6 * mL/beat IPPV 22.24 ± 7.01 17.72 ± 5.23 * 
  PEEP 99 ± 23 70 ± 25.5 *   PEEP 21.46 ± 7.12 16.07 ± 6.06 * 
                            
DAP  SpV 54 ± 7.5 50 ± 12.8  SI SpV 26.28 ± 5.93 20.86 ± 5.4 * 
mm Hg IPPV 66 ± 10.9 ° 44 ± 10 * mL/beat/m² IPPV 23.59 ± 6.04 18.97 ± 4.71 * 
  PEEP 59 ± 10 42 ± 10.3 *   PEEP 22.79 ± 6.28 16.94 ± 4.95 * 
                            
RAP  SpV 5.8 ± 3.4 6 ± 3.3 | LVSWI SpV 20.46 ± 5.23 14.39 ± 6.05 * 
mm Hg IPPV 5.2 ± 3.5 | 6.3 ± 3.7 *| g*m/m² IPPV 23.09 ± 7.68 12.31 ± 5.07 * 
  PEEP 6.5 ± 3.2 7.5 ± 3.6 *   PEEP 19.89 ± 7.22 9.24 ± 5.29 * 
                            
MPAP  SpV 11.3 ± 3.4 13 ± 4 * RVSWI SpV 2.03 ± 0.79 1.89 ± 0.93 
mm Hg IPPV 13.2 ± 4 °| 13 ± 4.1 | g*m/m² IPPV 2.67 ± 1.15 1.8 ± 0.68 * 
  PEEP 15.3 ± 3.3 ° 15 ± 3.1°   PEEP 2.79 ± 0.99 1.81 ± 0.65 * 
                            
SPAP  SpV 18 ± 4.1 20 ± 5.2 * SVR SpV 2015.7  ± 571.2  2022.8  ± 625.23 
mm Hg IPPV 20.5 ± 3.9 20 ± 4.5 | dynes*sec/cm5 IPPV 2511.3  ± 746 1948.6  ± 411.63* 
  PEEP 22.7 ± 2.8 ° 23 ± 5.1   PEEP 2243.4  ± 599.7  1807.7  ± 524.49* 
                            
DPAP  SpV 5.8 ± 3.5 7.5 ± 3.8 * PVR SpV 125.42 ± 47.58 121.2  ± 43.03 
mm Hg IPPV 6.7 ± 3.3 | 7.5 ± 4 dynes*sec/cm5 IPPV 162.23 ± 40.2  154.1  ± 36.48 
  PEEP 9.5 ± 4.9 ° 9.5 ± 5   PEEP 171.49 ± 45.08° 216.67 ± 124.45° 
                            
PCWP  SpV 7.7 ± 3.7 9.3 ± 4.3 *               
mm Hg IPPV 8.3 ± 4.2 | 9.3 ± 3.5 *|               
  PEEP 10.2 ± 3.1 ° 11 ± 4               
                                
                                
  Data are expressed as mean ± standard deviation         
  * significantly different from 1,5 MAC p = 0,05          
  | significantly different from PEEP p = 0,05          
  ° significantly different from SpV p = 0,05           
   Abbreviations of variables: see text            
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Effects of SpV and CV (IPPV and PEEP) on blood gas 
variables and respiratory parameters in 1.5 and 2 MAC sevoflurane 
anaesthesia: 
 
The 1.5 MAC CV protocol induced a decrease in PaCO² 
compared to SpV, this decrease was only significant for IPPV 
compared to SpV (p = 0.05). At 2 MAC there was also a decline in 
PaCO² during CV, this decrease was significant for IPPV and PEEP 
compared to SpV (resp. p = 0.0004 and p = 0.01). PaCO² during SpV 
was significantly higher at 2 MAC sevoflurane compared to 1.5 MAC 
(p = 0.01). There was no significant difference in PaO² at any 
anaesthesia stage.  
 
There was a significant rise in pH during CV compared to SpV 
(p = 0.003), only the rise during PEEP compared to SpV at 1.5 MAC 
was not significant. pH was significantly lower at 2 MAC compared to 
1.5 MAC anaesthetic concentration during SpV (p = 0.009). SBC 
increased significantly during IPPV and PEEP compared to SpV at 2 
MAC (resp. p = 0.04 and p = 0.03). There was no significant 
difference in PCV at any anaesthesia stage. There were significant 
but small changes in blood temperature during 2 MAC compared to 
1.5 MAC (p = 0.0002). 
 
The inspiratory pressure increased significantly during CV 
compared to SpV at both anaesthetic concentrations (p = 0.0001) and 
there was also a significant increase in inspiratory pressure during 
PEEP compared to IPPV (p = 0.0001). TV remained constant in all 
anaesthesia stages, but with large individual variations. There was no 
significant difference in RR between the 3 different types of 
ventilation, but RR was significantly lower at 2 MAC compared to 1,5 
MAC during SpV (p = 0.02). ETCO²% decreased significantly during 
CV compared to SpV at both MAC protocols. The 2 MAC SpV 
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protocol induced a significant increase in ETCO²% compared to 1.5 
MAC (p = 0.004). 
 
Table 3: Influences of SpV and CV on pH, blood gas analysis and respiratory 
parameters in sevoflurane anaesthetized dogs.                                              .      
      
VARIABLE VENT SEVOFLURANE CONCENTRATION 
  1.5 MAC 2 MAC 
BLOODTEMP.  SpV 38.7 ± 0.5 38.8 ± 0.4 * 
(°C) IPPV 38.8 ± 0.4 | 38.9 ± 0.4 * | 
  PEEP 39 ± 0.5 ° 39.1 ± 0.5 * ° 
PCV SpV 35 ± 8.9 36 ± 8.4 
  IPPV 35 ± 7.5 34 ± 9.5 
  PEEP 36 ± 10.6 36 ± 9.8 
pH SpV 7.255 ± 0.06 7.212 ± 0.08 * 
  IPPV 7.312 ± 0.03 ° 7.303 ± 0.02 ° 
  PEEP 7.295 ± 0.02 7.287 ± 0.03 ° 
PaCO2  SpV 47 ± 9.9 56 ± 15.6 * 
(mm Hg) IPPV 40 ± 4.6 ° 40 ± 2.4 ° 
  PEEP 43 ± 1.5 44 ± 3.5 ° 
PaO2  SpV 530 ± 28.5 513 ± 62.1 
(mm Hg) IPPV 551 ± 28.1 539 ± 22.5 
  PEEP 480 ± 109.3 547 ± 15.1 
RR  SpV 14 ± 14.3 9 ± 6.6 * 
(breaths/min.) IPPV 16 ± 3.6 14 ± 2.9 
  PEEP 14 ± 1.9 15 ± 1.9 
TV  SpV 451 ± 230.7 453 ± 181.5 
(ml) IPPV 402 ± 116.9 402 ± 91.1 
  PEEP 420 ± 116.9 390 ± 105.2 
Pinsp.  SpV -0.3 ± 0.8 0 ± 1.3 
(mm Hg) IPPV 9 ± 1°| 10 ± 1.4 °| 
  PEEP 14 ± 2.3 ° 13 ± 2 ° 
CO2 % ET SpV 6.3 ± 1.2 7.5 ± 1.8 * 
  IPPV 5.3 ± 0.3 ° 5.4 ± 0.6 ° 
  PEEP 5.6 ± 0.6° 5.6 ± 0.8 ° 
SBC SpV 18.83 ± 1.47 18.5 ± 1.76 
(mEq/ l) IPPV 19.8 ± 1.17 19.8 ± 1.17 ° 
  PEEP 20 ± 0.63 20 ± 0.89 ° 
  Data are expressed as mean ± standard deviation     
  * significantly different from 1, 5 MAC (p = 0,05)      
  ° significantly different from SpV (p = 0,05)       
  | significantly different from PEEP (p = 0,05)       
  Abbreviations of variables: see text        
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DISCUSSION 
 
Sevoflurane is a recently developed inhalational anaesthetic 
agent, which is presently very popular in human anaesthesia (Eger, 
1994; Young and Apfelbaum, 1995). Until now, few studies with 
sevoflurane in dogs under clinical anaesthesia circumstances are 
available (Oliva et al., 2000; Tacke et al., 2000). The cardiopulmonary 
influences of sevoflurane in experimental dogs were already reported 
but the design of these studies included no premedication but a mask 
induction (Bernard et al., 1990; Mutoh et al., 1997).  The present study 
was performed to investigate the cardiopulmonary effects in 1.5 and 2 
MAC sevoflurane anaesthetized dogs using a clinical protocol 
including standard premedication and induction. Moreover, the 
influences of different modes of controlled ventilation (IPPV and 
PEEP) were compared with the spontaneous breathing pattern.  
 
Spontaneous ventilation (SpV) is mostly used during clinical 
anaesthesia in dogs. However, this mode of breathing is often 
accompanied with hypoventilation. A moderate increase in PaCO² has 
certainly beneficial effects on the occurring cardiovascular depression, 
whereby the increased PaCO² is a potential stimulator of the 
sympathetic nerve system (Cullen and Eger, 1974). Artificial 
respiration (AR) overcomes the occurring hypoventilation. AR is also 
required when intrathoracic surgery is necessary or the patient is 
curarized.  
 
Inhalation anaesthetics including sevoflurane induce a dose-
dependent cardiopulmonary depression in all animals (Aida et al., 
1996; Bernard et al., 1992; Grosenbaugh and Muir, 1998). The MAC 
of sevoflurane in dogs has been established to be 2.36 volume  % 
(Kazama and Ikeda, 1988). One and a half MAC is generally accepted 
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as the standard to allow most surgical interventions. However, some 
cases require a higher MAC when no supplementary analgesics or 
related drugs are administered during anaesthesia. 
 
Basically, sevoflurane produces a dose dependent 
cardiopulmonary depression with systemic hypotension what is partly 
explained by an occuring peripheral vasodilatation. The influences of 
sevoflurane without premedication on the cardiopulmonary 
parameters were already intensively studied, whereby different MAC 
values were compared with the awake status in experimental dogs 
(Bernard et al., 1990; Frink et al., 1992; Harkin et al., 1994; Mutoh et 
al., 1997). In the present study only the changes induced by an 
increase in MAC were investigated. Fentanyl and propofol are 
relatively fast acting and short lasting agents. Interactions of these 
drugs after the instrumentation period of one hour with the sevoflurane 
protocol in the present study were not expected. On the other hand, 
although these drugs have a short half-life, it could not be excluded 
that their interfering effects were of longer duration. Droperidol has 
relatively long lasting effects. A possible influence of droperidol can 
therefore not be ruled out (Bissonnette et al., 1999). A fluid rate of 4 to 
8 ml/ kg/ hour is generally accepted for the maintenance of a stable 
water balance during anaesthesia (Giesecke and Egberth, 1985). No 
fluids were administered in the present study. Nevertheless, the 
thermodilution method includes the administration of different boli of 
saline. Overall, an estimated quantity of 2 to 4 ml/ kg/ hour was 
administered during the whole experimental period. The influences of 
this relatively low fluid administration in this study can probably be 
neglected. 
 
Two papers reported the cardiopulmonary influences of 
sevoflurane when increasing the MAC in spontaneous breathing dogs 
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(Harkin et al., 1994; Mutoh et al., 1997). Overall, the cardiopulmonary 
depression was characterized with non-significant decreases in 
cardiac output and index, stroke volume and index and pressure work 
index and a significant decrease in left ventricular stroke pressure. 
The decrease in mean and systolic arterial blood pressure only 
changed significantly in the study of Mutoh et al. (1997). All these 
findings were similar in the present study, although significant 
changes were observed or calculated mainly in the pulmonary 
pressures, the cardiac output and stroke volume and the LVSWI. 
Surprisingly, a significant increase in HR was also observed in the 
present study. This is in contrast to the literature, where a constant or 
a slight decrease in HR was reported (Harkin et al., 1994; Mutoh et 
al., 1997). The reason for this is not clear. Although the observed 
increase in HR was not very high, it was obvious and constant (about 
10 %) in all dogs. Most likely the increased HR might be related to 
different factors. First of all, Mutoh et al. (1997) reported that 
sevoflurane in dogs induced a stimulation of the baroreceptor-reflex 
due to a dose dependent decrease in blood pressure. Secondly, the 
increase in PaCO² in men resulted in a sympathic stimulation (Cullen 
and Eger, 1974). Both factors might explain the observed slight, but 
significant increase in HR.  
  
In our study significant decreases in SI, CI, and LVSWI with 
an increasing MAC value were seen. The decrease in SV and SI 
could be related to a decreased preload, an increased afterload, a 
decreased contractility or a combination of those (Suga et al., 1985). 
PCWP and SVR can be used as measures for preload and afterload, 
respectively (Muir and Mason, 1996; Suga et al., 1985). In the present 
study PCWP increased significantly, while the SVR remained 
constant. Mutoh et al. (1997) only found non-significant increases in 
RAP and PCWP, while PAP and SVR remained constant by 
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increasing the sevoflurane MAC. Thus, decreased contractility is the 
most obvious explanation for the depression of cardial function by 
increasing the MAC value. A reduced myocardial contractility is often 
compensated by an increase in end diastolic pressure (Kittleson, 
1988). This phenomenon most likely occurred in the present study 
since PCWP and PAP’s which are good reflections of the end diastolic 
pressure, increased (Brutsaert et al., 1985). PVR and RVSWI reflect 
the right ventricular afterload (Kaplan, 1986). Little changes occurred 
in the spontaneous breathing dogs by increasing the sevoflurane 
concentration.     
 
Cardiopulmonary influences of sevoflurane were investigated 
in chronically instrumented dogs ventilated with IPPV (Bernard et al., 
1990; Frink et al., 1992).  Several MAC multiples (1.2, 1.5 and 2 MAC) 
were compared with the awake values in these studies. Bernard et al. 
(1990) reported significant decreases in CO, arterial pressures and 
SV by increasing the MAC from 1.2 to 2 MAC. The systemic vascular 
resistance remained constant. The same trend was noticed by Frink et 
al. (1992) when increasing the MAC from 1.5 to 2 MAC; although no 
significancy was observed. This is in agreement with the findings in 
the present study. An increase in MAC from 1.5 to 2 MAC in IPPV 
ventilated dogs induced a severe cardiopulmonary depression. 
Arterial pressures were significantly lower during the high MAC 
protocol. This decrease was more pronounced compared to the same 
MAC protocol in spontaneously ventilated dogs.  The CO, CI, SV, SI, 
LVSWI and RVSWI decreased significantly. These observed 
decreases were more accentuated but not significantly different from 
the spontaneously breathing dogs. Right cardiac pressures increased 
also with increasing anaesthetic concentration; although only the RAP 
and PCWP were significantly different in the IPPV protocol.  
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Changing from SpV to IPPV using 1.5 MAC in our study 
surprisingly induced a small increase of arterial blood pressures and 
HR. In the same low MAC protocol little to no influences on the other 
cardiac parameters were observed by using IPPV. Data concerning 
the influences of AR on arterial blood pressure and vascular 
resistance in animals are conflicting. In horses a severe impact on the 
cardiopulmonary system using IPPV was reported (Aida et al., 1996). 
However, experiments in rats demonstrated a significant rise in 
arterial blood pressure and systemic vascular resistance when 
artificial respiration was applied (Sellden et al., 1986). Apparently, the 
influences of IPPV in smaller body weights were almost non-existing 
whereby a clear reason for our findings were not obvious. The same 
tendency was observed when changing from IPPV to PEEP 
ventilation. Right cardiac pressures increased when changing from 
SpV to IPPV at 1.5 MAC sevoflurane; but only the increase in MPAP 
was significant. During PEEP ventilation at 1.5 MAC the increases in 
right cardiac pressures were even more pronounced and only the 
increase in RAP was not significant. Overall, the existing 
cardiopulmonary depression was only slightly influenced by the 
different pressure ventilation patterns in the 1.5 MAC protocols.  
 
The situation changed completely when MAC was increased 
from 1.5 to 2. Artificial respiration with 2 MAC induced a severe impact 
on the arterial pressures and most of the cardiac related parameters. 
CO, CI, SV, SI, LVSWI and RVSWI decreased significantly. PEEP 
induced a more pronounced negative impact than IPPV, but the 
difference between both ventilation patterns was not significant. The 
right cardiac pressures increased while the arterial pressures were 
clearly lowered. These findings were according to those reported in 
the literature (Cassidy et al., 1978; Pinsky, 1990; Smiseth et al., 
1996). The main patho-physiologic mechanism for these 
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cardiovascular side effects of PEEP is a decreased venous return due 
to the increased intrathoracic pressure (Versprille, 1990) and a 
decreased coronary blood flow inversely related with the PEEP level 
(Jacobs and Venus, 1983). We did not find significant differences in 
CO, CI, SV, SI, LVSWI and RVSWI between IPPV and PEEP in this 
study. 
  
In the present study, pulmonary vascular resistance increased 
during AR compared to spontaneous ventilation at both anaesthetic 
concentrations, the difference was only significant for the PEEP 
ventilation mode. On the contrary, systemic vascular resistance 
decreased when changing from spontaneous to controlled ventilation 
at 2 MAC. Apparently, the reported vasodilating properties of 
sevoflurane were more pronounced at the higher anaesthetic 
concentration when combined with artificial breathing. An analogue 
slight influence was reported in men using 3 cm H²O PEEP; a steeper 
fall was observed when PEEP was increased to 10 cm H²O. 
Increasing PEEP above 10 cm H²O had only minor effects (Schreuder 
et al., 1982). The same tendancy was observed in dogs under 
controlled ventilation whereby a stepwise increase in PEEP induced a 
proportional decrease in CO (Sykes et al., 1970; Scharf et al., 1977). 
In the present study AR was applied during a relatively short period of 
20 minutes. The influence on the cardiopulmonary parameters was 
also reported to be proportionally depending on the length of the 
period in which positive pressure was applied (Shawley, 1987). 
Therefore, to lessen cardiovascular compromise, the amount of time 
either inspiratory or expiratory pressure is applied must be minimized. 
It could have been possible that significant changes occurred if the 
length of the observation period was enlarged. 
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Arterial carbon dioxide pressure is the most frequently used 
index of respiratory system response to general anaesthetics. All 
contemporary inhalation anaesthetics depress alveolar ventilation and 
as a consequence increase PaCO² in a dose-related fashion (Green, 
1995). Sevoflurane is a more potent ventilatory depressant than 
halothane (Green, 1995), and the characteristics of the ventilatory 
depression associated with sevoflurane are similar to that of isoflurane 
(Fourcade et al., 1971). As expected, in our study a significant rise in 
PaCO² and CO²ET % occurred when increasing Sevo concentration in 
spontaneous breathing dogs. This is consistent with the results of 
Mutoh et al. (1997).  
 
The present study showed that in anaesthetized 
spontaneously ventilating dogs increasing MAC values of sevoflurane 
from 1.5 to 2 induced a pronounced cardiopulmonary depression 
together with a significant increase in HR. However, this increase had 
little clinical consequence. The increased HR could be explained by 
the baroreceptor-reflex and/ or by sympathetic stimulation. The 
influences of artificial respiration on cardiopulmonary parameters at 
1.5 MAC anaesthetic concentration were relatively minimal. On the 
other hand, AR during 2 MAC sevoflurane anaesthesia had severe 
negative influences, especially on all cardiac parameters. PEEP 
ventilation had a greater impact than IPPV. 
 
In conclusion, sevoflurane anaesthesia at 1.5 MAC in 
premedicated healthy dogs induced a relatively moderate 
cardiopulmonary depression during spontaneous and controlled 
ventilation (IPPV and PEEP of 5 cm H²O) and can be used safely. 
Increasing the MAC from 1.5 to 2 caused a marked cardiopulmonary 
depression. Higher concentrations of sevoflurane should better be 
avoided during all ventilation modes in dogs.  
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Since the application of thoracoscopy for diagnostic 
procedures is under development in veterinary clinical practice, the 
search for an adequate anaesthetic technique has a high priority. 
Anaesthesia during thoracoscopy has to deal with several specific 
problems such as ventilation-to-perfusion mismatches, lung 
atelectasis, hypoxemia, reduced hypoxic pulmonary vasoconstriction, 
etc.  
 
During thoracoscopy one lung is entirely collapsed to create 
an optimal visualization and working space in the hemi-thorax. This 
can be achieved by two possible ventilation techniques: one lung 
ventilation (OLV) with passive lung collapse or two lung ventilation 
(TLV) with active lung collapse by gas insufflation. During OLV 
selective ventilation of one lung is applied using specific intubation 
techniques and materials such as double-lumen tubes, endobronchial 
intubation or bronchial blockers. During TLV the lung collapse is 
induced by gas insufflation in the hemi-thorax and can be performed 
with a standard endotracheal intubation technique. 
 
Both ventilation techniques induce hypoxemia since one lung 
is entirely collapsed and regions of atelectasis develop in the 
ventilated lung. The atelectasis creates ventilation-to-perfusion 
mismatches due to intra-pulmonary shunting. However, active 
vasoconstrictive mechanisms in the non-ventilated lung reduce the 
blood flow and minimize the shunt. This is the so-called “hypoxic 
pulmonary vasoconstriction” reflex (HPV). Another problem arises 
since the majority of inhalation anaesthetics inhibit HPV. Sevoflurane, 
was reported to not inhibit HPV in dogs.  
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This absence of HPV inhibition justifies the use of sevoflurane 
in the examined anaesthetic protocol applying two lung ventilation with 
different levels of CO2-insufflation. TLV was chosen since numerous 
technical problems arise using bronchial blockers or double lumen 
tubes during the one lung ventilation technique. Different levels of 
CO2-insufflation were investigated in search for the insufflation 
pressure with the least pronounced influence on cardiopulmonary 
parameters in combination with an adequate visualization of the hemi-
thorax.
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SUMMARY 
  
The cardiopulmonary effects of different levels of carbon 
dioxide insufflation (3, 5 and 2 mm Hg) under two-lung ventilation 
were studied in 6 sevoflurane (1.5 MAC) anaesthetized dogs during 
left sided thoracoscopy. 
 
An arterial catheter, Swan-Ganz catheter and multi-
anaesthetic gas analyser were used to monitor the cardiopulmonary 
parameters during the experiment. Baseline data were obtained 
before intrathoracic pressure elevation and the measurements were 
repeated at several intervals after left lung collapse induced by 
insufflation with carbon dioxide gas. The used intrapleural pressure 
levels were 3, 5 and 2 mm Hg. 
 
Arterial blood pressures, cardiac index, stroke index, left and 
right ventricular stroke work index, arterial haemoglobin saturation, 
arterial oxygen tension and systemic vascular resistance decreased 
significantly during hemithorax insufflation, whereas heart rate, right 
atrial pressure, mean, systolic and diastolic pulmonary arterial 
pressure, pulmonary capillary wedge pressure, pulmonary vascular 
resistance and arterial carbon dioxide tension significantly increased 
during intrapleural pressure elevation. 
 
Although carbon dioxide insufflation into the left hemithorax 
with an intrapleural pressure of 2 to 5 mm Hg compromises cardiac 
functioning in 1.5 MAC sevoflurane anaesthetized dogs, it can be an 
efficacious adjunct for thoracoscopic procedures. Intrathoracic view 
was satisfactory with an intrapleural pressure of 2 mm Hg. Therefore, 
the intrathoracic pressure rise during thoracoscopy with two-lung 
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ventilation should be kept as low as possible. Additional insufflation 
periods should be avoided, since a more rapid and more severe 
cardiopulmonary depression can occur. 
 
INTRODUCTION 
 
Compared with traditional surgery, the advantages of 
minimally invasive techniques for diagnosis and treatment of 
intrathoracic lesions have been well established in humans (Rodgers 
and Talbert, 1976; Toy and Smoot, 1992; Marchandise et al., 1993; 
Miller, 1993; Perrault et al., 1993; Tanguilig et al., 1993). 
Thoracoscopy is the examination of the chest cavity with an 
endoscope. A lot of diagnostic and therapeutic applications of 
thoracoscopy have been described and are presently used in human 
medicine. The use of thoracoscopy in veterinary medicine is only 
gradually starting. Although the technique can be performed in 
sedated standing horses, this is not possible in small animals such as 
dogs, pigs and sheep (Vachon and Fischer, 1998; Peroni et al., 2000). 
General anaesthesia is necessary to perform thoracoscopy in these 
smaller animals (Fujita et al., 1993; Jones et al., 1993; Faunt et al., 
1998). 
 
Specific problems in particular compromised ventilation occur 
during general anaesthesia for thoracoscopy. Thoracoscopic 
procedures require an immobilized and collapsed lung, facilitating 
intrathoracic viewing and working space. This can be achieved by two 
methods: the so-called one lung ventilation (OLV) with passive lung 
collapse or two lung ventilation (TLV) with lung compression induced 
by gas insufflation in one hemithorax. In the one-lung ventilation 
technique only one lung is selectively ventilated. This technique is 
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intensively used in human anaesthesia and needs specific intubation 
techniques with double-lumen tubes, endobronchial intubation or 
bronchial blockers. In all techniques bronchoscopic confirmation of an 
adequate tube placement is strongly recommended and can be 
considered as a disadvantage (Smith et al., 1986; Benumof, 1993). 
Gas (mostly carbon dioxide) insufflation is routinely used for 
laparoscopy and has been proved to be a safe, effective technique 
allowing the creation of intra-abdominal space for surgical 
interventions (Ishizaki, 1993). The same technique can be used for 
thoracoscopy. 
  
Both techniques (OLV and TLV) include significant risks for 
the patient and require intensive attention from the anaesthetist. The 
greatest risk during thoracoscopy is hypoxaemia, because one entire 
lung is collapsed and non functional. Even more, atelectasis can 
develop in the ventilated lung (Cohen et al., 1988). This complex 
phenomenon leads to significant ventilation-to-perfusion mismatches 
due to intrapulmonary shunting. Hypoxic pulmonary vasoconstriction 
(HPV) is a physiologic response in the lung that decreases the shunt 
fraction. Many factors, including the use of volatile anaesthetic agents, 
can reduce the magnitude of HPV (Ishibe et al., 1993).  
 
In veterinary medicine only two papers describe the technique 
of TLV with gas insufflation in experimental dogs and pigs (Jones et 
al., 1993; Faunt et al., 1998). In the present study several items were 
investigated. First of all, the possible use of sevoflurane as 
anaesthetic agent for thoracoscopy was evaluated. Furthermore, the 
influence of low-pressure (2, 3, and 5 mm Hg) intrathoracic insufflation 
of CO2 on cardiorespiratory parameters during non-selective intubation 
with TLV was examined.  
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MATERIALS AND METHODS 
 
The study was approved by the Ethical Committee of the 
Faculty of Veterinary Medicine, Ghent University (filenumber: 97/12). 
Six ASA I mongrel male dogs weighing 31.5 ± 5.8 kg (mean ± 
standard deviation) aged 3 to 7 years were used in the study. The 
dogs were vaccinated and dewormed on a regular basis. Clinical 
examination and a blood analysis (blood chemistry and haematology) 
confirmed the health status of the animals before the study. Chest 
radiographs revealed no abnormalities. No specific medication altering 
anaesthetic or analgesic requirements were administered at least 1 
month before the experiments.  
 
Food but not water was withheld for 12 hours before each 
experiment. The dogs were premedicated with 5 micrograms 
fentanyl/kg and 0,25 mg droperidol/kg of body weight (ThalamonalÒ, 
Janssen-Cilag, Berchem, Belgium) 30 minutes before induction of 
anaesthesia. Induction of anaesthesia was performed using propofol 
(6 mg/kg of BWT) (RapinovetÒ, Mallinckrodt Veterinary, Stockholm, 
Sweden) intravenously over 15 to 20 seconds. After loss of the 
swallow reflex the dogs were orally intubated (endotracheal tube 12 
mm ID, Rüsch, Germany).  
 
An anaesthesia machine (TitusÒ, Dräger, Lübeck, Germany) 
with a circle system and a precision out of circuit vaporiser (Vapor 
19,3Ò, Dräger, Lübeck, Germany) was used in the study. The soda 
lime (Dräger Sorb 800Ò, Dräger, Lübeck, Germany) was renewed 
before each experiment. The whole system was air dried between the 
experiments. The anaesthetic circuit was flushed with 100% oxygen 
for 5 minutes before the experiment. Sevoflurane (SevoraneÒ, Abbott, 
Ottignies, Belgium) (1.5 MAC x 2.36 vol%) (Kazama and Ikeda, 1988) 
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and 2 L oxygen/min fresh gas flow was used. The dogs were 
mechanically ventilated (IPPV) using a time-cycled ventilator (Ventilog 
3Ò, Dräger, Lübeck, Germany) and a tidal volume of 10 mL/kg. The 
respiratory rate was adjusted to maintain end-tidal CO2 concentration 
between 5 and 6.5 %. No intravenous infusions were administered 
during the trial. The dogs were placed in right lateral recumbency. 
 
Monitoring included a calibrated (Quick CalÔ  Calibration Gas, 
Datex-Ohmeda Corp., Helsinki, Finland) multi anaesthetic gas 
analyser (Capnomac UltimaÒ, Datex Engstrom Instrumentation Corp., 
Helsinki, Finland) for determination of the following parameters: 
inspiratory anaesthetic agent concentration (FiAA %), inspiratory 
oxygen fraction (FiO2), end tidal CO2 concentration (ET CO2 %) and 
respiratory rate (RR). Samples were taken at the Y-piece with a rate of 
200 mL/min and were scavenged. Tidal volume was monitored with a 
respirometer (VolumeterÒ, Dräger, Lübeck, Germany). The vaporizer 
settings were adjusted throughout the experiment to maintain an end-
tidal anaesthetic concentration of 1.5 MAC sevoflurane. Heart rate 
(HR) and haemoglobin saturation (SpO2 %) were monitored 
continuously using a pulse oximeter (N-20PA Portable Pulse 
OximeterÒ, Nellcor Puritan Bennett Inc., Pleasanton, CA, U.S.A.) with 
the probe placed on the tongue. 
 
During the first hour of anaesthesia the dogs were 
instrumented for cardiopulmonary monitoring. A thermodilution 
catheter (Swan-GanzÒ catheter, 7.5 french, American Edwards 
Laboratories, Santa Ana, U.S.A.) was placed in the left jugular vein 
through an introducer (Percutaneous Sheath Introducer SetÒ, Arrow, 
Reading, U.S.A.). The thermodilution catheter was advanced into the 
pulmonary artery using the characteristic pressure waveforms on the 
display of the haemodynamic monitor (Hellige Servomed SMV 104Ò, 
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Germany). The proximal port of the thermodilution catheter was 
positioned in the right atrium. The distal port and thermistor were 
positioned in the pulmonary artery in a way that by inflating the 
balloon at the catheter tip the wedge position was reached. The 
thermodilution catheter was connected to the pressure transducer 
(Monitoring-setÒ, Vascumed N.V., Ghent, Belgium) with an extension 
tube (LectrocathÒ, 150 cm, cap. 1.60 mL, Vygon, Ecouen, France) 
filled with heparinised saline (5 I.U. heparin per ml) to measure mean 
(MPAP), systolic (SPAP), diastolic (DPAP) pulmonary artery pressure, 
right atrial pressure (RAP) and pulmonary capillary wedge pressure 
(PCWP). The pressure transducer was placed at the heart level of the 
dog.  
 
The thermodilution catheter was connected to the cardiac 
ouput computer (COM-1Ò, American Edwards Laboratories, Santa 
Ana, U.S.A.) and a closed injectate delivery system (CO-setÒ+, Model 
93-610, Baxter Healthcare Corporation, Edwards Critical Care 
Division, Irvine, U.S.A.). Several cardiac output (CO) determinations 
were performed using 5 ml of a saline 0.9% solution at room 
temperature injected into the right atrium. The mean value of 3 
measurements close to each other was regarded as actual value. 
Blood temperature of the dog and injection temperature of the saline 
solution were measured using the cardiac output computer. 
 
A catheter (VasocanÒBraunüle, 22 gauge, B.Braun, 
Melsungen, Germany) was surgically placed into the right femoral 
artery. The catheter was connected to the pressure transducer 
(Monitoring-setÒ, Vascumed N.V., Ghent, Belgium) by an extension 
tube filled with heparinised saline. The mean (MAP), systolic (SAP) 
and diastolic arterial blood pressure (DAP) were monitored using a 
calibrated haemodynamic monitor (Hellige Servomed SMV 104Ò, 
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Germany). Arterial blood was collected in heparinised syringes and 
stored on ice (maximum during 15 minutes) for measurement of blood 
gas tensions (pCO2, pO2) and acid-base parameters (pH, standard 
bicarbonate (HCO3
-), standard base excess (SBE)) and PVC with a 
blood gas analyser calibrated at 37°C (ABL 5Ò, Radiometer 
Copenhagen, Denmark).  
 
Experimental Design 
The type of intervention and timing are given in Table 1. The 
dogs were anaesthetized for 1 hour at a concentration of 1.5 MAC 
sevoflurane with controlled ventilation (IPPV) before base line 
measurements were recorded (control 1). Afterwards intrathoracic 
pressure was raised to 3 mm Hg by intrapleural insufflation of CO2  (4 
L/min) through a 10-mm cannula (Thoracoscopic cannulaÒ; Richard 
Wolf GmbH, Knittlingen, Germany) placed in the dorsal third of the 
eight intercostal space. A high-flow, pressure-limited insufflating 
device (InsufflatorÒ; Richard Wolf GmbH, Knittlingen, Germany) was 
connected to the cannula and maintained a constant pressure.  
Measurements were done after 5, 10 and 15 minutes (measurements 
2, 3 and 4). After 20 minutes both lungs were expanded and a 
stabilisation period of 10 minutes was respected. For the following 
measurements intrathoracic pressure was increased to 5 and 2 mm 
Hg; measurements of the different parameters were recorded 5 
minutes after reaching intrathoracic pressure (measurements 6 and 
8). Between each intrathoracic pressure a stabilisation period of 10 
minutes was respected followed by a control measurement (control 2 
and 3). After final lung re-expansion, the dogs were ventilated during 
15 minutes with positive end expiratory pressure ventilation (PEEP to 
5 cm H2O) and final recordings were performed (control 4) (Table 1). 
All instruments and catheters were removed during this period.  
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 Table 1 : Time Schedule used for thoracoscopy with two lung  
                 ventilation in 6 sevoflurane (1.5 MAC) anaesthetized dogs 
   
TIME 
(minutes) 
INTRATHORACIC 
PRESSURE + VENTILATION 
PATTERN 
ACTION 
      
T0 0 mm Hg induction of anaesthesia 
  IPPV   
    instrumentation 
      
T60 0 mm Hg measurement 1 
    control 1 
      
T65 3 mm Hg measurement 2 
      
T70 3 mm Hg measurement 3 
      
T75 3 mm Hg measurement 4 
      
T80 0 mm Hg lung re-expansion 
      
T90 0 mm Hg measurement 5 
    control 2 
      
T100 5 mm Hg measurement 6 
    followed by lung re-expansion 
      
T110 0 mm Hg measurement 7 
    control 3 
      
T115 2 mm Hg measurement 8 
    followed by lung re-expansion 
      
  0 mm Hg   
T130 PEEP 5 cm H2O measurement 9 
    control 4 
      
      
  IPPV: intermittent positive pressure ventilation 
  PEEP: positive end expiratory pressure. 
      
 
Remaining gas in the pleural space was evacuated through the 
trocard by applying positive pressure to the rebreathing system. The 
extent of lung expansion was checked with the endoscope. When re-
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expansion was nearly complete a thorax drain was placed. 
Postoperative analgesia was provided with buprenorphine 10 µg/kg IM 
q6h (TemgesicÒ, Schering-Plough, Hull, England) and 0.5 mg/kg 
bupivacaine (Marcaine 0.5 %, Astra Pharmaceuticals, Södertälje, 
Sweden) intrapleurally. The dogs received amoxycillin clavulanate 
(8.75 mg/kg/day SC, SynuloxÒ Ready-To-Use, Pfizer Animal Health) 
during 5 days to prevent wound infection. 
 
Calculations 
Calculated parameters were determined as follows: (Gross et 
al., 1990; Davis et al., 1995) 
 
Body surface area (BSA; m²) 
BSA = Body Weight (g) ²/³ x 10.1 
    104 
   Cardiac index (CI; L/min/m²) 
  CI = CO 
          BSA 
 Stroke volume (SV; mL/beat) 
  SV = CO x 1000 
            HR 
 Stroke index (SI; mL/beat/m²) 
  SI = SV 
          BSA 
 Systemic vascular resistance (SVR; dynes.sec/cm5) 
  SVR = MAP – RAP x 80 
          CO 
Pulmonary vascular resistance (PVR; dynes.sec/ cm5) 
  PVR = MPAP – PCWP x 80 
             CO   
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Left ventricular stroke work index (LVSWI; g.m/m²) 
  LVSWI = 1.36 (MAP – PCWP) x SI 
         100 
 Right ventricular stroke work index (RVSWI; g.m/m²) 
  RVSWI = 1.36 (MPAP – RAP) x SI 
         100 
 End tidal CO2 content (CO2 ET; mm Hg)  
  CO2 ET = (750-47) x CO2 ET % 
         100 
 
Statistical Analysis 
Analysis of the data was done with repeated measures 
analysis of variance. Continuous dependent variables were analysed 
with Proc Mixed (SAS v8, SAS Institute Inc., SAS Campus Drive, 
Cary, NC, USA). Dependent variables expressing a proportion were 
analysed with Glimmix Macro (SAS v8) using a logit link function and 
a binomial error term. Ventilation, dose and the ‘ventilation by dose’ 
interaction term were the fixed factors in the model. Time was 
considered a repeated measure, and dog a random effect. An 
autoregressive covariance structure of order 1 was included in the 
analyses to take into account correlations between measurements at 
different time point intervals. 
 
RESULTS 
 
Initially, there was a significant increase in HR 5 minutes after 
increasing intrathoracic pressure (ITP) to 3 mm Hg (p=0.03), followed 
by a normalisation at 10 and 15 minutes later (p= 0.001 and p=0.03). 
After each lung re-expansion and at the end of anaesthesia HR 
differed significantly from control 1 (p=0.02) (Table 2).  
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  Table 2 : The influences of increased intrathoracic pressure     
                  (ITP: 3, 5 and 2 mm Hg) on cardiovascular parameters in    
                  6 sevoflurane  (1.5 MAC) anaesthetized dogs.      
                  
ITP mm Hg 0 3 3 3 0 
Time control 1 5 minutes 10 minutes 15 minutes control 2 
HR 104 ± 14.57 109 ± 22.17 101 ± 19.93 103 ± 15.86 114 ± 17.69 
beats/min           °     |     |     ° 
MAP 75 ± 7.54 61 ± 17.68 55 ± 16.34 54 ± 15.31 80 ± 12.76 
mm Hg           °, *     °, |     °       
SAP 106 ± 8.54 82 ± 24.71 78 ± 25.92 78 ± 25.5 111 ± 15.29 
mm Hg           °     °     °       
DAP 59 ± 9.49 51 ± 14.42 45 ± 12.55 44 ± 12.19 66 ± 11.62 
mm Hg           °, *     °     °       
RAP 4.75 ± 2.71 12.00 ± 2 12.13 ± 3.14 10.88 ± 3.68 5.38 ± 2.13 
mm Hg           °     °     °       
MPAP 12.63 ± 2.39 19.63 ± 2.45 20.13 ± 3.64 21.75 ± 4.4 14.75 ± 2.82 
mm Hg           °     °     °       
SPAP 20.75 ± 4.33 26.13 ± 3.48 27.75 ± 4.95 30.38 ± 6.44 21.88 ± 5 
mm Hg           °     °     °, |       
DPAP 8.00 ± 2.33 15.88 ± 2.53 15.75 ± 2.55 16.75 ± 3.85 10.25 ± 2.25 
mm Hg           °     °     °       
PCWP 7.50 ± 2.00 13.25 ± 2.05 13.00 ± 3.12 13.00 ± 2.27 7.88 ± 2.53 
mm Hg           °     °     °       
ITP mm Hg 5 0 2 0       
Time 5 minutes control 3 5 minutes control 4     
HR 109 ± 19.61 115 ± 18.56 112 ± 19.85 115 ± 18.25     
beats/min         °        °     
MAP 54 ± 14.58 74 ± 12.47 57 ± 9.56 67 ± 7.97     
mm Hg    °         °, *         
SAP 78 ± 25.03 106 ± 16.03 81 ± 19.87 98 ± 12.31     
mm Hg    °         °         
DAP 44 ± 11.38 62 ± 10.81 47 ± 7.91 51 ± 4.71     
mm Hg    °         °         
RAP 11.38 ± 2.97 5.25 ± 2.25 10.38 ± 1.77 5.13 ± 2.23     
mm Hg    °         °, §         
MPAP 22 ± 4.31 13.5 ± 3.07 21.8 ± 2.82 14.8 ± 2.71     
mm Hg    °         °         
SPAP 29.1 ± 6.29 19.5 ± 3.66 28.6 ± 4.1 21.4 ± 3.38     
mm Hg    °         °         
DPAP 16.3 ± 3.06 10.3 ± 2.31 15.8 ± 3.11 9.88 ± 3.52     
mm Hg    °         °         
PCWP 13.1 ± 2.75 7.5 ± 2.33 12.1 ± 2.75 8.13 ± 1.96     
mm Hg     °           °             
                                
  Data are expressed as mean ± standard deviation; ° significantly different from 
  control 1 (p=0.05); | significantly different from 5 minutes after 3 mm Hg     
  ITP (p=0.05); * significantly different from 5 mm Hg ITP (p=0.05); § significantly  
  different from 3 mm Hg ITP (p=0.05); Abbreviations of variables: see text.    
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         MAP, SAP and DAP decreased significantly when ITP increased 
to 3, 5 and 2 mm Hg compared to control 1(p<0.0001). MAP 
continued to decrease during the 15-minute period of ITP of 3 mm Hg, 
but this was only significantly different between 5 and 10 minutes 
(p=0.05). The 5 mm Hg ITP induced the lowest MAP compared to 2 
and 3 mm Hg at 5 minutes after ITP elevation (p=0.007 and p=0.04). 
There was no significant difference in SAP between 2, 3 and 5 mm Hg 
ITP; again 5 mm Hg ITP produced the lowest DAP. Ten minutes after 
lung re-expansion and the end of the experiment MAP, SAP and DAP 
returned to baseline values (control 1) (Table 2 and Figure 1).        
  
RAP, MPAP, SPAP, DPAP and PCWP increased significantly 
during ITP rise to 3, 5 and 2 mm Hg compared to control 1. During 3 
mm Hg ITP RAP, MPAP, DPAP and PCWP remained relatively 
constant during the entire period. SPAP increased significantly after 
15 minutes of ITP 3 mm Hg compared to 5 minutes after pressure 
elevation (p=0.03). RAP was significantly lower at 2 mm Hg ITP 
compared to 3 mm Hg. MPAP, SPAP, DPAP and PCWP were not 
significantly different between the 3 ITP levels. There were no 
significant differences in these right heart parameters after lung re-
expansion and at the end of anaesthesia compared to values before 
ITP rise (control 1) (Table 2 and Figure 1). 
 
Initially, CO, CI, SV and SI decreased significantly during 3 
mm Hg ITP compared to control 1. However, these parameters 
increased gradually afterwards. The differences in CO, SV and SI 
between 5 and 15 minutes of 3 mm Hg ITP were significant (p=0.04, 
p=0.006 and p=0.02). SV and SI were significantly lower at 5 and 2 
mm Hg ITP compared to values before ITP elevation (control 1). 
There was no significant difference in CO, CI, SV and SI between the 
3 ITP levels. On the contrary, these parameters returned to control 
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values (control 1) after ITP elevation to 5 and 2 mm Hg (control 3 and 
4). There was a significant overshoot of CO and CI after the first lung 
re-expansion (p=0.04), but this was less pronounced after 5 and 2 mm 
Hg of ITP. SV and SI returned to baseline (control 1) after lung re-
expansion. At the end of anaesthesia these parameters were not 
significantly different from values before starting ITP increase (control 
1) (Table 2 continued and Figure 1). 
 
LVSWI decreased significantly after ITP increase to 3, 5 and 2 
mm Hg compared to control 1. There were no significant differences in 
LVSWI between 5 and 15 minutes in the 3 mm Hg protocol. On the 
other hand, RVSWI increased non-significantly at 5 and 2 mm Hg ITP 
compared to control 1; RVSWI increased significantly only between 5 
and 15 minutes of 3 mm Hg ITP (p=0.03). LVSWI and RVSWI were 
not significantly different between the 3 pressure levels and returned 
to the start values (control 1) after lung re-expansion and at the end of 
anaesthesia (Table 2 continued). 
 
PVR increased significantly after ITP of 3, 5 and 2 mm Hg 
compared to control 1 and remained constant during the entire period 
of 3 mm Hg ITP. There was no significant difference between the 3 
mm Hg ITP levels. PVR decreased to base line values (control 1) after 
lung re-expansion and at the end of anaesthesia (Table 2 continued). 
 
Five minutes after ITP 3 mm Hg SVR remained constant, but 
decreased significantly after 10 and 15 minutes compared to 5 
minutes post and before pressure elevation (control 1) (p<0.0001). 
SVR was also significantly lower compared to control 1 during 5 and 2 
mm Hg ITP. There was a significant difference between 3 and 5 mm  
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  Table 2 (continued) : The influences of increased intrathoracic pressure  
               (ITP: 3, 5 and 2 mm Hg) on cardiovascular parameters in 6 sevoflurane  
               anaesthetized dogs  
                                
ITP mm Hg 0 3 3 3 0 
Time control 1 5 minutes 10 minutes 15 minutes control 2 
CO 2.68 ± 0.38 1.85 ± 0.72 2.07 ± 0.88 2.35 ± 0.81 3.28 ± 0.7 
L/min           °     °     °, |     ° 
CI 2.70 ± 0.45 1.87 ± 0.64 2.05 ± 0.76 2.33 ± 0.66 3.33 ± 0.91 
L/min/m²           °     °     °     ° 
SV 26.11 ± 4.22 16.86 ± 3.87 19.96 ± 5.79 22.49 ± 5.51 28.88 ± 4.89 
mL/beat           °     °     °, |       
SI 26.72 ± 7.71 17.07 ± 4.84 20.02 ± 5.5 22.56 ± 5.19 29.63 ± 8.69 
mL/beat/m²         °    °    °, |      
LVSWI 24.86 ± 10.22 11.50 ± 5.87 12.12 ± 7.62 12.91 ± 6.72 29.38 ± 12.23 
g*m/m²           °     °     °       
RVSWI 2.89 ± 1.09 1.85 ± 0.96 2.26 ± 1.35 3.46 ± 2.58 3.92 ± 2.13 
g*m/m²         °    °    |      
PVR 156.7 ± 37.34 299.3 ± 93.2 293.4 ± 106 290.9 ± 85.9 167.4 ± 39.72 
dynes*sec/cm5           °     °     °       
SVR 2114 ± 323.7 2118 ± 353 1671 ± 194 1461 ± 267 1831 ± 169.8 
dynes*sec/cm5         °    °, |    °, |    ° 
SpO2 98 ± 1.69 95 ± 2.14 94 ± 3.07 92 ± 4.75 96 ± 2.39 
%           °     °     °, |      
ITP mm Hg 5 0 2 0      
Time 5 minutes control 3 5 minutes control 4     
CO 2.40 ± 1.03 3.19 ± 0.55 2.51 ± 0.54 2.91 ± 0.53     
L/min     °           °           
CI 2.37 ± 0.87 3.22 ± 0.67 2.54 ± 0.58 2.92 ± 0.49     
L/min/m²                       
SV 21.30 ± 5.62 27.87 ± 3.29 22.39 ± 5.97 25.52 ± 3.72     
mL/beat     °           °           
SI 21.33 ± 5.00 28.49 ± 6.81 23.33 ± 7.52 25.97 ± 5.89     
mL/beat/m²    °         °        
LVSWI 12.47 ± 6.79 25.76 ± 7.91 14.37 ± 5.24 21.00 ± 3.59     
g*m/m²     °           °           
RVSWI 3.34 ± 2.25 3.28 ± 1.43 3.61 ± 1.39 3.46 ± 1.22     
g*m/m²                       
PVR 298.0 ± 77.67 154.2 ± 38.8 305.7 ± 72.7 185.3 ± 37.4     
dynes*sec/cm5     °           °           
SVR 1440 ± 179.5 1719 ± 102 1501 ± 143 1724 ± 308     
dynes*sec/cm5    °, §    °    °   °     
SpO2 92 ± 4.28 97 ± 1.92 91 ± 4.41 97 ± 1.92     
%     °           °             
                                
  Data are expressed as mean ± standard deviation; ° significantly different from control 1 (p=0.05); 
   | significantly different from 5 minutes after 3 mm Hg ITP (p=0.05); § ignificantly different from  
  3  mm Hg ITP (p=0.05); Abbreviations: see text 
                                
 
CHAPTER 5 
 
 
 151
Hg ITP (p=0.004). SVR values did not return to baseline values 
(control 1) after lung re-expansion and at the end of anaesthesia, but 
remained significantly lower (Table 2 continued). 
  
SpO2 % decreased significantly during ITP rise of 3, 5 and 2 
mm Hg compared to control 1 (p<0.0001) and continued decreasing 
significantly between 5 and 15 minutes of ITP of 3 mm Hg. There 
were no significant differences between the 3 pressure levels. SpO2 % 
returned to normal values (control 1) after lung re-expansion and at 
the end of anaesthesia (Table 2 continued). 
 
 
Fig. 1a : The influences of increased ITP (3, 5 and 2 mm Hg) on PaO2 and  
               cardiovascular parameters in 6 sevoflurane (1.5 MAC) anaesthetized     
              dogs.  significantly different from control value 1;  significantly   
              different from 5 minutes after 3 mm Hg ITP;  significantly different from  
              5 mm Hg ITP.  Values are expressed as mean ± standard deviation. 
 
  
  
 
Blood temperature decreased slightly but significantly in time 
(p<0.0001). PCV changed significantly over time with a significant 
decrease at the end of anaesthesia (p=0.003). The pH decreased 
significantly from control 1 during the whole anaesthesia duration 
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(p<0.0001). There were no significant differences between the 3 ITP 
levels. PaCO2
 increased significantly during 3, 5 and 2 mm Hg ITP 
compared to control 1 (p<0.0001) and continued increasing 
progressively during 3 mm Hg ITP. There were no significant 
differences between the 3 different ITP levels. PaCO2
 decreased after 
lung re-expansion. However, PaCO2 at the end of anaesthesia was 
significantly higher compared to control 1 (p=0.008) (Table 3).  
 
PaO2 decreased significantly during the 3 pressure levels 
(p<0.0001) compared to control 1. The decrease in PaO2 during 3 mm 
Hg ITP was significant between 5 and 15 minutes after elevation of 
intrathoracic pressure (p=0.02). PaO2 was significantly lower at 5 and 
2 mm Hg compared to PaO2 after 5 minutes of 3 mm Hg ITP (p=0.01 
and p=0.03). There was no significant difference in PaO2 between 5 
and 2 mm Hg ITP elevation. After lung re-expansion and at the end of 
anaesthesia PaO2 still remained significantly lower compared to 
control 1 (p<0.0001) (Table 3 and Figure 1).  
 
Inspiratory pressure (Pinsp.) in dogs significantly increased 
with IPPV and addition of ITP at 3, 5 and 2 mm Hg of CO2 -insufflation. 
There were no significant differences between the 3 different ITP 
levels. Pinsp. returned to base line values (control 1) after termination 
of lung re-expansion of dogs in the 3 and 5 mm Hg ITP group but not 
in dogs treated with 5 cm H2O PEEP (p=0.04). There were no 
significant changes in TV, CO2 ET % and RR during the entire 
protocol. Standard bicarbonate concentration (SBC) decreased 
significantly from before ITP elevation (control 1) at 3, 5 and 2 mm Hg. 
There were no significant differences between the 3 different pressure 
levels. SBC returned to base line value (control 1) after 5 and 2 mm 
Hg ITP, but remained low after the longer period of 3 mm Hg ITP 
elevation (p=0.008) (Table 3). 
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Table 3 : The influences of increased intrathoracic pressure (ITP: 3, 5 and 2 mm   
                 Hg) on cardiovascular parameters in 6 sevoflurane anaesthetized dogs 
ITP mm Hg 0 3 3 3 0 
Time control 1 5 minutes 10 minutes 15 minutes control 2 
BLOODT. 37.24 ± 0.55 36.95 ± 0.69 36.95 ± 0.75 36.91 ± 0.74 36.70 ± 0.77 
(°C)                          
PCV 31.01 ± 3.52 32.16 ± 4.69 32.16 ± 4.36 32.20 ± 3.89 31.86 ± 4.19 
                           
pH 7.30 ± 0.02 7.23 ± 0.06 7.18 ± 0.05 7.14 ± 0.06 7.23 ± 0.05 
          °    °, |    °, |    ° 
PaCO2 40.38 ± 3.16 50.38 ± 6.19 59.75 ± 13.77 67.13 ± 10.95 47.13 ± 5.51 
(mm Hg)         °    °    °      
PaO2 507 ± 58.37 212 ± 56.31 153 ± 60.66 122 ± 62.26 296 ± 78.64 
(mm Hg)         °    °    °, |    ° 
RR 12.50 ± 1.85 13.25 ± 2.31 13.25 ± 2.12 14.13 ± 4.05 13.13 ± 2.42 
(breaths/min)                          
TV 336 ± 30.68 338 ± 51.27 359 ± 27.48 346 ± 51.23 341 ± 31.37 
(mL)                          
Pinsp. 9.13 ± 1.55 21.00 ± 2.78 21.38 ± 3.54 22.38 ± 2.00 8.88 ± 2.30 
(mm Hg)         °    °    °      
CO2 % ET 5.53 ± 0.32 5.74 ± 0.97 5.98 ± 1.31 6.24 ± 1.06 5.46 ± 0.41 
                           
SBC 19.13 ± 1.46 18.25 ± 1.16 17.88 ± 1.13 17.75 ± 1.58 17.75 ± 1.58 
(mEq/L)        °    °    °    ° 
ITP mm Hg 5 0 2 0      
Time 5 minutes control 3 5 minutes control 4     
BLOODT. 36.78 ± 0.83 36.6 ± 0.82 36.6 ± 0.83 36.45 ± 0.92     
(°C)                        
PCV 32.28 ± 4.66 33.01 ± 4.6 29.96 ± 1.81 30.39 ± 2.32     
                   °     
pH 7.17 ± 0.05 7.24 ± 0.04 7.17 ± 0.04 7.23 ± 0.07     
     °    °    °   °     
PaCO2 61.38 ± 7.11 47.5 ± 6.23 60.29 ± 5.82 50.43 ± 7.76     
(mm Hg)    °         °   °     
PaO2 131 ± 63.94 334 ± 116.9 150 ± 95.75 328 ± 109.1     
(mm Hg)    °, |    °    °, |   °     
RR 14.25 ± 5.09 13.13 ± 2.42 14.13 ± 2.47 13.38 ± 2.92     
(breaths/min)                        
TV 324 ± 100.3 348 ± 40.27 358 ± 30.59 330 ± 37.03     
(mL)                        
Pinsp. 22.50 ± 2.88 9.38 ± 2.26 21.63 ± 2.77 11.50 ± 3.02    
(mm Hg)    °         °   °    
CO2 % ET 5.71 ± 0.52 5.41 ± 0.41 5.51 ± 0.94 5.73 ± 0.66     
                         
SBC 17.88 ± 1.46 18.75 ± 1.58 18.00 ± 1.41 18.71 ± 1.8     
(mEq/L)    °         °           
                                
  Data are expressed as mean ± standard deviation; ° significantly different from control 1 (p=0.05); 
  | significantly different from 5 minutes after 3 mm Hg  ITP (p=0.05);  
  Abbreviations of variables: see   text. 
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DISCUSSION 
 
Minimally invasive surgery techniques, including thoracoscopy 
are quickly gaining ground in human and veterinary medicine. Until 
recently, few studies were available about the applicable ventilation 
techniques for anaesthesia of dogs, pigs, sheep and horses during 
thoracoscopy (Fujita et al., 1993; Jones et al., 1993; Faunt et al., 
1998; Vachon and Fischer, 1998; Peroni et al., 2000). Thoracoscopy 
requires general anaesthesia in dogs, sheep and pigs, whereas the 
technique can be performed in sedated standing horses. The basic 
procedure involves the introduction of a rigid or flexible fibreoptic 
endoscope into the thoracic cavity, and the use of air or another gas 
to create a pneumothorax allowing visualization of intrathoracic 
structures. If the animals are placed in lateral recumbency, it is 
necessary to collapse the upper lung. This can be achieved by two 
possible ventilation techniques: one lung ventilation (OLV) with 
passive lung collapse or two lung ventilation (TLV) with active lung 
collapse by gas insufflation. 
 
During OLV selective ventilation of one lung is applied for 
which specific intubation including double-lumen tubes, endobronchial 
intubation or bronchial blockers is necessary. Positioning is technically 
difficult in dogs and sheep (Muneyuki et al., 1983; Fujita et al., 1993; 
Cantwell et al., 2000). Due to malpositioning (up to 30 %) in men 
routine bronchoscopy after double-lumen tube or bronchial blocker 
placement is certainly recommended. However, bronchoscopy is 
expensive, time consuming and not universally available (Kleine et al., 
1998). Another technical problem is the limited use of commercially 
available tube systems for animals with smaller body weights such as 
cats and toy breed dogs. Furthermore, the potentially more 
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pronounced cardiopulmonary impact of OLV and TLV with gas 
insufflation in animals with smaller body weights has not yet been 
investigated. 
 
Abdominal insufflation with gas is routine for laparoscopic 
procedures to produce the required viewing space. This insufflation 
has certainly adverse cardiopulmonary effects. The effects vary with 
the gas used, the presence or absence of mechanical ventilation, and 
the pressure and duration of insufflation (Johannsen et al., 1989; 
Windberger et al., 1994). With TLV for thoracoscopy insufflating the 
thorax minimally enhances the optical cavity; however, it must be 
applied with extreme caution. TLV with gas insufflation is seldom used 
in human anaesthesia for thoracoscopy because of occurring 
haemodynamic impairment (Brock et al., 2000). 
 
Both ventilation techniques induce hypoxaemia since one lung 
is entirely collapsed and regions of atelectasis develop in the 
ventilated lung (Cohen et al., 1988). This induces ventilation-perfusion 
mismatches due to intra-pulmonary shunting. However, active 
vasoconstrictive mechanisms in the non-ventilated lung reduce the 
blood flow and minimize the shunt. This is the so-called hypoxic 
pulmonary vasoconstriction reflex. Several techniques can be applied 
to improve oxygenation during thoracoscopy: selective continuous 
airway pressure (CPAP) to the non-ventilated lung, positive end 
expiratory pressure (PEEP) to the ventilated lung, a combination of 
both or the use of high frequency ventilation to the non-dependent 
lung (Alfery et al., 1981; Benumof, 1982; Nakatsuka et al., 1988; Fujita 
et al., 1993). 
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Until now only two studies described TLV with gas insufflation 
in smaller animals. Faunt et al. (1998) examined the cardiopulmonary 
effects of TLV with N2O insufflation for thoracoscopy in isoflurane 
anaesthetized dogs. In this study intrathoracic pressures were not 
measured, but were stated to be below 10 mm Hg. TLV with sustained 
pneumothorax was well tolerated in these clinically healthy dogs. In 
another study the effects on haemodynamic parameters of 5, 10 and 
15 mm Hg of CO2 insufflation during TLV were evaluated in isoflurane 
anaesthetized pigs (Jones et al., 1993). Routinely used positive 
pressure insufflation during thoracoscopy was not recommended 
because of the significant haemodynamic compromise in this 
experiment. 
 
In the present study the cardiopulmonary effects of varying 
degrees of intrathoracic pressure elevation after CO2-insufflation 
during 1.5 MAC sevoflurane anaesthesia in continuous two-lung 
ventilated dogs were examined. Conventional intubation was chosen 
to avoid the laborious difficulties of endobronchial intubation or 
bronchial blocker placement and to skip the need for specialized 
equipment. Three different levels of intrathoracic pressure elevation of 
the left hemi-thorax (3, 5 and 2 mm Hg) after CO2-insufflation were 
evaluated during IPPV. The intrathoracic pressure level that induced a 
sufficient visualisation into the thorax and the least pronounced 
cardiopulmonary side effects was tested, since only one short 
communication about the maximum intrathoracic pressure increase (3 
to 10 mm Hg) during thoracoscopy in dogs is available (Daly et al., 
1999).  
 
Inhalation anaesthetics including sevoflurane induce a dose-
dependent cardiopulmonary depression in all animals (Bernard et al., 
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1992; Aida et al., 1996; Grosenbaugh and Muir, 1998). The MAC of 
sevoflurane in dogs has been established to be 2.36 volume  % 
(Kazama and Ikeda, 1988). One and a half MAC is generally accepted 
as the standard to allow most surgical interventions. However, some 
cases require a higher MAC when no supplementary analgesics or 
related drugs are administered during anaesthesia. Furthermore, 
several studies showed that 4% sevoflurane does not inhibit the 
hypoxic pulmonary vasoconstriction reflex in dogs (Domino et al., 
1986; Okutomi and Ikeda, 1990). This specific characteristic might be 
justified in the present study because of the occurring ventilation-
perfusion mismatches. 
 
Fentanyl and propofol are relatively fast acting and short 
lasting agents. Interactions of these drugs after the instrumentation 
period of one hour with sevoflurane protocol were not likely to be 
present. However, although these drugs have a short half-life, it could 
not be excluded that their interfering effects were of longer duration. 
On the other hand, droperidol has relatively long lasting effects. A 
possible influence of droperidol can therefore not be ruled out 
(Bissonnette et al., 1999).  
 
A fluid rate of 4 to 8 ml/ kg/ h is generally accepted for the 
maintenance of a stable water balance during anaesthesia (Giesecke 
and Egbert, 1985). No fluids were administered in the present study. 
Nevertheless, the thermodilution method includes the administration 
of different boli of saline. Overall, an estimated quantity of 2 to 4 ml/ 
kg/ h was administered during the whole experimental period. The 
influences of this relatively low fluid administration in this study were 
probably neglectable. 
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In the present study all direct cardiac parameters (blood 
pressures, CO, SV, SI, LVSWI) initially decreased significantly during 
ITP increase to 3, 5 and 2 mm Hg. Afterwards, there was a gradual 
correction of these parameters probably induced by the occurring 
hypercapnia (Walley et al., 1990). After lung re-expansion there was a 
clear overshoot in cardiac output and cardiac index related to the 
increased HR at that moment, since SV remained constant during this 
period. Heart rate, on the other hand, increased at the start of ITP 
increase at every level and increased even more after lung 
insufflation. The tachycardia could result from a sympathetic 
stimulation induced by a stress response related to the increase in 
PaCO2 and/ or from stimulation of the baroreceptor-reflex due to a 
dose dependent decrease in blood pressure induced by sevoflurane in 
dogs (Cullen and Eger, 1974; Mutoh et al., 1997). These findings were 
in contrast with the results of Faunt et al. (1998). In this study an 
increase in CI, stroke volume index, MPAP and total peripheral 
vascular resistance was observed. Jones et al. (1993) and Daly et al. 
(1999), reported decreases in CO and arterial blood pressure in an 
analogue protocol, while HR remained relatively constant. The 
decrease in direct cardiac parameters in our study could be 
subsequent to the reduced venous return due to increased 
intrathoracic pressure, as described in humans, and/ or to a 
decreased myocardial contractility induced by sevoflurane 
anaesthesia (Mutoh et al., 1997; Brock et al., 2000; Polis et al., 2001). 
The reduced venous return is comparable with the one induced by a 
tension pneumothorax (Conolly, 1993; Light, 1994). 
 
Right heart parameters (RAP, PAP, PCWP) and PVR 
increased significantly during intrathoracic pressure elevation at every 
level compared to values before CO²-insufflation in the present study. 
This was consistent with previous studies (Jones et al., 1993; Faunt et 
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al., 1998). In contrast with the other right heart parameters, RVSWI 
decreased significantly during the first 10 minutes of 3 mm Hg ITP and 
then increased significantly after 15 minutes compared to 5 minutes 
after ITP rise. RVSWI increased at 5 and 2 mm Hg IT pressure 
compared to before CO2-insufflation. The initial decrease in RVSWI is 
difficult to explain, since an increase was expected. This finding might 
be related to the position of the Swan-Ganz catheter either in the left 
or the right lung. The exact position of the catheter in the lung 
(ventilated or collapsed) was not checked. The increase in RAP, PAP, 
PCWP and PVR can be explained by the rise in pulmonary tissue 
pressure that leads to a decrease in pulmonary perfusion after CO2-
insufflation, as well as by hypoxic vasoconstriction in the collapsed 
pulmonary parenchyma (Ohtsuka, 1999). Large increases in 
intrathoracic pressure are presumed to decrease venous return and 
increase pulmonary vascular pressures so that stroke work and 
cardiac output are compromised, leading to hypotension and 
hypoperfusion (Lenaghan et al., 1969; Conolly, 1993). 
 
SVR decreased significantly after CO2-insufflation and 
remained low during the entire procedure. This could be partly 
explained by the vasodilating properties of sevoflurane, but also by 
the occurring hypercapnia during thoracoscopy. In a previous study 
SVR remained constant in 1.5 MAC sevoflurane anaesthetized dogs. 
A significant decrease in SVR was observed only at 2 MAC 
sevoflurane (Polis et al., 2001). The decreased SVR is consistent with 
the study of Faunt et al. (1998) where a small decrease in SVR was 
found. Jones et al. (1993) observed a constant SVR at low ITP (5 mm 
Hg), an increased SVR at 10 mm Hg and a decreased SVR at 15 mm 
Hg. 
SpO2 and PaO2 decreased significantly after CO2-insufflation, 
whereby the decrease was more rapid and pronounced after 
 
CHAPTER 5 
 
 
 160
consecutive ITP elevations compared to the first pressure rise. SpO2 
returned quickly to base line value after lung insufflations, but PaO2 
remained significantly lower even at the end of anaesthesia. This was 
also reported in analogue studies (Faunt et al., 1998; Daly et al., 
1999). The phenomenon might be explained by an increased amount 
of blood flow due to the effect of gravity in the underlying lung, while 
its lung volume is decreased by compression of the mediastinal 
weight. This results in inefficient oxygenation of circulating blood due 
to ventilation/perfusion mismatch and blood shunting.  
 
PaCO2 increased significantly during CO2-insufflation and 
continued to increase during the 15-minute period of intrathoracic 
pressure of 3 mm Hg despite constant ventilator settings. The 
increase could be related to the induced capnothorax (Peden and 
Prys-Roberts, 1993). In the study of Faunt et al. (1998) PaCO2 
increased also, although insufflation was done with N2O, there was 
found no evidence of N2O resorption from the thorax. Hypercapnia 
causes acidemia, resulting in decreased pH. In the present study the 
calculated P(a-A) CO2 -gradient did not increase. The use of 
capnography and pulse oximetry is certainly recommended during 
thoracoscopic interventions because indirect moment-to-moment 
indications of PaCO2 and haemoglobin saturation with oxygen are 
provided. 
 
In conclusion, thoracoscopic procedures in sevoflurane (1.5 
MAC) anaesthetized dogs with low pressure (2 mm Hg) CO2-
insufflation into one hemithorax allows safe visualization of the 
intrathoracic space for short periods. The thoracoscopic procedure 
should be accomplished in one short episode of CO2-insufflation since 
additional insufflation periods can lead to more rapidly occurring and 
more pronounced cardiopulmonary depression. 
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The use of sevoflurane is still rather expensive for veterinary 
practice. Therefore, methods inducing a decreased consumption of 
inhalant anaesthetic agent can be indicated to reduce anaesthetic 
costs. This can be achieved by reduction of fresh gas flows and/or by 
combination of inhalation anaesthesia with analgesic drugs. A 
“balanced anaesthesia” regimen combining potent opioids with 
sevoflurane should result in a MAC reducing effect and less 
anaesthetic agent. During the last decade, treatment of animal pain, 
its recognition, alleviation and subsequent prevention has gained 
increasing attention. This trend provides a relevant argument in 
support of adequate pain relief and the application of “balanced 
anaesthesia” techniques in general practice. 
 
In order to obtain a method for beneficial cost optimisation and 
adequate pain relief when using sevoflurane, premedication with a 
long-acting sufentanil formulation was investigated. Hence, 40 dogs 
were enclosed in a study combining sevoflurane with sufentanil LA 
administered at different time intervals before induction of 
anaesthesia. The emphasis in this study was put on the 
antinociceptive and sedative effects of sufentanil LA and the dosage 
reducing effect on sevoflurane anaesthesia in dogs, since “pre-
emptive analgesia” is nowadays considered as the keystone for post-
operative pain relief (Chapter 8). In addition, potential influences on 
cardio-respiratory parameters when using this drug combination were 
evaluated in chapter 7. The administration of a long-acting formulation 
of sufentanil should facilitate pre- per- and post-operative analgesia in 
veterinary practice, because a single intramuscular injection could 
provide satisfactory pain relief during 24 hours. 
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To perform the study repeated blood pressure measurements 
and arterial blood sampling were necessary. Multiple femoral artery 
punctures were unfeasible and therefore catheter and vascular access 
port implantation was imposed (Chapter 6). Two possible techniques 
were considered: conventional externalised or totally implantable 
catheter systems. Conventional externalised catheter systems have a 
rate of complications that limits its clinical and animal experimental 
use. These complications have led to the development of the totally 
implantable catheter system. The system consists of a titanium port 
and a poly-urethane catheter. The port is implanted subcutaneously 
and can be accessed by a hypodermic needle. The totally implantable 
system gives only limited infection risks compared to the use of 
externalised catheters and was therefore preferred in our study. 
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SUMMARY 
 
In the present study a modified method using coated 
polyurethane catheters into the femoral artery and a titanium vascular 
access port (VAP) with a silicone membrane was described in forty 
dogs. This device allowed repeated arterial blood pressure 
measurement and blood sampling in conscious and anaesthetised 
dogs for an average period of 2 weeks. Minor clinical influences nor 
catheter extraction were observed. On the other hand, infection with 
Pseudomonas aeruginosa induced by a contaminated flush solution 
was diagnosed in 4 dogs. These dogs recovered rapidly after an 
appropriate antibiotic therapy. 
  
It was concluded that the described arterial catheterisation 
technique with vascular access port over a two weeks period was 
suitable and technically feasible for experimental protocols in dogs. 
 
INTRODUCTION 
  
Anaesthetic studies in experimental dogs often require 
repetitive blood sampling and blood pressure monitoring in 
unrestrained animals over a relatively long period of time. The 
repetitive puncture of arteries and veins or multiple consecutive 
peripheral catheter placement is accompanied by technical problems 
and stress responses, but also by iatrogenically induced damage of 
the blood vessels including thrombosis and sclerosis (Mesfin et al., 
1988; Bagley and Flanders, 1990; Endres et al., 1990; Grosse-
Siestrup and Lajous-Petter, 1990). Therefore, these methods are only 
suitable for the prelevation of a limited number of blood samples.
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 A potential option is the placement of a permanent 
intravenous or intra-arterial catheter combined with an implant, as 
mentioned in literature (Hai, 1982; Garner and Laks, 1985; Béliveau et 
al., 1990; Abrams-Ogg et al., 1992; Evans et al., 1994). However, 
maintaining chronically indwelling catheters and avoiding destruction, 
dislodgement, or infection of the catheters is often a challenge. Local 
infection, sepsis, migration, extravasation and early occlusion of the 
catheter are major complications of commonly used catheter implants 
(Evans et al., 1994). Therefore, antibiotics are essential to prevent 
infection after implantation. Furthermore, as in humans, aseptic 
conditions during surgery and blood sampling are also of major 
importance (Burrows, 1982; Vazques and Jarrad, 1984). The catheter 
and vascular access port patency demands frequent flushing with 
heparinised saline. 
  
The aim of the present study was to describe a modified 
surgical arterial catheterisation technique in combination with the use 
of a vascular access port for repetitive blood sampling and blood 
pressure measurement during and after experimental anaesthetic 
protocols in dogs (Fig. 1).  
 
Fig.1. Vascular access port 
(AccessTM Technologies, 
Skokie, USA) 
 Connection to the 
coated polyurethane catheter 
 
 
 
 2.2 cm  
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Materials and Methods 
 
The study was approved by the Ethical committee of the 
Faculty of Veterinary Medicine, Ghent University (filenumber: 
39/2000). Forty adult female Beagles weighing 11.97 ± 1.40 kg (mean 
± SD) from 1 to 2 years old were used in the study. The dogs were 
dewormed and vaccinated before the experiment. Clinical and blood 
examination one week before and the day of the experiment 
confirmed the good health status of the animals. Animals had free 
access to tap water and commercial dog food (Advance TM Adult, 
Master Foods N.V., Belgium). 
 
Anaesthetic protocol 
The dogs were fasted 12 hours before surgical intervention. 
Acepromazine (0.05 mg/kg Placivet® 2%, Codifar N.V., Wommelgem, 
Belgium) was administered intramuscularly as premedication. 
Anaesthesia was induced 30 minutes later using propofol (4-6 mg/kg 
Rapinovet®, Mallinckrodt Veterinary, Aalst, Belgium) administered 
intravenously to effect. The dogs were intubated (endotracheal tube 6 
mm ID, Rüsch, Germany) and connected to a commercial anaesthetic 
machine (TitusÒ, Dräger, Lübeck, Germany) with a circle system 
delivering 1 L/min of oxygen. The dogs breathed spontaneously 
throughout the surgical procedure. An anaesthetic gas analyser 
(Capnomac UltimaÒ, Datex Engstrom Instrumentation Corp., Helsinki, 
Finland) and pulse oximeter (N-20PA Portable Pulse OximeterÒ, 
Nellcor Puritan Bennett Inc., Pleasanton, CA, U.S.A.) were used for 
non-invasive monitoring. No intravenous infusions were administered 
during anaesthesia. 
 
Anaesthesia was maintained with propofol administered 
intravenously by an infusion pump (Ohmeda 9000 Syringe pump®, 
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Ohmeda, West Yorkshire, UK) at a dosage of 0.5 mg/kg/min. 
Analgesia and anaesthesia of the hind quarters was assured with an 
epidural technique using a 50/50 (v/v) mixture of lidocain 2% 
(Xylocaine® 2%, Astra Zeneca, Brussels, Belgium) and bupivacain 
0.5% (Marcaine® 0.5%, Astra Zeneca, Brussels, Belgium) at a dosage 
of 1 ml/4 kg of body weight. Two dogs received half of the epidural 
dosage because the subarachnoidal space was punctured. For 
additional postoperative analgesia, the dogs were treated with 
carprofen (4 mg/kg PO) during 3 days, starting the day before surgery. 
The dog received a single injection of amoxicillin long acting (15 
mg/kg SC) (Duphamox LA, Fort Dodge Animal Health Benelux, 
Brussel, Belgium) the day of catheter implantation.  
 
Surgical procedure 
After the dogs had been placed in left lateral recumbency, the 
right inguinal area, the medial side of the right knee and the backside 
of the dogs were surgically prepared. A 60 cm coated polyurethane 
catheter (Hydrocoat TM Catheter 3.5 Fr; Access TM Technologies, 
Skokie, USA) with a bead at 8 cm from the catheter tip and filled with 
heparinised saline (5 IU/ ml of Heparine®, Leo, Belgium) was used for 
arterial catheterisation. The catheter tip was transected obliquely and 
was grasped with a forceps (Semkin dressing forceps) for better 
handling. The catheter was occluded at the free end with a 
haemostatic clamp to prevent bleeding when inserting it to the femoral 
artery. A 4 cm incision was made through skin and subcutis above the 
femoral groove. The femoral artery was exposed by separation of the 
sartorius and gracilis muscles starting in the femoral triangle. The 
artery was freed from the femoral nerve and vein by blunt dissection 
(Fig. 2). Hence, the femoral artery was elevated and occluded during 
the surgical handling by gentle pulling on 2 sutures (Safil® green 3/0, 
B/Braun, Melsungen, Germany) positioned under the artery (Fig. 3). 
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Topical lidocain was administered to counteract the induced iatrogenic 
vasospasm of the femoral artery during handling. A small hole was 
made into the artery with a 19 gauge needle (19 G x 1”; 1.1 x 25 mm; 
Terumo Europe N.V., Leuven, Belgium) and the catheter tip was 
inserted into the artery towards the aorta for about 8 cm (Fig. 4). The 
proximal suture was used to fix the artery around the inserted catheter 
(Fig. 5). An additional suture was placed immediately behind the bead 
to assure an adequate ligation of the artery and the distal suture was 
used to ligate the femoral artery to the bead.  
 
Fig.2. Surgical exposition     
  of the femoral artery 
 1/ femoral vein and nerve 
 2/ femoral artery 
 
 
 
 
 
 
 
 
 
                                       
 
Fig.3. Elevation of the 
femoral artery by  
2 stay sutures 
 
 
 
 
 
 
 
1 
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Fig.4. Insertion of the 
catheter into the  
femoral artery 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Ligation of the 
femoral artery around the 
inserted catheter 
 
 
 
 
 
 
 
 
 
 
 
A second skin incision was made medial of the knee. The 
catheter was pulled subcutaneous from the femoral triangle to the 
knee with an atraumatic forceps (straight Rochester-Carmalt 
Haemostatic forceps). The catheter was secured using a single 
subcutaneous suture at the medial level of the knee. Finally a 
paramedian incision was made proximal from the ilium on the back of 
the dog. A small amount of subcutaneous fat was prelevated allowing 
bead 
femoral 
artery 
proximal 
suture 
bead 
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3 
2 
1 
the formation of a suitable pocket for the titanium vascular access port 
(Access TM Technologies, Skokie, USA). The catheter was tunnelled 
further subcutaneously from the knee to the backside of the dog with 
the same atraumatic forceps (Fig. 6).  The vascular port was attached 
to the catheter allowing enough length for a so called tension loop 
around the port (Fig. 7-8). Catheter patency was tested using 
heparinised saline and a Huber point needle (Posi-Grip Huber Point 
Needle 22 gauge x 0-3/4’’, Access TM Technologies, Skokie, USA) 
placed through the silicone membrane of the vascular access port. 
The vascular access port was sutured with 3 single sutures (Safil® 
green 3/0, B/Braun, Melsungen, Germany) into the subcutaneous 
tissue. 
 
After a final control of permeability, the catheter was filled with 
heparinised saline (200 IU/ml) and all skin incisions were closed with 
Safil® (fig. 9). The catheters and implants were removed 17.9 ± 8.7 
days after implantation (mean ± SD) under a standardised isoflurane 
anaesthesia. 
 
Fig. 6. Subcutaneous tunneling 
from the medial knee incision 
to the lumbar incision 
       
 
     1/ Subcutaneous tunnelling 
     2/ Top of the atraumatic forceps 
     3/ Katheter 
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Fig.7. Attaching the 
vascular access port to 
the catheter 
1/ vascular access port 
2/ coated polyurethane 
catheter 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Insertion of the 
vascular access port in a 
subcutaneous pocket 
 
 
 
 
 
 
 
 
 
 
1
2 
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Fig.9. Testing of catheter patency 
 
1/ Huber point needle 2/ Vascular access port 3/ Arterial blood sample  
4/ Lumbar incision site 
 
Experimental design 
A haemodynamic study was carried out 2 to 6 days after 
catheter and vascular access port implantation. Measurements were 
performed during 24 hours. The arterial catheter was flushed 
percutaneously through the silicone membrane of the VAP every two 
days before the experiment with 1 ml of heparinised saline (200 
IU/ml). The vascular access port was used for arterial blood pressure 
measurement at several time points. This was done by perforating the 
membrane of the port through the skin with a Huber point needle. The 
needle was connected to an extension tube filled with heparinised 
saline and a pressure transducer (Vascumed N.V., Gent, Belgium) 
placed at the level of the heart. Mean, systolic and diastolic blood 
pressure was measured (Hellige Servomed SMV 104Ò, Germany). 
1 
2 
3 
4 
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Arterial blood for blood gas analysis was sampled using the same 
method.  
 
Clinical observation and examination 
A clinical examination was done and rectal temperature of the 
dogs was recorded on a daily basis.  
 
RESULTS 
 
Anaesthesia and surgery were uneventful. The surgical 
implantation time ranged from 35 to 75 minutes. All 40 dogs tolerated 
the sampling procedures (14 samples in 24 hours) well without 
external signs of discomfort. Blood sampling and blood pressure 
measurement were successful and easy to perform in all dogs. 
  
Several complications were encountered. An inadvertent 
implantation of the catheter into the femoral vein was diagnosed in 
one dog. This dog had a swelling of the hind leg and venous blood 
(PaO2: 33 mm Hg) could be sampled from the vascular access port. 
The catheter was removed and a period of one month was respected 
before a new catheter could be implanted into the femoral artery of the 
same side without problems. Another dog was lame in the surgically 
treated hind leg the day of the experiment, however without pain or 
swelling. Lameness disappeared spontaneously within 4 days without 
therapy. One dog removed the sutures of the inguinal wound without 
damaging the arterial catheter. The wound was sutured again under 
local anaesthesia with lidocain (XylocaineÒ 2%, Astra, Brussel, 
Belgium). Finally, a seroma occurred around the VAP in one of the 
dogs and was surgically treated by placing a Penrose drain (Penrose 
Tubing, Sherwood Medical, Tullamore, Ireland) after removal of the 
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VAP. The swelling caused no difficulties for blood sampling or blood 
pressure measurement. 
 
Mean rectal temperature of all dogs was 39.3 ± 0.48°C on the 
day of the experiment (2 to 6 days after catheter implantation). Four 
dogs had fever (more than 40.0°C) one to two days after catheter 
implantation. However, on clinical examination no signs of lameness 
or inflammation on the catheter site were observed in these dogs. 
Samples for bacteriologic examination were taken from the 
heparinised flush solution used in these dogs. Contamination of the 
solution with Pseudomonas aeruginosa was found by a bacteriologic 
culture. An appropriate antimicrobial therapy guided by an antibiogram 
was done for 5 to 10 days with enrofloxacine SC (5 mg/kg/day, 
BaytrilÒ 5%, Bayer, Leverkusen, Germany) and resulted in full clinical 
recovery. The arterial catheter and vascular access port of one of 
these dogs showed no bacteriological growth after surgical removal.  
 
The catheters remained patent in all animals for at least 4.2 ± 
2.2 days (mean ± SD). After the experiment the catheters were not 
further flushed in order to have an obstructed catheter by time of 
removal 17.9 ± 8.7 days after implantation (mean ± SD). This 
facilitated catheter removal, which could be done without an additional 
ligation of the femoral artery. After removal of catheters and vascular 
access ports skin incisions healed rapidly. No specific problems 
induced by the ligation of the femoral artery were encountered over 
time. 
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DISCUSSION 
  
In the present study a permanent arterial catheter and totally 
implantable vascular access port system were inserted into the 
femoral artery of dogs for repetitive arterial blood sampling and 
invasive arterial blood pressure measurement at several time intervals 
during experimental procedures. The surgical technique was slightly 
modified from previously published studies (Garner and Laks, 1985; 
Grosse-Siestrup and Lajous-Petter, 1990; Evans et al., 1994). 
 
 Coated polyurethane catheters in combination with titanium 
vascular access ports were used in the present study. Compared to 
polyvinyl chloride, silicone and Teflon catheters, heparinised 
polyurethane were proven to be the least thrombogenic of all 
materials (Solomon et al., 1987). Moreover, silicone carries a greater 
risk for subcutaneous infection and induces a greater inflammation 
and kinking risk (Sheretz et al., 1995). In the present study, the 
catheter was inserted for about 8 cm into the femoral artery. 
Immediately after surgical handling of the artery a marked collapse of 
the vessel was observed making the insertion of the catheter difficult. 
Topical lidocain was administered to counteract the iatrogenically 
induced vasospasm (Wadstrom and Gerdin, 1991; Kim et al., 1996). 
To facilitate catheter implantation the catheter tip was cut off obliquely 
in combination with an opening in the vessel wall. Efficiency of 
catheter placement improved with experience. No problems of the 
hind limb vascularisation were observed after occlusion of the distal 
part of the femoral artery. Most likely a sufficient amount of collateral 
vessels assured an adequate circulation of the hind limb rapidly 
(Schaper and Ito, 1996). All catheters remained patent during the 
experiment. The incision wounds healed rapidly in the majority of the 
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dogs, particularly the femoral wound. This was also reported in similar 
studies (Hai, 1982). 
 
The vascular access port consisted of a titanium base with 
multiple holes for securing it to the surrounding tissue and a central 
silicone diaphragm for puncturing. Multiple membrane punctures are 
guaranteed without vascular access port leakage when using Huber 
point needles with off-centre tips. The port was secured on the lumbar 
region away from the femoral incision in a separate pocket to 
minimize the potential for incisional swelling, pain or inflammation 
from interfering with multiple port punction. The lumbar port position 
was also facilitating blood sampling. In other studies the vascular 
access port was implanted in the right hemi-cervical region of the 
dogs facilitating access to the jugular vein (Evans et al., 1994).  
  
Blood sampling and blood pressure measurement was easy 
requiring only minimal restraint. In most trained animals one person 
could do the blood sampling; the assistance of a second person was 
only necessary in nervous dogs. For blood pressure measurement 
previous flushing with heparinised saline was advisable to get a sharp 
blood pressure waveform on the haemodynamic monitor. 
  
The rectal temperature remained within acceptable ranges in 
most dogs. However, some dogs had a transient slightly increased 
temperature after catheter implantation. The impact of anaesthesia 
and surgery and the implantation of a foreign body (catheter and VAP) 
had certainly an impact on the body temperature. A slight transient 
increase in body temperature was also observed in similar studies 
after intravenous catheterisation in pigs (Van Leengoed et al., 1987; 
Pijpers et al., 1989). Four dogs had an abnormal and persistent 
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increase in body temperature (> 40°C) without signs of lameness or 
local infection around the femoral artery or vascular access port. In 
human studies the most likely mechanism for catheter infection was 
reported to be caused by the normal bacterial skin flora, which can 
gain access during implantation of the catheter (Eykeyn, 1984). The 
aetiology of the infection in the present study was a contamination of 
the heparinised saline solution with Pseudomonas aeruginosa, 
although the flush solution was prepared weekly and stored 
aseptically. After an appropriate antibiotic treatment with enrofloxacine 
complete recovery was obtained. However, the anaesthetic 
experiment was postponed for several days until the body 
temperature of the dogs returned to normal values. Heparin solution 
was renewed daily to prevent this phenomenon. Occasionally and 
successfully treated bacteraemia were also observed in similar 
studies describing totally implantable catheter systems in dogs 
(Grosse-Siestrup and Lajous-Petter, 1990). 
   
Other problems such as suture removement and seroma 
formation were of minor clinical importance and were easily treated 
using standard techniques (Garner and Laks, 1985). Since the distal 
part of the femoral artery was occluded, the artery could probably not 
be reused for the same purpose afterwards.  
  
In conclusion, the above described modified arterial 
catheterisation technique with vascular access port is suitable and 
technically feasible for experimental haemodynamic protocols in dogs. 
This catheter system can be applied to improve the well-being of 
experimental animals, to facilitate experimental work, to simplify serial 
blood sampling. However, proper handling and aseptic blood sampling 
procedures are prerequisites. 
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SUMMARY 
 
The purpose of the present study was to evaluate the 
haemodynamic effects of sufentanil long acting premedication in 
sevoflurane anaesthetized dogs in an open randomised study. Forty 
dogs were divided over 5 parallel groups of 8 dogs each. Two control 
groups were used: one group of dogs (A) received sufentanil long 
acting (50 µg/kg IM) and a second group (B) the sufentanil vehicle 
followed by a standard inhalation anaesthesia of 90 minutes. After 
premedication with sufentanil long acting immediately before (C0), 15 
minutes (D15) or 30 minutes (E30) before induction with thiopental (IV) 
the dogs were anaesthetized for 90 minutes with sevoflurane in 
oxygen.  
  
Heart rate (HR), direct mean arterial blood pressure (MAP), 
respiration rate (RR), arterial oxygen haemoglobin saturation (SaO2) 
and sevoflurane concentration were measured every 10 minutes 
during anaesthesia and at 2, 4 and 24 hours after initiation of 
anaesthesia. Acid-base and blood gas analyses were performed at 
the same time points.  
 
The present study showed that premedication with sufentanil 
LA followed by sevoflurane anaesthesia enhanced moderately some 
cardiopulmonary side effects accompanying clinically adjusted 
sevoflurane anaesthesia. The addition of sufentanil LA as 
premedication caused a decrease in heart rate and an increase in 
PaCO2, while MAP was well maintained. The clinical importance is 
probably limited during inhalation anaesthesia where a high inspired 
oxygen fraction resulted in high PaO2 and SaO2 levels. Temporary 
support of ventilation with IPPV however might be occasionally 
necessary. Thirty minutes between sufentanil LA premedication and 
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induction of anaesthesia might be preferable, since less respiratory 
depression occurred in group E30. In the post-anaesthetic period the 
bradycardia persisted and was still present after 24 hours.  Although 
RR was lower then the control group without sufentanil pretreatment, 
PaCO2 and PaO2 were within an acceptable range in the 
postanaesthetic period up to 24 hours.  
 
INTRODUCTION 
 
The search for an optimal method to control acute pre-, per- 
and post-operative pain in veterinary medicine is still ongoing. Opioids 
are still of enormous therapeutic importance as the drug of choice for 
the treatment of moderate to severe pain. The major action of opioids 
is analgesia by binding to specific receptors (µ, ?, d, s, e) localised 
mainly in the brain and spinal cord (Pert and Snyder, 1973; Stein, 
1993). In general, the clinically most effective opioids act selectively at 
µ receptors (Nolan, 2000). Intermittent administration of short-acting 
opioids on an as-needed basis leads to peaks and troughs in drug 
plasma level. Coupled to an inadequate dosage or too lengthy dosing 
intervals this can lead to insufficient control of peri- and postoperative 
pain (Oden, 1989; Sinatra, 1991). Pre-anaesthetic drugs classically 
include anticholinergics, tranquilizers or a2-agonists, but nowadays 
opioids are often included in the premedication protocol because of 
their analgesic characteristics (Taylor, 1999). The clinical advantage is 
a dosage reduction of the drugs used for general anaesthesia which 
eventually leads to improved patient safety (Brunner et al., 1994; 
Moon et al., 1995). Furthermore administration of analgesics before 
the surgical stimulus arises (pre-emptive analgesia) is thought to be 
important for better control of postoperative pain (Lascelles et al., 
1995). 
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The problems associated with intermittent administration of 
short-acting opioids might be overcome with the intramuscular 
administration of a potent opioid in a long-acting formulation. Such a 
drug could than be used as premedication, providing effective pre-
emptive analgesia over an extended period of time including the 
postanaesthetic period. The opioid sufentanil is a short-acting thiamyl 
analogue of the µ-agonist fentanyl (T 1/2 = 2 - 2.5 hours), but it is 11.5 
times more potent (Brunner et al., 1994). It is used as an anaesthetic 
supplement to provide analgesia in balanced anaesthesia protocols in 
men. The clinical use of a balanced anaesthetic protocol using 
sufentanil and midazolam in dogs has been reported (Hellebrekers 
and Sap, 1991). 
 
A long acting formulation of sufentanil (on a medium chain 
triglyceride base) has been investigated in several preclinical studies 
(Engelen et al., 1996a; Engelen et al., 1996b; Engelen et al., 1996c; 
Short and Vlaminck, 1998; Verbeeck et al., 1998). The dosage and 
the pharmacokinetic profile were confirmed in a dose finding trial and 
the safety was assessed in a tolerance study (Verbeeck et al., 1998; 
Hoeben et al., 1999; Sterkens, 1999). After intramuscular 
administration of 50 µg/kg BWT plasma levels of sufentanil very 
rapidly increased and peak levels around 1.53 ± 0.45 ng/ml were 
observed around 6 hours after injection. After this peak, the plasma 
concentration of sufentanil slowly decreased. The T1/2 was 15.8 ± 5.1 
hours. A dosage of 50 µg/kg of sufentanil LA provided plasma levels 
between 0.85 and 1.5 ng sufentanil/ml for at least 12 hours (Short, 
1996). 
In these studies sufentanil LA induced not only sedation but 
also the typical opioid side-effects such as reductions in heart rate, 
arterial blood pressure, rectal temperature, respiratory rate, and an 
increase in arterial carbon dioxide tension (Abdul-Rasool et al., 1989; 
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Werner et al., 1991; Engelen et al., 1996a; Engelen et al., 1996b; 
Engelen et al., 1996c; Short, 1996; Short and Vlaminck, 1998; 
Verbeeck et al., 1998; Hoeben et al., 1999; Sterkens et al., 1999). A 
classic anaesthetic technique to provide surgical anaesthesia in 
veterinary medicine consists in an intravenous induction of 
anaesthesia and subsequent maintenance by delivering a volatile 
agent with oxygen. 
 
Thiopental, a short acting barbiturate and a popular veterinary 
induction agent, is known to induce induction apnoea, respiratory 
acidosis and hypoxaemia (Rawlings and Kolata, 1983; Muir, 1998a; 
Muir, 1998b). It also affects the cardiovascular system with 
hypotension, bradycardia followed by reflex tachycardia, hypertension 
and arrhythmias (Muir, 1998a; Muir, 1998b). Sevoflurane is a 
halogenated hydrocarbon developed by Wallin et al. (1975). In Europe 
it is commercially available as an inhalant anaesthetic for men since 
the early nineties. It is also used as a volatile anaesthetic in animals 
and its use in this field is expected to increase in the future. Like all 
volatile anaesthetics it also affects the cardiovascular and respiratory 
system (Mutoh et al., 1997; Polis et al., 2001a; Polis et al., 2001b). In 
a previous study in sevoflurane anaesthetized dogs dose dependent 
decreases in blood pressure, cardiac output, stroke volume and 
respiration rate in combination with an increase in arterial carbon 
dioxide tension were observed (Polis et al., 2001a).  
 
Because the proposed therapeutic dose of sufentanil LA (50 
µg/kg) is known to depress several cardiovascular and respiratory 
parameters, the use of sufentanil LA premedication before thiopental 
induction and sevoflurane as anaesthetic maintenance is expected to 
enhance cardiovascular and respiratory side-effects of the general 
anaesthetics. The present study was done to evaluate cardiovascular 
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status and gas exchange during and following clinically conducted 
sevoflurane anaesthesia when sufentanil LA was used as a 
premedication administered at different time points before induction.  
 
MATERIALS AND METHODS 
 
The study was approved by the Ethical committee of the 
Faculty of Veterinary Medicine, Ghent University (filenumber: 
39/2000). Forty adult female Beagles weighing 11.97 ± 1.40 kg (mean 
± SD) from 1 to 2 years old were used in the study. The dogs were 
dewormed and vaccinated 1 month before the experiment. Clinical 
examination one week before the experiment confirmed the good 
health status of the animals.  
 
Study Protocol 
The present study was an open randomised study with 40 
dogs divided over 5 parallel groups. The study was conducted in 40 
phases; each phase consisted of 1 dog monitored 24 hours after the 
administration of the drugs. No blinding was performed. 
 
  Table 1: Study groups involved in the study of sufentanil LA                                                    
  followed by sevoflurane anaesthesia in dogs (n=40). 
STUDY 
No. of 
DOGS SUFENTANIL 
GROUP   (µg/kg) 
      
Time interval between sufentanil/vehicle 
administration and initiation of inhalation 
anaesthesia 
A (control suf) 8 50 * 
 B  (control sevo)  8 0 (vehicle) § 
 8 50 0 
 8 50 15 
 8 50 30 
 *   Dogs receive no inhalation anaesthesia, but only sufentanil at T0 
 §  Dogs receive sufentanil-vehicle and inhalation anaesthesia at T0 
     Initiation of inhalation anaesthesia was defined as T0; except for group A 
       Time expressed in minutes 
C0 
D15 
E30 
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The dogs in group A (control suf) received sufentanil LA at T0 
without inhalation anaesthesia. The dogs from group B (control sevo) 
received only the sufentanil-vehicle at T0 followed by inhalation 
anaesthesia. In groups C0,  D15 and E30 a time interval of respectively 
0, 15 and 30 minutes between sufentanil LA administration and 
anaesthesia induction was respected (Table 1). 
 
Preparation of the dogs 
A titanium vascular access port with a silicone membrane 
(Access Technologies, Skokie, IL, USA) connected to the femoral 
artery was surgically implanted 3 to 6 days before each experiment. 
This device was used for blood sampling and blood pressure 
measurement. Anaesthesia for this procedure consisted in a total 
intravenous protocol with propofol combined with epidural anaesthesia 
using lidocaine and bupivacaine. Analgesia was supplemented with 
carprofen given at a dosage of 4 mg/kg orally for 3 days, starting the 
evening before surgery. Patency of the vessel access port was 
controlled by daily flushing with 1 ml of heparinised saline (200-300 
I.U. heparin per ml). Three to five days after the experiment the port 
was surgically removed under isoflurane anaesthesia. 
 
Premedication and Induction of Anaesthesia 
The dogs of groups A, C0, D15 and E30 received sufentanil long 
acting formulation (sufentanil (0.5 mg/ml); Janssen Animal Health, 
Beerse, Belgium) at a dosage of 50 µg/kg of BWT administered IM in 
the lumbar muscles. The dogs of group B received only sufentanil-
vehicle. Anaesthesia (group B, C0, D15 and E30) was induced with 
thiopental (Pentothal®, Abbott Laboratories Ltd., Queenborough, UK). 
Four mg/kg was injected as a bolus and further dosing was slowly 
done to effect. “Effect” was defined as the moment that eyeballs 
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rotated ventrally and that intubation could be easily performed.  Mean 
injection dose was 13.3 ± 2.5 mg/kg of BWT. 
 
Maintenance of Anaesthesia 
              The dogs were positioned in lateral recumbency and 
connected to an anaesthetic machine with a circle system (Titus®, 
Dräger, Lübeck, Germany) and a sevoflurane out of circuit vaporiser 
(Vapor 19.3®, Dräger, Lübeck, Germany). The anaesthetic circuit was 
flushed with 100% oxygen for 5 minutes before the experiment. 
During the first 5 minutes of anaesthesia, a fresh gas flow of 2 l/min 
O2 was used which was subsequently reduced to 1 l/min. The dogs 
breathed spontaneously, but manual ventilation  was performed when 
marked respiratory depression occurred (PaCO2  > 55 mm Hg and/or 
RR< 15 breaths/min). During anaesthesia the percentage of 
sevoflurane was adjusted to obtain and maintain an anaesthetic depth 
suitable to perform surgical interventions much like it would have been 
done in clinical conditions. Such a level was thought to exist when the 
eye-lid reflex was absent and the eyeballs were ventrally rotated. 
Moreover a standardised pain stimulus was administered by clamping 
the tail for 5 seconds every 10 minutes at a distance of approximately 
3 cm from its top with a straight Rochester-Carmalt haemostatic 
forceps (10 cm) closed to the first ratchet lock. If a reaction (a 
movement, and/or an increase in HR of more than 15%) was 
observed, vaporizer settings were adjusted upwards with 0.5% on the 
vaporizer scale. If no reaction occurred, vaporizer settings were 
decreased step wise. Depth of anaesthesia was also controlled by 
observation of eye-lid reflex and position of the eyeballs and if 
necessary adjusted. Anaesthesia was continued for 90 minutes. No 
intravenous infusions were administered during the study. 
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Measurements and monitoring 
 A calibrated multigas analyser including a pulse oximetry 
unit (Quick Cal TM calibration gas® and Capnomac Ultima®, Datex 
Engstrom Instrumentation Corp., Helsinki, Finland) was used to 
monitor heart rate (HR), respiratory rate (RR), end tidal CO2%, 
inspiratory and end tidal sevoflurane concentration and peripheral 
oxygen haemoglobin saturation (SpO2%). MAP was recorded using a 
blood pressure transducer (Vascumed N.V., Gent, Belgium) 
connected to a blood pressure measuring device (Hellige Servomed 
SMV 104, Germany) following standard calibration procedure. The 
pressure transducer was connected to the vascular access port using 
extension tubing filled with heparinised saline (200-300 I.U. heparin 
per ml) and fitted with a special Huber point needle (Access 
Technologies, Skokie, IL, USA) used to perforate the silicone 
membrane of the vascular access port. Arterial blood was sampled 
through the vascular access port. The arterial oxygen (PaO2 in mm 
Hg) and carbon dioxide tension (PaCO2 in mm Hg), pH and arterial 
oxygen saturation (SaO2 in %) were measured immediately after 
sampling with a calibrated blood gas analyser and corrected for body 
temperature (ABL 5Ò, Radiometer Copenhagen, Denmark).   
   
 All parameters were measured immediately before 
intramuscular administration of sufentanil LA or the vehicle, 
immediately before inhalation anaesthesia (T0; except group A), and 
every 10 minutes during 90 minutes of inhalation anaesthesia. The 
same measurements were continued in the post anaesthetic period at 
120 minutes (T120), 240 minutes (T240) and 24 hours (T1440).  
  
 At the end of inhalation anaesthesia, the dogs breathed 
oxygen until extubation was possible. The dogs were transferred to 
the recovery box. If the rectal temperature was lower than 36°C, an 
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infrared heating source was installed in the recovery box. The 
occurrence of critical events was recorded in the time period T0 to 
T1440 when predetermined limits were surpassed. Critical values of 
each parameter are represented in Table 2. 
 
  Table 2:     Limits of the presence of critical events in the study of    
  sufentanil LA followed by sevoflurane anaesthesia in dogs (n=40). 
PARAMETER LIMIT CRITICAL VALUE 
Heart Rate < 45 beats/min 
Mean Arterial Blood Pressure < 75 mm Hg 
Respiratory Rate < 15 breaths/min 
PaCO2 > 55 mm Hg 
PaO2 < 75 mm Hg 
pH < 7.25 
Arterial O2 Saturation < 90 % 
  Abbreviations : see text. 
 
Statistical Analysis 
The dogs were sorted according to decreasing body weight 
and divided into 8 classes of 5 dogs each. In each class, the body 
weights were comparable. Within each class the 5 dogs were 
randomly allocated to the five different study groups and the 40 
phases by a computer randomisation program. The statistical tests 
were two-sided and used a 0.05 type I error (a=5%). 
The StatXact software (StatXact 3 For Windows (1995), Users 
Manual, CYTEL Software, Cambridge, MA 02139 USA) was used for 
the Kruskal-Wallis one-way analysis of variance tests, for the 
Wilcoxon Mann-Whitney U tests and for the Fisher’s exact tests 
(Siegel,1977). 
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The treatment groups A (control suf) and B (control sevo) 
were control groups. No statistics were done for these groups, since 
the effects of sufentanil LA and sevoflurane are studied previously in 
dogs (Bernard et al., 1990; Engelen et al., 1996a; Engelen et al., 
1996b; Engelen et al., 1996c; Short, 1996; Short and Vlaminck, 1998; 
Verbeeck et al., 1998; Hoeben et al., 1999; Sterkens et al., 1999). The 
body weights of the dogs were compared by means of the Kruskal-
Wallis one-way analysis of variance test to check the randomisation 
procedure. 
 
To evaluate the homogeneity of the several treatment groups, 
baseline comparisons (T0) was also performed on HR, MAP, RR, pH 
and blood gases of each treatment group by means of the Kruskal-
Wallis one-way analysis of variance test. For each parameter (HR, 
MAP, RR, PaCO2, PaO2, pH, SaO2) the following tests were 
performed: statistical comparisons on the mean over time (T0 to T90) 
was performed between the treatment groups C0, D15 and E30 by 
means of the Kruskal-Wallis one-way analysis of variance test 
followed by two-by-two Wilcoxon Mann-Whitney U tests. Each of the 
treatment groups C0, D15 and E30 was compared with the control 
groups A and B by Wilcoxon Mann-Whitney U tests.   
 
The individual time points after inhalation anaesthesia (T120, 
T240 and T1440) were analysed in the same way as the variable mean 
over time. The number of dogs with a critical event was calculated. 
The amounts of dogs with a critical parameter value were used to 
compare the treatment groups by means of the Fisher’s exact test. 
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RESULTS 
 
 Results for different measured variables are given in Table 3 and 
4 and Figures 1 to 6. No significant differences in baseline values per 
study group and per parameter were observed. The analgesic and 
sedative effects of sufentanil LA and the side effects which occurred in 
this experiment will be discussed in a second paper.  
 
Anaesthesia period (T0 to T90) 
HR was significantly lower in sufentanil treated inhalation 
groups D15 and E30 compared to group B (control sevo) (p<0.01). HR 
was significantly lower in group A (control suf) compared to groups C0 
and D15 (p<0.05). Minimum and maximum (min-max) values for HR 
were 52 (group A at T60) and 155 (group B at T0) beats/minute 
respectively. MAP was similar in all inhalation groups (B, C0,  D15 and 
E30). MAP was  lower in  all inhalation groups compared to group A 
and this difference was significant for groups C0, D15 and E30 
(p<0.001).  Min-max values for MAP were 36 (group B at T90) and 137 
(group C0 at T0) mm Hg. RR was similar in all inhalation groups (B, C
0, 
D15,  E30). RR was higher in group A compared to all inhalation groups 
and this difference was significant for groups C0, D15 and E30 (p<0.001 
and p<0.01). Min-max for RR were 2 (group D15 at T10) and 160 
(group A at T20) breaths/minute.  PaCO2 was higher in the sufentanil 
treated inhalation groups compared to group B (control sevo) but this 
was significant for group C0 and D15 only (p<0.01). PaCO2 was also 
significantly higher in groups C0 and D15 compared to group E30 
(p<0.01). PaCO2 was higher in all inhalation groups compared to 
group A and this difference was significant for groups C0, D15 and E30 
(p<0.001 and p<0.01). Min-max values of PaCO2 were 21 (group C
0 at 
T0) and 74 (group D
15 at T10) mm Hg. PaO2 was similar in all inhalation 
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groups (B, C0, D15 and E30) and significantly higher compared to group 
A (p<0.01). No significant differences between sufentanil treated 
inhalation groups and group B (control sevo) occurred. Min-max 
values of PaO2 were 63 (group B at T0) and 605 (group B at T70) mm 
Hg. SaO2 values in the inhalation groups were similar. SaO2 was 
higher in the inhalation groups compared to group A and this 
difference was significant for groups C0,  D15 and E30 (p<0.001); no 
differences were observed compared to group B (control sevo). SaO2 
values in the inhalation groups were similar. Min-max values of SaO2 
were 88 (group C0 at T0) and 100 (all groups) %. pH was significantly 
lower in groups C0, D15 and E30 compared to groups A and B (p<0.001 
and p<0.01). pH min-max values were 7.10 (group E30 at T10 and T20; 
group C0 at T10) and 7.42 (group C
0 at T0 and group A at T90).  
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Post-anaesthetic period (T120 to T1440) 
HR was significantly lower at all time points in the sufentanil 
treated inhalation groups C0, D15 and E30 compared to group B 
(control sevo) (p<0.05 to p<0.001). HR was not significantly different 
between these groups except in group D15, where HR was 
significantly lower compared to group C0 at time point T240 (p<0.05). 
HR was not significantly different between sufentanil treated inhalation 
groups C0, D15 and E30 and group A (control suf) except for time point 
T240 where HR in group C
0 was significantly higher (p<0.01). Min-max 
values for HR were 44 (group E30 at T240) and 170 (group B at T120). 
MAP was lower in all sufentanil treated groups compared to group B 
(control sevo). At T120 this difference was statistically significant when 
compared with groups C0 and E30 (p<0.01 and p<0.001). At T1440 MAP 
in group C0 was significantly higher compared to group A (control suf). 
Min-max values for MAP were between 71 (group A at T120) and 165 
(group C0 at T1440) mm Hg.  
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Table 3A : Cardiopulmonary effects in sufentanil LA and sevoflurane anaesthetized dogs (n=40). 
                  
  Groups T=presuf T=0 T=10 T=20 T=30 T=40 T=50 
                  
HR Group A 107.5 ± 6.1 107.5 ± 6.1 95.9 ± 7.7 89.3 ± 3.9 85.6 ± 5.6 85.0 ± 6.6 78.8 ± 5.7 
beats                 
per Group B 109.0 ± 6.1 109.0 ± 6.1 141.8 ± 3.4 136.3 ± 3.3  129.9 ± 4.1 126.5 ± 3.7 123.8 ± 2.8 
minute                 
  Group C 106.5 ± 7.1 106.5 ± 7.1 125.6 ± 6.6 122.8 ± 6.5 111.0 ± 9.0 104.0 ± 8.4 101.4 ± 7.5 
      * * * * * * 
  Group D 105.5 ± 3.8 93.0 ± 4.4 116.6 ± 5.1 116.0 ± 6.5 110.9 ± 6.2 106.6 ± 5.9 104.4 ± 5.5 
      *,| *,| *,| *,| *,| *,| 
  Group E 102.5 ± 5.0 85.8 ± 4.8 107.4 ± 8.4 109.3 ± 8.6 108.0 ± 7.2 107.3 ± 6.1 104.4 ± 6.3 
      | | | | | | 
MAP Group A 117.8 ± 3.4 117.8 ± 3.4 105.8 ± 3.1 104.0 ± 4.2 102.0 ± 4.3 105.0 ± 2.3 105.8 ± 2.2 
mm Hg                 
  Group B 116.4 ± 2.8 116.4 ± 2.8 64.6 ± 3.4 62.5 ± 3.7 65.5 ± 4.2 65.0 ± 3.8 65.5 ± 4.3 
                  
  Group C 119.6 ± 3.2 119.6 ± 3.2 68.1 ± 2.0 61.4 ± 3.6 60.4 ± 2.6 64.8 ± 1.6 66.5 ± 1.6 
      * * * * * * 
  Group D 120.0 ± 4.5 106.3 ± 2.8 70.4 ± 2.9 63.8 ± 3.1 64.3 ± 3.3 65.8 ± 3.4 65.5 ± 3.2 
      * * * * * * 
  Group E 114.5 ± 8.1 102.1 ± 5.6 63.0 ± 3.4 63.3 ± 2.8 63.8 ± 2.8 63.6 ± 3.4 62.3 ± 3.9 
      * * * * * * 
RR Group A 24.3 ± 1.7 24.3 ± 1.7 68.0 ± 15.7 81.3 ± 14.9 71.0 ± 10.9 49.8 ± 7.2 37.0 ± 7.3 
breaths                 
per Group B 27.8 ± 1.1 27.8 ± 1.1 15.6 ± 2.4 12.9 ± 0.6 13.1 ± 1.4 13.0 ± 1.3 13.4 ± 1.6 
minute                 
  Group C 28.3 ± 2.6 28.3 ± 2.6 25.8 ± 5.8 17.1 ± 4.8 14.4 ± 4.0 15.0 ± 3.9 14.5 ± 3.6 
      * * * * * * 
  Group D 24.0 ± 1.7 66.0 ± 19.7 15.0 ± 4.2 11.9 ± 2.3 12.1 ± 1.9 12.6 ± 2.3 12.9 ± 2.6 
      * * * * * * 
  Group E 25.0 ± 2.9 87.5 ± 13.9 14.4 ± 2.4 12.3 ± 1.9 12.6 ± 1.9 13.6 ± 2.2 15.8 ± 4.1 
      *,| *,| *,| *,| *,| *,| 
Data are expressed as mean ± standard deviation. * significantly different from group A (p < 0.05)  
 | significantly different from group B (p < 0.05); § significantly different from group D (p < 0.05). 
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Table 3B : Cardiopulmonary effects in sufentanil LA and sevoflurane anaesthetized dogs (n=40). 
                  
  Groups T=60 T=70 T=80 T=90 T=120 T=240 T=1440 
                  
HR Group A 78.0 ± 6.4 76.5 ± 5.8 84.3 ± 8.3 80.0 ± 6.7 88.3 ± 6.3 71.3 ± 5.8 71.8 ± 4.3 
beats                 
per Group B 122.6 ± 3.5 121.3 ± 3.4 120.0 ± 3.6 118.3 ± 3.6 156.3 ± 3.7 132.0 ± 7.9 101.3 ± 7.5 
minute                 
  Group C 101.6 ± 7.5 101.0 ± 7.8 99.9 ± 7.9 99.9 ± 8.7 99.8 ± 9.2 104.5 ± 7.1 75.8 ± 5.3 
    * * * * | *,| | 
  Group D 100.9 ± 5.4 101.3 ± 6.7 96.3 ± 4.7 94.8 ± 4.3 96.5 ± 9.0 80.8 ± 5.3 78.8 ± 8.4 
    *,| *,| *,| *,| | | | 
  Group E 104.4 ± 6.1 102.8 ± 6.1 101.0 ± 5.3 97.5 ± 4.7 98.6 ± 7.2 80.6 ± 8.0 68.8 ± 5.5 
    | | | | | | | 
MAP Group A 98.3 ± 2.7 96.1 ± 3.6 94.8 ± 3.3 94.3 ± 2.4 104.1 ± 6.9 113.1 ± 3.5 108.9 ± 4.4 
mm Hg                 
  Group B 67.4 ± 4.4 69.1 ± 4.6 68.5 ± 5.0 67.1 ± 5.1 132.4 ± 4.0 122.1 ± 2.9 126.3 ± 2.4 
                  
  Group C 67.9 ± 2.4 64.6 ± 2.3 64.3 ± 2.9 64.3 ± 3.0 109.9 ± 4.5 118.0 ± 5.8 126.8 ± 6.4 
    * * * * |   * 
  Group D 63.8 ± 3.4 65.0 ± 3.2 64.4 ± 3.3 66.8 ± 3.5 112.9 ± 7.4 110.3 ± 4.8 119.3 ± 7.1 
    * * * *       
  Group E 61.8 ± 2.5 62.0 ± 3.0 62.9 ± 3.2 62.4 ± 3.5 103.9 ± 4.1 109.6 ± 5.6 115.4 ± 8.0 
    * * * * |     
RR Group A 39.0 ± 5.7 47.5 ± 10.8 42.3 ± 10.4 41.5 ± 6.7 43.0 ± 9.1 34.5 ± 14.0 22.5 ± 2.4 
breaths                 
per Group B 13.9 ± 1.3 13.4 ± 1.2 13.1 ± 1.0 13.6 ± 1.1 30.6 ± 3.1 43.0 ± 16.8 40.8 ± 6.5 
minute                 
  Group C 16.4 ± 3.0 17.1 ± 3.0 17.4 ± 3.3 17.6 ± 3.5 25.0 ± 3.7 22.5 ± 2.8 23.3 ± 2.5 
    * * * * *   | 
  Group D 13.9 ± 2.4 14.9 ± 2.5 14.8 ± 2.7 13.8 ± 2.0 27.5 ± 3.0 19.0 ± 1.5 23.3 ± 1.6 
    * * * *   | | 
  Group E 13.0 ± 2.5 14.9 ± 3.3 13.6 ± 2.8 13.1 ± 2.5 20.8 ± 2.1 18.3 ± 1.8 22.3 ± 1.6 
    *,| *,| *,| *,| *,|, § | | 
Data are expressed as mean ± standard deviation. * significantly different from group A (p < 0.05)  
 | significantly different from group B (p < 0.05); § significantly different from group D (p < 0.05). 
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 Table 4A : Acid-base balance and blood gas analysis in sufentanil LA      
 and sevoflurane anaesthetized dogs (n=40).      
                  
    T=control T=0 T=10 T=20 T=30 T=40 T=50 
                  
PaO2 A 105.6 ± 3.8 105.6 ± 3.8 104.3 ± 3.5 100.0 ± 2.9 100.1 ± 2.1 99.9 ± 4.1 97.4 ± 2.4 
                 
mm Hg B 107.3 ± 2.0 107.3 ± 2.0 493.5 ± 19.0 505.0 ± 20.3  497.4 ± 16.8 509.0 ± 14.7 516.8 ± 18.6 
                  
  C 105.4 ± 6.4 105.4 ± 6.4 484.5 ± 12.4 469.9 ± 15.7 503.3 ± 16.5 481.9 ± 20.9 462.1 ± 20.1 
      * * * * * * 
  D 107.8 ± 1.4 103.8 ± 2.2 442.3 ± 38.0 494.4 ± 11.5 498.1 ± 14.8 510.8 ± 10.2 484.9 ± 15.5 
      * * * * * * 
  E 108.0 ± 2.1 105.0 ± 2.4 499.5 ± 12.9 488.0 ± 24.2 475.9 ± 25.0 480.1 ± 26.5 495.8 ± 16.0 
      * * * * * * 
SaO2 A 96.6 ± 0.3 96.6 ± 0.3 96.5 ± 0.4 96.1 ± 0.4 96.4 ± 0.3 96.3 ± 0.5 96.0 ± 0.3 
                 
%  B 97.1 ± 0.2 97.1 ± 0.2 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 
                  
  C 96.1 ± 1.2 96.1 ± 1.2 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 
      * * * * * * 
  D 97.3 ± 0.2 97.0 ± 0.2 99.9 ± 0.1 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 
      * * * * * * 
  E 97.0 ± 0.2 96.9 ± 0.3 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 
      * * * * * * 
pH A 7.37 ± 0.01 7.37 ± 0.01 7.35 ± 0.01 7.34 ± 0.01 7.33 ± 0.01 7.34 ± 0.01 7.34 ± 0.01 
                  
  B 7.34 ± 0.01 7.34 ± 0.01 7.26 ± 0.01 7.25 ± 0.01 7.25 ± 0.01 7.26 ± 0.01 7.27 ± 0.01 
                  
  C 7.36 ± 0.01 7.36 ± 0.01 7.17 ± 0.02 7.16 ± 0.02 7.18 ± 0.02 7.20 ± 0.01 7.20 ± 0.01 
      *,| *,| *,| *,| *,| *,| 
  D 7.36 ± 0.01 7.34 ± 0.01 7.17 ± 0.01 7.17 ± 0.01 7.19 ± 0.01 7.20 ± 0.01 7.21 ± 0.01 
      *,| *,| *,| *,| *,| *,| 
  E 7.34 ± 0.01 7.31 ± 0.02 7.17 ± 0.02 7.19 ± 0.02 7.20 ± 0.01 7.22 ± 0.02 7.22 ± 0.02 
      *,| *,| *,| *,| *,| *,| 
PaCO2 A 33.3 ± 0.9 33.3 ± 0.9 34.6 ± 0.9 36.9 ± 1.4 37.1 ± 1.3 35.5 ± 1.2 35.0 ± 1.4 
                 
mm Hg B 31.9 ± 0.7 31.9 ± 0.7 45.1 ± 3.2 48.1 ± 1.7 47.4 ± 1.9 45.9 ± 1.5 44.9 ± 1.7 
                  
  C 32.8 ± 1.0 32.8 ± 1.0 34.6 ± 0.6 62.8 ± 1.9 62.0 ± 1.9 59.9 ± 1.2 57.5 ± 1.7 
      *,|,§ *,|,§ *,|,§ *,|,§ *,|,§ *,|,§ 
  D 32.8 ± 1.0 34.6 ± 0.6 62.8 ± 3.1 62.0 ± 1.9 59.9 ± 1.2 57.5 ± 1.7 57.5 ± 1.7 
      *,|,§ *,|,§ *,|,§ *,|,§ *,|,§ *,|,§ 
  E 32.0 ± 1.1 31.9 ± 1.9 54.8 ± 1.6 51.6 ± 2.8 49.3 ± 2.8 46.9 ± 3.3 47.9 ± 3.3 
      | | | | | | 
Data are expressed as mean ± standard deviation. * significantly different from group A (p < 0.05) 
 | significantly different from group B (p < 0.05); § significantly different from group E (p < 0.05). 
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 Table 4B : Acid-base balance and blood gas analysis in sufentanil LA      
 and sevoflurane anaesthetized dogs (n=40).      
                  
    T=60 T=70 T=80 T=90 T=120 T=240 T=1440 
                  
PaO2 A 98.9 ± 2.5 98.9 ± 2.5 98.3 ± 3.0 98.1 ± 4.4 101.0 ± 3.0 94.9 ± 2.8 91.5 ± 2.5 
                 
mm Hg B 521.8 ± 14.4 513.6 ± 19.2 472.1 ± 27.2 519.9 ± 15.8 110.6 ± 1.3 107.3 ± 3.1 104.9 ± 2.6 
                  
  C 475.4 ± 32.8 476.4 ± 13.9 487.8 ± 25.0 498.8 ± 13.7 95.3 ± 2.5 93.6 ± 1.9 88.3 ± 2.4 
    * * * * | | | 
  D 508.0 ± 12.1 494.9 ± 16.4 505.1 ± 15.8 525.0 ± 10.2 96.1 ± 2.4 90.0 ± 1.3 93.5 ± 3.4 
    * * * * | | | 
  E 513.5 ± 18.4 497.0 ± 19.6 488.0 ± 21.6 487.8 ± 22.3 101.4 ± 4.1 90.3 ± 3.0 89.0 ± 1.5 
    * * * *   | | 
SaO2 A 96.1 ± 0.4 96.3 ± 0.3 96.1 ± 0.4 96.4 ± 0.4 96.6 ± 0.3 96.5 ± 0.3 95.9 ± 0.6 
                 
%  B 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 97.6 ± 0.2 97.1 ± 0.2 97.0 ± 0.2 
                  
  C 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 96.0 ± 0.3 96.1 ± 0.4 95.5 ± 0.6 
    * * * * |     
  D 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 96.4 ± 0.3 96.0 ± 0.2 96.1 ± 0.4 
    * * * * | |   
  E 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 96.8 ± 0.5 96.1 ± 0.4 96.0 ± 0.3 
    * * * * |     
pH A 7.33 ± 0.01 7.33 ± 0.01 7.34 ± 0.01 7.34 ± 0.01 7.32 ± 0.01 7.31 ± 0.01 7.34 ± 0.01 
                  
  B 7.27 ± 0..01 7.28 ± 0.01 7.28 ± 0.02 7.28 ± 0.01 7.34 ± 0.01 7.35 ± 0.01 7.35 ± 0.01 
                  
  C 7.20 ± 0.01 7.20 ± 0.01 7.21 ± 0.01 7.21 ± 0.01 7.28 ± 0.02 7.28 ± 0.01 7.31 ± 0.01 
    *,| *,| *,| *,| | | | 
  D 7.21 ± 0.01 7.21 ± 0.01 7.22 ± 0.01 7.21 ± 0.01 7.28 ± 0.01 7.26 ± 0.01 7.33 ± 0.01 
    *,| *,| *,| *,| | *,|   
  E 7.22 ± 0.02 7.22 ± 0.02 7.22 ± 0.02 7.23 ± 0.02 7.26 ± 0.01 7.26 ± 0.01 7.33 ± 0.01 
    *,| *,| *,| *,| *,| *,|   
PaCO2 A 35.5  ± 1.0 37.5 ± 2.5 38.0 ± 3.0 37.1 ± 2.9 36.8 ± 2.0 40.3 ± 2.1 38.3 ± 2.0 
                 
mm Hg B 43.8 ± 1.5 44.1 ± 1.6 40.5 ± 2.2 43.0 ± 1.6 31.0 ± 0.7 29.5 ± 1.1  32.4 ± 1.0 
                  
  C 57.5 ± 1.7 57.9 ± 1.2 56.5 ± 0.9 55.3 ± 1.5 57.5 ± 1.6 42.4 ± 1.8 39.4 ± 1.6 
    *,|,§ *,|,§ *,|,§ *,|,§ | | | 
  D 57.9 ± 1.2 56.5 ± 0.9 55.3 ± 1.5 57.5 ± 1.6 42.4 ± 1.8 45.5 ± 1.7 39.4 ± 1.6 
    *,|,§ *,|,§ *,|,§ *,|,§ *,| | | 
  E 50.0 ± 3.0 50.3 ± 2.1 49.5 ± 2.5 47.3 ± 2.2 39.9 ± 1.7 40.4 ± 3.0  42.8 ± 1.4 
    | | | | | | | 
Data are expressed as mean ± standard deviation. * significantly different from group A (p < 0.05) 
 | significantly different from group B (p < 0.05); § significantly different from group E (p < 0.05). 
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Following the end of inhalation anaesthesia RR increased in 
all groups. RR was lower in sufentanil treated inhalation groups 
compared to group B (control sevo). This difference was significant at 
T120 for group E
30 (p<0.05) , at T240 for groups D
15 and E30 (p<0.01) 
and at T1440 for groups C
0,  D15 and E30 (p<0.05 and p<0.01). There 
was no significant difference between the sufentanil treated inhalation 
groups; except at T120 where group E
30 had a lower RR compared to 
D15 (p<0.05). Respiratory rate in group A (control suf) was higher than 
in the sufentanil treated inhalation groups in the post-anaesthetic 
period. This difference was significant at T120 compared to groups C
0 
and E30 (p<0.05 and p<0.01). The min-max values for RR were 12 (1 
dog in groups A, C0,  D15 and E30 at T240) and 160 (group B at T240) 
breaths/minute. Following the end of inhalation anaesthesia PaCO2 
decreased rapidly in all groups until T120 and remained stable for the 
remainder of the post-anaesthetic period. PaCO2 was significantly 
higher in the sufentanil treated inhalation groups compared to group B 
(control sevo) at all time points (p<0.001 and p<0.05). PaCO2  in 
group A (control suf ) was similar as in the sufentanil treated inhalation 
groups; except at T120 where PaCO2 was significantly higher in group 
D15 compared to A (p<0.05). Min-max values for PaCO2 were 25 
(group B at T240) and 54 (group D
15 at T240). Following the end of 
inhalation anaesthesia PaO2 decreased rapidly to baseline values in 
all groups. PaO2 was lower in the sufentanil treated inhalation groups 
compared to group B (control sevo). This difference was significant at 
all time points (at T120 not for group E
30) (from p<0.05 to p<0.001). No 
significant differences existed between the  sufentanil treated 
inhalation groups (C0, D15 and E30) and group A (control suf). Min-max 
values for PaO2 were 75 (group C
0 at T1440) and 122 (group B at T240) 
mm Hg. SaO2 was lower in the sufentanil treated inhalation groups 
compared to group B (control sevo). At time point T120 the difference 
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was significant for group C0 and D15 (p<0.01 and p<0.05), at T240 for 
group D15 (p<0.01) and at T1440 for groups C
0 and E30 (p<0.05). No 
significant differences existed between the  sufentanil treated 
inhalation groups (C0, D15 and E30) and group A (control suf). Min-max 
values for SaO2 were 92 (group A and C
0 at T1440) and 99 (group E
30 
at T120) %. pH was significantly lower in the sufentanil treated 
inhalation groups compared to group B (control sevo) at all time points 
(p<0.05 to p<0.001); except for groups D15 and E30 at T1440. pH in 
group A (control suf) was higher compared to the other sufentanil 
groups; but this was only significant for group E30 at T120 and T240 and 
for group D15 at T240. Min-max values for pH were 7.22 (group D
15 at 
T120 and group E
30 at T120 and T240) and 7.40 (group A at T1440 and 
group B at T240).  
 
Critical events 
Incidence of critical events for the different parameters and 
groups are given in Table 5. A HR below the critical value of 45 
beats/minute was observed in only one dog (group E30 at T240). In 
group A (control suf) MAP (71 mm Hg) decreased below the critical 
value in only one dog at T120. All dogs of all inhalation groups showed 
MAP values below the critical value of 75 mmHg at one or more time 
points compared to only one dog in group A (p<0.01). No significant 
differences in critical MAP values between the sufentanil treated 
inhalation groups compared to group B (control sevo) were observed. 
The majority of the dogs of each inhalation group showed critical 
events for RR. There were no significant differences in the number of 
critical values between the sufentanil treated inhalation groups 
compared to group B (control sevo). Significantly more RR values 
below the critical level of 15 breaths/min occurred in groups C0,  D15 
and E30 compared to group A (p<0.05). Manual ventilation was applied 
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3 times (2 dogs in group C0 and 1 in group E30), for the dog in group 
E30 controlled ventilation was necessary during the complete 
anaesthetic period. Critical events (above 55 mm Hg) for PaCO2 were 
only observed during the anaesthesia period, whereby significantly 
more critical PaCO2 values were seen in groups C
0 and D15 compared 
to group A and B (control sevo) (p<0.05 and p<0.01). Only one critical 
value (below 75 mm Hg) with a PaO2 of 63 mm Hg occurred in group 
C0 immediately after anaesthesia induction (T0). Over the entire study 
period (T0 to T1440) only one dog showed a SaO2 % below the critical 
value of 90% (88% in group C0 at T0). Most of the critical pH values 
(below 7.25) occurred during the inhalation period. Four dogs showed 
critical values in group B compared to 8 dogs in groups C0,  D15 and 
E30, respectively. Significantly more pH values over time (T0 to T1440) 
below 7.25 were observed in groups C0, D15 and E30 compared to 
group A (p<0.01) but not compared to group B.   
 
DISCUSSION 
 
In the present study HR during the anaesthetic period (T0 to 
T90) was lower in the groups treated with sufentanil compared to group 
B (control sevo). This decrease in HR was expected to occur with 
sufentanil administration. Opioids and especially potent narcotic drugs 
such as sufentanil induce a dose-dependent centrally mediated 
bradycardia, which may be obtund by parasympathicolytic drugs 
(Reddy, 1980; De Hert, 1991; Nolan and Reid, 1991). Studies in dogs 
have shown that anaesthesia with high doses of sufentanil produced 
only minimal haemodynamic changes (De Castro et al., 1979; Reddy 
et al., 1980; Eriksen et al., 1981; Philbin et al., 1984; Abdul-Rasool 
and Ward, 1989). In all inhalation groups however an initial rise in HR 
followed by a decline after 20 minutes was observed. This initial 
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increase might be related to thiopental used for induction. Thiopental 
administration was reported to induce an initial increase in HR 
probably due to the baroreceptor mediated sympathetic reflex 
stimulation of the heart followed by a decrease in HR. This is in line 
with the findings in the present study (Turner and Ilkiw, 1990; De Hert, 
1991; Ilkiw et al., 1991). The degree of bradycardia observed in all 
sufentanil treated inhalation groups could also be influenced by 
sevoflurane anaesthesia, since tachycardia resulting from sympathetic 
and baroreceptor reflex stimulation was observed in sevoflurane 
anaesthetized dogs (Mutoh et al., 1997; Polis et al., 2001a). In 
contrast to the anaesthetic period where bradycardia was probably 
partially compensated by thiopental (induction) and sevoflurane 
(maintenance), a long-lasting bradycardia persisted for 24 hours after 
anaesthesia. HR decreased below the critical value of 45 beats/min in 
only one dog (E30 at T240) out of 40 dogs. This critical value for HR 
was chosen arbitrarily. The importance of a bradycardia as factor of 
oxygen delivery to the tissues will depend also on concomitant factors 
such as haemoglobin concentration, oxygen saturation and oxygen 
consumption. 
 
In group A (control suf) MAP decreased moderately during the 
first 2 hours after administration, afterwards MAP remained slightly 
below baseline values for 24 hours after administration. Small 
decreases in MAP were reported after sufentanil administration in 
dogs (De Castro et al., 1979; Berthelsen et al., 1980; Reddy, 1980; 
Berthelsen et al., 1981) and this was confirmed in the present study. 
During the anaesthesia period (T0 to T90) the lower MAP in the 
inhalation groups and the increased incidence of mean blood pressure 
values below 75 mm Hg (critical value) could be attributed to the effect 
of sevoflurane. The latter is reported to depress systemic blood 
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pressure in dogs in a dose-dependent manner (Bernard et al., 1990; 
Frink et al., 1992; Harkin et al., 1994; Mutoh et al., 1997; Polis et al., 
2001a). In this study sevoflurane administration was adjusted 
according to the reaction to a standardised pain stimulus. During 
anaesthesia all inhalation groups had a similar MAP course despite 
different end-tidal sevoflurane concentration were used. End-tidal 
sevoflurane concentrations used in the sufentanil treated inhalation 
groups were lower than in the sevoflurane control group. The similar 
MAP in the different groups can be explained by a relatively small 
difference in end-tidal sevoflurane concentration between the different 
groups (see study part II).  
 
In group A (control suf) RR increased sharply after sufentanil 
LA administration up to 160 breaths/min while PaCO2 showed only a 
slight increase. An initial transient period of panting is a common 
finding in dogs when high doses of opioids are administered or when 
neurolept-analgesic combinations are given (Lukasik, 1999; Nolan, 
2000). The occurrence of panting is probably related to alteration of 
the thermoregulatory centre in the hypothalamus (Lascelles, 2000). To 
the contrary, in all inhalation groups a respiratory depression 
characterised by a decreased RR and pH and increased PaCO2 
developed accompanied by an increased incidence of critical values 
for these parameters. This depression was, as expected, more 
pronounced in the sufentanil treated inhalation groups. First, 
inhalation anaesthetics including sevoflurane depress spontaneous 
ventilation in a dose-dependent manner (Mutoh et al., 1997). 
Secondly, sufentanil like other opioids produces also a dose-
dependent respiratory depression, which may occasionally be rapid 
and severe (Monk et al., 1988; Abdul-Rasool and Ward, 1989). The 
respiratory depression is caused by a decreased responsiveness of 
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the respiratory centre to carbon dioxide, while the hypoxic stimulus to 
breathing is unaffected (Florez et al., 1968). This is potentially one of 
the most serious side effects in humans, but it is rarely a clinical 
problem in dogs and cats unless the drugs are combined with other 
potent respiratory depressants as is the case during general 
anaesthesia (Nolan and Reid, 1991). The  more pronounced 
respiratory depression during  sevoflurane anaesthesia  following 
sufentanil treatment can also be explained by the combined 
respiratory depressant effect of sufentanil and sevoflurane (Steffey et 
al., 1993; Steffey et al., 1994; Mutoh et al., 1997). The rather smaller 
increase in PaCO2 in group E during anaesthesia (PaCO2 significantly 
lower compared to C0 and D15) suggests a lower degree of respiratory 
depression when sufentanil LA premedication was done 30 minutes 
before induction of anaesthesia. In the postanaesthetic period RR was 
higher in group B (control sevo) compared to the sufentanil treated 
inhalation groups. This can be explained by the specific 
pharmacokinetic profile of sufentanil LA with long lasting  plasma 
levels (Short, 1996). 
 
PaO2 and SaO2 during anaesthesia were significantly higher in 
all inhalation groups compared to group A (control suf) due to a high 
inspired oxygen fraction. For the same reason PaO2 and SaO2 values 
were normal during anaesthesia and not different between the 
inhalation groups despite a higher PaCO2 and lower RR due to 
enhanced respiratory depression in the sufentanil treated groups. 
During the postanaesthetic period however when room air was 
breathed the persistent respiratory depression can explain the lower 
PaO2 in groups C
0,  D15 and E30 compared to group B (control sevo). 
Since no hypoxia (no value below 75 mm Hg) occurred, this was 
probably clinically not relevant. 
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In the present study use of sufentanil LA as premedication 
moderately enhanced some cardiopulmonary side effects 
accompanying clinically adjusted sevoflurane anaesthesia. The 
addition of sufentanil LA as premedication caused a decrease in HR 
and an increase in PaCO2, while MAP was well maintained. The 
clinical importance is probably limited during inhalation anaesthesia 
where a high inspired oxygen fraction was accompanied by a high 
PaO2 and SaO2 (with exception of only one dog shortly after 
induction). Temporary support of ventilation with IPPV however might 
be occasionally necessary. Therefore clinical observation and/or 
respiratory function monitoring with spirometry or capnography would 
be helpful. Thirty minutes between sufentanil LA premedication and 
induction of anaesthesia might be preferable, since less respiratory 
depression occurred in group E30. In the postanaesthetic period the 
bradycardia persisted and was still present after 24 hours.  Although 
RR was lower then the control group without sufentanil pretreatment, 
PaCO2 and PaO2 were within an acceptable range in the 
postanaesthetic period up to 24 hours.  
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SUMMARY 
 
The purpose of the present study was to determine an optimal 
time interval between the administration of sufentanil long acting and 
the induction of sevoflurane anaesthesia induced by thiopental in 
dogs. The occurrence of sedation, antinociceptive and sevoflurane-
sparing effects together with other potential side effects were 
evaluated. Forty dogs were divided over 5 parallel groups of 8 dogs 
each. Two control groups were used: one group of dogs (A) received 
sufentanil LA (50 µg/kg IM) and a second group (B) the sufentanil 
vehicle followed by a standard inhalation anaesthesia of 90 minutes. 
After premedication with sufentanil LA immediately before (C0), 15 
minutes (D15) or 30 minutes (E30) prior to induction with thiopental (IV) 
the dogs were anaesthetized for 90 minutes with sevoflurane in 
oxygen.  
 
Pain and sedation scores were evaluated every 10 minutes 
during anaesthesia and at 2 (T120), 4 (T240) and 24 hours (T1440) after 
induction. The occurrence of adverse events such as hypothermia, 
lateral recumbency, ataxia, noise-sensitivity, vomiting, defaecation, 
salivation, nystagmus, excitation… was observed at the same time 
points.  
 
In the post-anaesthetic period pain scores were lower and 
sedation scores higher in the sufentanil treated groups. In many dogs 
diminished pain and elevated sedation scores persisted for 24 hours. 
Sufentanil LA offered a significant sevoflurane sparing effect, which 
was most pronounced when it was administered 15 minutes before 
induction of anaesthesia. Several dogs showed ataxia, lateral 
recumbency, arousal on auditory stimulation, defaecation, salivation 
and excitation at several time points after sufentanil administration. 
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 In conclusion, sufentanil LA in addition to sevoflurane 
anaesthesia offered beneficial dosage reducing analgesic effects; 
although several clinically irrelevant opioid side effects occurred. The 
most advantageous dosage reducing effect occurred when 
premedication with sufentanil LA was done 15 minutes before 
induction of sevoflurane anaesthesia. 
 
INTRODUCTION 
 
Opioid drugs have been used for the relief of pain for over 
2000 years and today they are still of enormous therapeutic 
importance as the drug of choice for the treatment of moderate to 
severe pain. Pre-emptive analgesia is used to reduce surgical 
nociceptive input and subsequent postoperative pain (Pascoe, 1992). 
A clinical advantage of pre-emptive analgesia is the dose reduction of 
anaesthetic drugs by integrating analgesic therapy into a balanced 
anaesthetic regimen, which eventually results in improved patient 
safety (Brunner et al., 1994; Moon et al., 1995).  
 
The short-acting narcotic, sufentanil, is used as an 
anaesthetic supplement to provide analgesia in balanced anaesthesia 
protocols in both men and dogs. (Hellebrekers and Sap, 1991). The 
intermittent administration of short-acting opioids however might be 
associated with specific problems as too lengthy dosing intervals. This 
might be overcome with the intramuscular administration of a potent 
opioid in a long-acting formulation. In the present study a long acting 
formulation of sufentanil (sufentanil LA) was used as premedication to 
provide effective analgesia for an extended period of time. It was 
postulated that the pharmacokinetic properties of sufentanil LA might 
overcome the problems associated with the use of short acting 
opioids, such as peaks and troughs in drug plasma level contributing 
to poor postoperative analgesia (Oden, 1989; Sinatra, 1991). Several 
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preclinical studies pointed out that a dose of 50 µg/kg IM of sufentanil 
LA was effective in dogs (Engelen et al., 1996a; Engelen et al., 1996b; 
Engelen et al., 1996c; Short and Vlaminck, 1998; Verbeeck et al., 
1998).  
 
Sevoflurane, a halogenated hydrocarbon developed by Wallin 
et al. (1975), is used as a volatile anaesthetic in men and animals. Its 
use in veterinary anaesthesia is expected to increase in the future. 
Like all volatile anaesthetics it affects the cardiovascular and 
respiratory system (Mutoh et al., 1997; Polis et al., 2001). Thiopental, 
a popular induction agent, is known to induce induction apnoea, 
respiratory acidosis and hypoxaemia (Rawlings and Kolata, 1983; 
Muir, 1998a; Muir, 1998b). It also affects the cardiovascular system 
with hypotension, bradycardia followed by reflex tachycardia, 
hypertension and arrhythmias (Muir, 1998a; Muir, 1998b).                                                                                               
 
The present experiments were performed to determine an 
optimal time interval between sufentanil LA administration and 
induction of sevoflurane anaesthesia in dogs. The occurrence of 
sedation, antinociceptive and sevoflurane-sparing effects together 
with other potential side effects such as hypothermia, lateral 
recumbency, ataxia, noise-sensitivity, vomiting, defaecation, 
salivation, nystagmus and excitation were evaluated.  
 
MATERIALS AND METHODS 
 
The study was approved by the Ethical committee of the 
Faculty of Veterinary Medicine, Ghent University (filenumber: 
39/2000). Forty adult female Beagles weighing 8.4 to 13.6 kg from 1 
to 2 years old were used in the study. The dogs were dewormed and 
vaccinated before the experiment. Clinical examination one week 
before the experiment confirmed the good health status of the 
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animals. No specific medication altering anaesthetic or analgesic 
requirements was administered previously to the dogs. 
 
Study Protocol 
The present study was an open randomised study with 40 
dogs divided over 5 parallel groups (n=8). The study was conducted in 
40 phases; each phase consisted of 1 dog monitored 24 hours after 
the administration of the drugs. No blinding was performed. 
 
The dogs in group A (control suf) received sufentanil LA at T0 
without inhalation anaesthesia. The dogs from group B (control sevo) 
received only the sufentanil-vehicle at T0 followed by inhalation 
anaesthesia. In groups C0,  D15 and E30 a time interval of respectively 
0, 15 and 30 minutes between sufentanil LA administration and 
anaesthesia induction was respected (Table 1). 
 
Premedication and Induction of Anaesthesia 
The dogs of groups A, C0, D15 and E30 received sufentanil long 
acting formulation (sufentanil (0.5 mg/ml); Janssen Animal Health, 
Beerse, Belgium) at a dosage of 50 µg/kg of BWT administered IM in 
the lumbar muscles. The dogs of group B received only sufentanil-
vehicle. Anaesthesia (group B, C0, D15 and E30) was induced with 
thiopental (Pentothal®, Abbott Laboratories Ltd., Queenborough, UK). 
Four mg/kg was injected as a bolus and further dosing was slowly 
done to effect. “Effect” was defined as the moment that eyeballs 
rotated ventrally and that intubation could be easily performed.  Mean 
injection dose was 13.3 ± 2.5 mg/kg of BWT. 
 
Maintenance of Anaesthesia 
              The dogs were positioned in lateral recumbency on a surgery 
table supplied with a thick isolating pad. Room temperature was kept 
relatively high and was stable during the experiments. Overall mean 
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room temperature was 23.0 ± 3.0°C. The dogs were connected to an 
anaesthetic machine with a circle system (Titus®, Dräger, Lübeck, 
Germany) and a sevoflurane out of circuit vaporiser (Vapor 19.3®, 
Dräger, Lübeck, Germany). The anaesthetic circuit was flushed with 
100 % oxygen for 5 minutes before the experiment. During the first 5 
minutes of anaesthesia, a fresh gas flow of 2 l/min O2 was used which 
was subsequently reduced to 1 l/min. During anaesthesia the 
percentage of sevoflurane was adjusted to obtain and maintain an 
anaesthetic depth suitable to perform surgical interventions much like 
it would have been done under clinical conditions. Such a level was 
thought to exist when the eye-lid reflex was absent and the eyeballs 
were ventrally rotated. Moreover a standardised pain stimulus was 
administered (see further). If a reaction (a movement, or an increase 
in HR of more than 15%) was observed, vaporizer settings were 
increased by 0.5% on the dial. If no reaction occurred, vaporizer 
settings were decreased in the same way. Depth of anaesthesia was 
also controlled by observation of eye-lid reflex and position of the 
eyeballs and if necessary adjusted. Anaesthesia was continued for 90 
minutes. No intravenous infusions were administered during the study.  
 
Measurements and Monitoring 
 A calibrated multigas analyser including a pulse oximetry 
unit (Quick Cal TM calibration gas® and Capnomac Ultima®, Datex 
Engstrom Instrumentation Corp., Helsinki, Finland) was used to 
monitor heart rate, respiratory rate, end tidal CO2%, inspiratory and 
end tidal sevoflurane concentrations and arterial oxygen haemoglobin 
saturation (SpO2%). Mean arterial blood pressure (MAP) was 
recorded using a blood pressure transducer (Vascumed N.V., Gent, 
Belgium) connected to a blood pressure measuring device (Hellige 
Servomed SMV 104, Germany) following standard calibration 
procedure. The rectal temperature was measured with a digital 
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thermometer with an accuracy of 0.1°C (C402®, Terumo Europe N.V., 
Leuven, Belgium). 
  
 Pain and sedation scores were only recorded in the pre- and 
post-anaesthetic period. Sedation and analgesia were always scored 
by the same observer. Scoring system and results are listed in Tables 
2 and 3. The degree of analgesia was evaluated using a standardised 
pain stimulus. This consisted in clamping the tail at a distance of 
approximately 3 cm from its top with a straight Rochester-Carmalt 
haemostatic forceps closed to the first ratchet lock for 5 seconds. Any 
reaction to this stimulus (movement, more than a 15% increase in HR) 
was considered as a pain response and scored according to the 
scoring system in Table 2. During anaesthesia the same pain stimulus 
was used to adjust depth of anaesthesia. 
  
 Table 2 : Sedation and pain scores in sufentanil long-acting and   
 sevoflurane anaesthetized dogs. 
Scores Sedation Pain 
0 no sedation no pain 
1 drowsiness minimal response # 
2 mild sedation * clear response ## 
3 deep sedation **   
 * responsive to environmental stimuli   
 ** unresponsive to environmental stimuli   
 # minimal aversive movements   
 ## strong aversive movements   
  
 Rectal temperature was measured immediately before IM 
sufentanil LA or the vehicle administration, immediately before 
inhalation anaesthesia (T0), each 10 minutes from T0 till T90 (except for 
the adverse effects), at T120, T240 and T1440. All dogs were observed for 
sedative and analgesic effects and the occurrence of adverse events 
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(lateral recumbency, ataxia, noise-sensitivity, vomiting, defaecation, 
salivation, nystagmus, excitation, …) immediately before 
administration of sufentanil/vehicle, immediately before initiation of 
inhalation anaesthesia (T0) and at T90, T120, T240 and T1440.  
  
 At the end of inhalation anaesthesia, oxygen was supplied 
until extubation was possible. The dogs were transferred to the 
recovery box. If the rectal temperature was lower than 36°C, an 
infrared heating source was installed in the recovery box.  
 
Statistical Analysis 
The dogs were sorted according to decreasing body weight and 
divided into 8 classes of 5 dogs each. In each class, the body weights 
were comparable. Within each class the 5 dogs were randomly 
allocated to the five different study groups and the 40 phases by a 
computer randomisation program. The statistical tests were two-sided 
and used a 0.05 type I error (a=5%). 
 
The StatXact software (StatXact 3 For Windows (1995), Users 
Manual, CYTEL Software, Cambridge, MA 02139 USA) was used for 
the Kruskal-Wallis one-way analysis of variance tests, for the 
Wilcoxon Mann-Whitney U tests and for the Fisher’s exact tests 
(Siegel, 1977). 
 
The treatment groups A (control suf) and B (control sevo) 
were control groups. No statistics were done for these groups, since 
the effects of sufentanil LA and sevoflurane were studied previously in 
dogs (Bernard et al., 1990; Engelen et al., 1996a; Engelen et al., 
1996b; Engelen et al., 1996c; Short, 1996; Short and Vlaminck, 1998; 
Verbeeck et al., 1998; Hoeben et al., 1999; Sterkens et al., 1999).  
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The body weights recorded seven days before the first study 
phase were compared by means of the Kruskal-Wallis one-way 
analysis of variance test to check the randomisation procedure. To 
evaluate the homogeneity of the several treatment groups, baseline 
comparisons (T0) were also performed on rectal temperature, sedation 
scores and analgesia scores of each treatment group by means of the 
Kruskal-Wallis one-way analysis of variance test. 
 
For each parameter (rectal temperature, overall analysis of 
critical events, adverse events) the following tests were performed: 
statistical comparisons on the mean over time (T0 to T90) was 
performed between the treatment groups C0, D15 and E30 by means of 
the Kruskal-Wallis one-way analysis of variance test followed by two-
by-two Wilcoxon Mann-Whitney U tests. Each of the treatment groups 
C0, D15 and E30 was compared with the control groups A and B by 
Wilcoxon Mann-Whitney U tests.   
 
The individual time points after inhalation anaesthesia (T120, 
T240 and T1140) were analysed in the same way as the variable mean 
over time. For sedation and analgesia scores statistics were 
performed on the individual values of each time point (T120,  T240 and 
T1140).  Statistical comparisons were performed between the treatment 
groups C0, D15 and E30 by means of the Kruskal-Wallis one-way 
analysis of variance test followed by two-by-two Wilcoxon Mann-
Whitney U tests.  Each of the treatment groups C0,  D15 and E30 were 
compared with the treatment groups A and B by Wilcoxon Mann-
Whitney U tests.   
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RESULTS 
  
Results for different measured variables are given in Table 3 
and 4. No significant differences in baseline values per study group 
and per parameter were observed. At T0 sedation scores were 
significantly higher in groups D15 and E30 (injected 15 and 30 minutes 
before T0 respectively) compared to groups A, B and C
0 (p<0.01 and 
p<0.001). In the post-anaesthetic period, compared to group B 
(control sevo) sedation scores in sufentanil treated inhalation groups 
were significantly higher at T120 in group E
30 (p<0.01), at T240 in group 
C0,  D15 and E30 (p<0.001)  and at T1440 in group E
30 (p<0.05). At T120 
sedation scores in group E30 were significantly higher compared to 
group A (control suf) (p<0.05).  
  
Antinociceptive effects of sufentanil LA were suggested by 
differences in pain scores in the pre- and post-anaesthetic period.  
Pain score at T0 was significantly lower in group E
30 compared to 
group B and C0 (p<0.05). Compared to group B (control sevo) pain 
scores in sufentanil treated inhalation groups were significantly lower 
at T120 in group C
0 and E30 (p<0.01 and p<0.05), at T240 in group C
0, 
D15 and E30 (p<0.01; p<0.05 and p<0.01)  and at T1440 in group C
0 and 
E30 (p<0.05). At T120 pain scores in group C
0 were significantly lower 
compared to group A (control suf) (p<0.05).  
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Table 3: Sedation and pain scores in sufentanil LA and sevoflurane 
anaesthetized dogs (n = 40). 
   Amount of dogs per study group 
Dog groups Sedation Score Tpresuf T0 T90 T120 T240 T1440 
Group A 0   8 0 1 0 5 
  1   0 2 5 6 3 
  2   0 6 2 2 0 
  3   0 0 0 0 0 
Group B 0   8 0 1 8 8 
  1   0 0 7 0 0 
  2   0 0 0 0 0 
  3   0 8 0 0 0 
Group C 0   8 0 0 0 4 
  1   0 0 5 6 4 
  2   0 0 1 2 0 
  3   0 8 2 0 0 
Group D 0 8 2 0 0 0 5 
  1 0 6 0 5 3 3 
  2 0 0 0 2 5 0 
  3 0 0 8 1 0 0 
Group E 0 8 0 0 0 0 3 
  1 0 7 0 2 3 5 
  2 0 1 0 3 5 0 
  3 0 0 8 3 0 0 
Dog groups Pain Score Tpresuf T0 T90 T120 T240 T1440 
Group A 0   1 4 3 5 4 
  1   2 2 3 1 0 
  2   5 2 2 2 4 
Group B 0   1 8 1 1 1 
  1   0 0 0 0 0 
  2   7 0 7 7 7 
Group C 0   0 8 8 8 7 
  1   2 0 0 0 0 
  2   6 0 0 0 1 
Group D 0 1 3 8 5 7 4 
  1 1 0 0 0 0 1 
  2 6 5 0 3 1 3 
Group E 0 1 5 8 7 7 6 
  1 1 1 0 0 1 0 
  2 6 2 0 1 0 2 
Sedation score: 0 = no sedation present; 1 = drowsiness; 2 = mild sedation; 3 = deep sedation
      Pain score: 0 = no evidence of pain; 1 = minimum response; 2 = clear response 
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The mean end-tidal sevoflurane concentration (Sevo ET%) in 
group B (control sevo) over the time T0 to T90 was 2.4 ± 0.2% and 
considered to be 100%. There was a significant reduction in Sevo 
ET% in all sufentanil treated groups (C0,  D15, E30) compared to group 
B (p<0.05; p<0.01 and p<0.001). Differences between these groups 
were not significant. Sevo ET% was reduced by 29.2%  in group D15 
(mean Sevo ET%: 1.7 ± 0.4%), by 19.8% in group C0 (mean Sevo 
ET%: 1.9 ± 0.5%) and by 16.2% in group E30 (mean Sevo ET%: 2.0 ± 
0.1%). The amount of thiopental administered in group B was 
considered to be 100% (mean: 15.9 mg/kg ± 2.7). The amount of 
thiopental needed for induction in sufentanil treated groups was 
significantly reduced. This reduction was 6.8% (mean: 14.8 ± 1.4 
mg/kg) in group C0 (non-significant), 30.2% (mean: 11.1 ± 1.6 mg/kg) 
in group D15 (p<0.01) and 29.4% (mean: 11.2 ± 2.5 mg/kg) in group 
E30 (p<0.01), all compared to group B. The reduction in administered 
thiopental was significantly lower in groups D15 and E30 compared to 
group C0 (p<0.01). 
 
Body temperature decreased in all groups during the 
anaesthesia period (T0 to T90). Body temperature in group D
15 and E30 
was significantly lower compared to group A and C0 (p<0.01 and 
p<0,05). There was no significant differences between group B 
(control sevo) and the sufentanil treated inhalation groups. In group A 
(control suf) the initial decrease in temperature was more gradually 
than in the inhalation groups. In the post-anaesthetic period body 
temperature returned quickly to baseline values in group B (control 
sevo). In the sufentanil treated groups C0, D15 and E30 body 
temperature remained low and compared to group B the difference 
was significant at every time point (T120,  T240 and T1440). In the post-
anaesthetic period body temperature remained rather constant in all 
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sufentanil groups and hypothermia was observed even after 24 hours. 
Body temperature was significantly lower in group E30 compared to C0 
at T120 and T240 (p<0.05). Body temperature was significantly lower 
compared to group A at T120 in groups D
15 and E30 (p<0.05 and 
p<0.01) and at T240 in group E
30 (p<0.05). Minimum body temperature 
observed were in group A 36.3°C (T240), in group B 36.7°C  (T80, T90), 
in group C0 35.9°C (T240), in group D
15 35.7°C (T90, T120) and in group 
E30 35.3°C (T70, T240). When body temperature in the post-anaesthetic 
period descended below 36.0°C an infrared heating source was 
installed at ± 70 cm above the dogs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the post-anaesthetic period  lateral recumbency was not 
observed in group B (control sevo). The incidence of lateral 
recumbency in group C0 decreased from 62.5% (T120) to 12.5% (T240) 
and 0% (T1440). In group D
15 incidence of lateral recumbency 
decreased from 25% (T120) to12.5% (T240) and 0% (T1440). In group E
30 
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this decrease was from 75% to 62.5% and 12.5% respectively. In 
group A (control suf) lateral recumbency was observed in maximally 
50% of the dogs (T90), this decreased to 12.5% (T120), 25.0% (T240) 
and 0% (T1440). 
 
At T0 12.5% of the dogs in group E
30 were ataxic and none in 
the other groups. In the control group B (control sevo) ataxia was only 
observed in 50% of the dogs at T120 . The incidence of ataxia in group 
C0 was 37.5% (T120), this increased to 87.5% (T240) and decreased to 
0% (T1440). In group D
15 ataxia  was 50% (T120), this decreased to 
37.5% (T240) and 12.5% (T1440). In group E
30 the  incidence of ataxia 
was 50% (T120), this decreased to 37.5% (T240 and T1440). In group A 
(control suf) ataxia was observed in 37.5% of the dogs (T90), this 
changed to 12.5% (T120), 75.0 % (T240) and 12.5% (T1440). 
  
Incidence of increased noise sensitivity at T120 was 25% 
(group B), 62.5% (group C0), 25% (group D15 and E30). At T240 the 
incidence was 25% (group B), 50% (group C0 and E30), 62.5% (group 
D15). Incidence of increased noise sensitivity was observed in group A 
in 87.5% (T120), 100% (T240) and 75.0% (T1440). 
 
In group B (control sevo) 12.5% of the dogs defaecated in the 
period T240-T1440. Defaecation was observed in group C
0 in the period 
T120- T240 (12.5%). Defaecation was seen in group D
15 in the period 
T90-T120 (62.5%) and T120-T240 (12.5%). Defaecation was seen in group 
E30 in the period T120-T240 (50.0%) and T240-T1440 (12.5%). In group A 
(control suf) 12,5% of the dogs defaecated  in de period T90- T120 and  
T120-T240. Vomiting nor the presence of nystagmus was observed in 
any dog at any time point. Salivation was seen in group A (control suf) 
in 25.0% and 12.5% of the dogs at T90 and at T120 respectively. 25.0% 
of the dogs in groups B, C0 and D15 showed excitation at T120. No 
other adverse events were observed at any time point.  
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 Table 4: The presence of adverse events (%) in sufentanil long-acting  
 and sevoflurane anaesthetized dogs (n= 40). 
Adverse Effects Dog groups T90 T120 T240 T1440 
Lateral recumbency A 50 12,5 25 0 
  B 100 0 0 0 
  C 100 62,5 12,5 0 
  D 100 25 12,5 0 
  E 100 75 62,5 12,5 
Ataxia A 37,5 12,5 75 12,5 
  B 0 50 0 0 
  C 0 37,5 87,5 0 
  D 0 50 37,5 12,5 
  E 0 50 37,5 37,5 
Noise-sensitivity A 100 87,5 100 75 
  B 0 25 25 25 
  C 0 62,5 50 25 
  D 0 25 62,5 0 
  E 0 25 50 12,5 
Defaecation A 25 12,5 12,5 0 
  B 0 0 0 12,5 
  C 0 0 12,5 0 
  D 12,5 62,5 12,5 0 
  E 0 0 50 12,5 
Salivation A 25,0 12,5 0 0 
  B 0 0 0 0 
  C 0 0 0 0 
  D 0 0 0 0 
  E 0 0 0 0 
Excitation A 0 0 0 0 
  B 0 25 0 0 
  C 0 25 0 0 
  D 0 25 0 0 
  E 0 0 0 0 
  Presence of adverse events is expressed as percentage per study group. 
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DISCUSSION 
 
Haemodynamic observations during this study were 
discussed in the first part (Chapter 7). Additional observations were 
the degree of sedation, antinociceptive and sevoflurane-sparing 
effects and the occurrence of side effects. 
 
Early signs of sedation and analgesia occurred 15 minutes 
after sufentanil LA administration and were long lasting (24 hours). 
The fast decrease in pain scores in groups D15 and E30 with 
respectively 3 and 5 dogs/8 with minimal pain scores at T0 indicated a 
rapid systemic resorption from the IM injection site. In previous studies 
sufentanil LA plasma levels very rapidly increased (0.55 ± 0.12 ng/ml 
and 0.59 ± 0.34 ng/ml (mean ± SD) 15 and 30 minutes after 
intramuscular administration respectively) and peak levels around 
1.53 ± 0.45 ng/ml were observed around 6 hours after IM injection. 
Sufentanil LA plasma levels of 0.85 ng/ml were necessary to provide 
good analgesia during major surgery (Short, 1996; Short and 
Vlaminck, 1998; Verbeeck et al., 1998; Hoeben et al., 1999; Sterkens 
et al., 1999). Only one dog showed mild sedation at T0. The analgesic 
effect was pronounced with 20/24 dogs at T120 and 22/24 dogs at T240 
with minimal pain scores.  
 
Analgesic effects and to a lesser extent, the sedative effects, 
were long lasting (24 hours). At T1440  still 17/24 dogs showed minimal 
pain scores compared to only one dog in group B (control sevo). In 
group B (control sevo) no recumbency was observed in the recovery 
period. In groups C0, D15 and E30 25% to 75% dogs were still 
recumbent at T120 and 12.5%- 62.5% at T240. This illustrates the strong 
sedative effects of sufentanil LA. A specific problem rose when the 
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presence of ataxia in the dogs had to be evaluated, because many 
dogs couldn’t walk, adequate scoring was not always possible. 
Probably the dogs were ataxic at those time points. Nevertheless, at 
T240 when no dogs were ataxic in group B ataxia was still observed in 
several dogs in all sufentanil groups at T240 (37.5%-87.5%)  and T1440 
(12.5%-37.5%). This was indicative for the long residual sedative 
effect of sufentanil LA in these dogs. Sedative effects at T1440 were 
limited to drowsiness in 12/24 dogs compared to none in group B 
(control sevo). The long lasting analgesic and sedative effects in all 
sufentanil groups could be related to a slow decrease in plasma 
sufentanil concentration. T1/2 of sufentanil was reported to be 15.8 ± 
5.1 hours (Verbeeck et al., 1998; Hoeben et al., 1999; Sterkens, 
1999). 
 
Significantly more sevoflurane (100%) had to be administered 
in group B (control sevo) compared to the sufentanil-sevoflurane 
groups. The sparing effect of sufentanil LA after IM administration on 
sevoflurane anaesthesia found (29.2%) was very similar as the 
sparing effect accompanying IV administration of fentanyl and 
sufentanil during enflurane and isoflurane anaesthesia in dogs (Hall et 
al., 1987a; Schwieger et al., 1991; Hellyer et al., 2001). To our 
knowledge sevoflurane sparing effects of opioids in dogs are not yet 
described. The anesthetic sparing effect is likely caused by a 
“reduction” of the MAC value of the inhalation anesthetic. The MAC-
value of potent volatile anaesthetics is reduced by increasing plasma 
concentrations of opioids (Valverde et al., 1989; Sebel et al., 1992; 
Brunner et al., 1994; Ilkiw et al., 1997). The degree by which MAC is 
reduced may be used as a measure of opioids potency (McEwan et 
al., 1993). Following intravenous application of opioids (alfentanil, 
butorphanol, fentanyl, morphine, nalbuphine, remifentanil, sufentanil) 
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during inhalation anaesthesia MAC reductions up to 73% have been 
reported (Murphy and Hug, 1982a; Murphy and Hug, 1982b; Hall et 
al., 1987a; Hall et al., 1987b; Schwieger et al., 1991; Michelsen et al., 
1996; Hellyer et al., 2001).  
 
The barbiturate-sparing effect was very similar in groups D15 
(30.2%) and E30 (29.4%), but, as expected, much less (6.8%) in group 
C0. The barbiturate induction dosage amount is markedly less reduced 
(10-20%) when tranquilizers are used as premedication. 
Premedication with midazolam and diazepam, two benzodiazepines, 
reduced the thiamylal (ultra-short acting barbiturate) dose required to 
accomplish endotracheal intubation in dogs (Muir et al., 1991; 
Tranquilli et al., 1991; Greene et al., 1993). The amount of thiopental 
required to produce loss of the eyelid reflex is reduced with the 
concomitant use of opiates and benzodiazepines (butorphanol and 
diazepam) for premedication in humans (Sklar et al., 1989). To our 
knowledge, barbiturate sparing effects of opioids were not reported in 
dogs. 
 
An important side effect was the development of hypothermia 
in all sufentanil treated groups that persisted for 24 hours even in the 
presence of an external heating source. Body temperature is 
controlled by a complex, highly integrated system that carefully 
balances heat production and heat loss. Heat is produced as a 
byproduct of metabolism, and as a result of muscular work, shivering, 
and chemical thermogenesis, whereas heat is lost from the body 
through the channels of heat exchange: radiation, conduction, 
convection and evaporation (Machon et al., 1999). In the present 
study the decreased body temperature during inhalation anaesthesia 
was expected since hypothermia is a common and potentially serious 
complication of general anaesthesia on one hand and opioid 
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administration on the other hand (Bissonnette, 1991). Opioids as 
alfentanil, pethidine, fentanyl and sufentanil impair thermoregulatory 
control by increasing the thresholds for sweating and decreasing the 
thresholds for vasoconstriction and shivering (Ikeda et al., 1997; 
Alfonsi, 1998). As expected, the body temperature of the dogs from 
group B (control sevo) returned very fast to base line values. 
Hypothermia was probably partially induced by stimulation of the 
serotonine receptors and by cessation of shivering in the dogs. 
Shivering is a source of metabolic heat production (Okada et al., 
1998). Body temperature deregulating effects by inhibition of shivering 
are also described in humans after parenteral administration of 
pethidine, sufentanil and alfentanil (Ikeda et al., 1997; Alfonsi et al., 
1998). 
 
Noise sensitivity was evaluated with hand clapping; a clear 
response of the dog was scored as present noise sensitivity. In the 
post-anaesthetic period the treated sufentanil dogs could be easily 
aroused from their sedation by auditory stimulation. Their reaction to 
hand clapping was exaggerated, but they were sedated again soon 
after cessation of hand clapping. This exaggerated response to loud 
noises is also seen after fentanyl administration (Thurmon et al., 1996; 
Lukasik, 1999). 
 
None of the dogs of any study group vomited over the entire 
study protocol. Initially, morphine induces vomiting by activating the 
chemoreceptor trigger zone, probably through a partial dopamine 
agonist effect, but appears to be the only opioid, which induces 
vomiting in dogs and cats (Kromer, 1988; Zuckerman and Ferrante, 
1998). Defaecation in sufentanil treated dogs tended to be more 
frequent than in the control group B with up to 60% at certain time 
points compared to 12%. Defaecation is also frequently seen after 
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fentanyl injection due to the occurring anal sphincter relaxation 
(Thurmon et al., 1996; Lukasik, 1999). In contrast, in human studies 
opioids are associated with a generalized depressant effect on 
gastrointestinal motility with reduced propulsive peristaltic activity 
during prolonged opioid administration (reflex inhibition) (Zuckerman 
and Ferrante, 1998). Salivation was noticed in group A at T90 and T120, 
but not in other groups. Salivation was also described after morphine 
administration in cats and after methadone administration in dogs 
(Burroughs, 1953; Davis and Donnely, 1968). 
 
Excitation was only seen at T120 in groups B, C
0 and D15 in two 
dogs per group. Morphine in clinical doses can induce excitement on 
rare occasions in dogs and cats (Lukasik, 1999; Nolan, 2000). 
Excitation after sufentanil administration is not mentioned in literature, 
probably because the registered short acting formulation of sufentanil 
is mostly used for intra-operative analgesia and not for postoperative 
pain relief.  
 
In conclusion, the present study showed that the combination 
of sufentanil LA and sevoflurane anaesthesia was associated with a 
significant reduction in end-tidal sevoflurane concentrations necessary 
to avoid reaction to a standardized pain stimulus. This effect was most 
pronounced when sufentanil LA was administered 15 minutes before 
induction of anaesthesia. In the post-anaesthetic period pain scores 
were lower and sedation scores higher in the sufentanil-treated 
groups. In many dogs diminished pain and elevated sedation scores 
persisted during 24 hours. Hypothermia was observed in all sufentanil 
groups and persisted during 24 hours in spite of external heating 
source. Other side effects such as lateral recumbency, ataxia, arousal 
on auditory stimulation, defaecation, salivation and excitation in some 
dogs were not clinically relevant.  
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Major progress in human and veterinary anaesthesia has been 
established the last few decades. Sevoflurane was introduced into the 
anaesthetic theatre in the early seventies (Wallin et al., 1975). 
Sevoflurane meets entirely the new trend in volatile anaesthetic drugs 
permitting more precise control of anaesthesia and perhaps most 
importantly, more rapid recovery from the effects of anaesthesia 
(Eger, 1994). Up to now, a lot of research has been done on 
sevoflurane anaesthesia in human medicine (Katoh and Ikeda, 1987; 
Lerman, 1993). However, research on sevoflurane in veterinary 
anaesthesia is rather limited. Especially its clinical use in dogs and the 
potential clinical applications of sevoflurane in small animal 
anaesthesia are not studied widely yet. A review on the physico-
chemical and anaesthetic properties of sevoflurane in human and 
small animal medicine was described in chapters 1 and 2. 
 
In chapter 3 the influences of sevoflurane on recovery times 
and haemodynamic parameters in dogs after 1 hour of anaesthesia 
were evaluated in a clinical study. The emphasis was put on the 
clinical aspect of the study. Was the low blood-gas solubility of 
sevoflurane also accompanied by rapid recoveries in premedicated 
dogs? Moreover, emergency times were compared with those after 
halothane and isoflurane anaesthesia at 2 anaesthetic concentrations 
(1.5 and 2 MAC). A neurolept-analgesic mixture, fentanyl and 
droperidol, was chosen as premedication to simulate clinical 
anaesthesia. Droperidol has a long duration of action and can 
influence the recovery profile (Thurmon et al., 1996; Bissonnette et al., 
1999). Anaesthesia was induced with propofol, a short acting 
induction agent, with rapid metabolisation (Shafer et al., 1988). Its low 
biological half life was probably minimally influencing recovery after 1 
hour of anaesthesia (Shafer, 1993; Smith et al., 1994). 
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However, anaesthetic recovery is influenced by many other 
factors. The most important factor is the blood/gas partition coefficient 
of the anaesthetic agent. A low blood/gas partition coefficient allows 
more rapid drug elimination and results in a shorter emergence time. 
The blood/gas solubilities of sevoflurane, isoflurane and halothane in 
man are respectively 0.68, 1.46 and 2.54 (Strum and Eger, 1987; 
Steffey, 1996). Of minor importance for anaesthetic recovery are the 
oil/gas partition coefficient, metabolisation percentage, alveolar 
ventilation, cardiac output, duration of anaesthesia, percutaneous 
losses, etc. (Stoelting and Eger, 1969; Carpenter et al., 1987; 
Lockhart et al., 1991; Steffey, 1996).  
 
In the present work no significant emergence times between 
the 3 anaesthetic agents occurred, although the emergence time was 
the longest for halothane at both anaesthetic concentrations. It could 
be concluded that it was more difficult to show the kinetic advantages 
of less soluble anaesthetics, as sevoflurane after short duration 
anaesthetic exposures of 1 hour (Eger and Johnson, 1987). In 
addition, residual effects of premedication in clinical anaesthesia 
exerted a depressant effect on cognitive function nullifying any kinetic 
advantage of sevoflurane over isoflurane and halothane. In 
conclusion, clinically there was little difference in emergence times 
between halothane, isoflurane, and sevoflurane in premedicated dogs 
after 1 hour of inhalation anaesthesia. 
 
The influence of ventilation mode on cardiopulmonary 
parameters in sevoflurane anaesthetized dogs was also evaluated 
during clinical anaesthesia (chapter 4). Three types of ventilation 
namely spontaneous ventilation, intermittent positive pressure 
ventilation and positive end expiratory pressure (5 cm H2O) were 
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compared at 2 anaesthetic concentrations (1.5 and 2 MAC) of 
sevoflurane in a clinical protocol including standard premedication and 
induction. This study shows that in anaesthetized spontaneously 
ventilating dogs increasing MAC values of sevoflurane from 1.5 to 2 
induced a pronounced cardiopulmonary depression together with a 
significant increase in HR. However, this increase was clinically not 
very relevant. The increased HR could be explained by the 
baroreceptor-reflex and/or by sympathetic stimulation. The 
cardiopulmonary depression was characterized by decreases in SI, 
CI, LVSWI and increases in PCWP and PAP. This cardiac depression 
was probably related to the presence of a decreased myocardial 
contractility caused by increasing the MAC value (Suga et al., 1985; 
Mutoh et al., 1997). A reduced myocardial contractility is often 
compensated by an increase in end diastolic pressure (Kittleson, 
1988). Hence, PCWP and PAP which are good reflections of the end 
diastolic pressure, increased in the present study (Brutsaert et al., 
1985). However, it should be underlined that it remains difficult to 
explain the pharmacologic effects in this setting because several 
drugs were used concomitantly. 
 
Changing from SpV to IPPV or PEEP using 1.5 MAC induced 
a small increase of arterial blood pressures, right cardiac pressures 
and HR. Little to no influences on other cardiac parameters were 
observed. On the other hand, the situation changed completely with 
increasing to 2 MAC. Artificial ventilation with 2 MAC sevoflurane 
induced a sever impact on the arterial pressures and cardiac related 
parameters. CO, CI, SV, SI, LVSWI and RVSWI decreased 
significantly. The impact was more pronounced with PEEP, but the 
difference between PEEP and IPPV was not significant. Right cardiac 
pressures increased, while arterial pressures decreased. The main 
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patho-physiologic mechanism for these cardiovascular side effects of 
PEEP was a decreased venous return due to the increased 
intrathoracic pressure and a decreased coronary blood flow inversely 
related with the PEEP level (Jacobs and Venus, 1983; Versprille, 
1990). 
 
In conclusion, sevoflurane anaesthesia at 1.5 MAC in 
premedicated healthy dogs induced a relatively moderate 
cardiopulmonary depression during spontaneous and controlled 
ventilation (IPPV and PEEP of 5 cm H²O) and could therefore be used 
safely for clinical anaesthesia. On the contrary, increasing the MAC 
from 1.5 to 2 caused a marked cardiopulmonary depression. 
Consequently, higher concentrations of sevoflurane must be avoided 
during all ventilation modes in dogs.  
 
The following chapters discussed some practical applications 
of sevoflurane in specific anaesthesia protocols (TLV with CO2-
insufflation, the use of pre-emptive analgesia: sevoflurane in 
combination with sufentanil LA). In chapter 5 the effects of 
intrathoracic pressure elevation during continuous two-lung ventilation 
for thoracoscopy on the cardio-respiratory parameters in sevoflurane 
anaesthetized dogs were studied. An anaesthesia protocol using 
standard endotracheal intubation was studied to evaluate its potential 
use in veterinary practice, since alternative techniques using OLV with 
bronchial blockers or double lumen tubes are technically difficult or 
expensive for veterinary practice. Moreover, these techniques require 
bronchoscopic confirmation of adequate tube placement (Smith et al., 
1986; Benumof, 1993). Therefore, TLV with active lung collapse was 
chosen in the protocol. This technique was accompanied by a severe 
hypoxemia induced by the collapse of one lung. Regions of atelectasis 
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were clearly observed during thoracoscopy confirming the occurrence 
of ventilation-perfusion mismatches due to intra-pulmonary shunting 
(Cohen et al., 1988). Nevertheless, active vasoconstrictive 
mechanisms in the non-ventilated lung might reduce the blood flow 
and minimize the shunt. This is known as the so-called hypoxic 
pulmonary vasoconstriction reflex. Recently it has been shown in dogs 
and piglets that sevoflurane (up to 2 MAC) had no significant effect on 
HPV (Domino et al., 1986; Okutomi and Ikeda, 1990; Lesitsky et al., 
1998; Kerbaul et al., 2000). 
 
Three different levels of intrathoracic pressure elevation in the 
left hemi-thorax (CO2-insufflation 3, 5 and 2 mm Hg) were evaluated 
during IPPV in the present study. All direct cardiac parameters  (blood 
pressures, CO, SV, SI, LVSWI) initially decreased significantly during 
ITP increase to 3, 5 and 2 mm Hg. Afterwards there was a gradual 
correction of these parameters probably induced by the occurring 
hypercapnia (Walley et al., 1990). Hypercapnia was observed during 
CO2-insufflation most likely because of the induced capnothorax 
(Peden and Prys-Roberts, 1993). The decrease in direct cardiac 
parameters was probably due to decreased venous return caused by 
ITP elevation and/or to a decreased myocardial contractility induced 
by sevoflurane (Mutoh et al., 1997; Brock et al., 2000; Polis et al., 
2001). On the other hand, right cardiac parameters (RAP, PAP, 
PCWP) increased significantly during ITP elevation at every level 
compared to values before CO2-insufflation. Possible explanations 
were the pulmonary tissue pressure rise and the potential hypoxic 
pulmonary vasoconstriction in the collapsed pulmonary parenchyma 
(Ohtsuka et al., 1999). ITP increase resulted in decreased venous 
return and increased pulmonary vascular pressure compromising SI 
and CO and resulting in hypotension and hypoperfusion (Lenaghan et 
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al., 1969; Connolly, 1993). As expected, SpO2 and PaO2 decreased 
significantly after CO2-insufflation, whereby the decrease was more 
rapid and pronounced after consecutive ITP elevations compared to 
the first pressure rise. In contrast with SpO2, PaO2 remained low at the 
end of anaesthesia probably by an increased amount of blood flow in 
the underlying lung, while its lung volume was compressed by the 
mediastinal weight. This resulted in hypoxemia caused by existing 
ventilation/perfusion mismatch and blood shunting.  
 
In conclusion, thoracoscopic procedures in sevoflurane (1.5 
MAC) anaesthetized dogs at low pressure (2 mm Hg CO2-insufflation) 
into one hemithorax allowed an optimal visualisation of the 
intrathoracic structures for short periods. The TLV technique with 
standard intubation and CO2-insufflation using sevoflurane can be 
applied in veterinary practice, although the thoracoscopy should be 
accomplished in one short period of CO2-insufflation since additional 
insufflation periods could lead to more rapidly occurring and more 
pronounced cardiopulmonary depression. Therefore, it might be 
interesting to compare this technique with OLV using bronchial 
blockers in a following study, however OLV is technically more difficult 
to perform and requires more equipment (bronchial blockers, double 
lumen tubes, bronchoscope). 
 
In the following chapters the combination of sufentanil LA with 
sevoflurane was studied. Repetitive blood sampling and blood 
pressure monitoring in unrestrained animals over a relatively long 
period of time were required. The repetitive puncture of arteries and 
veins or multiple consecutive peripheral catheter placement is 
certainly accompanied by technical problems and stress responses, 
but also by iatrogenically induced damage of the blood vessels 
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including thrombosis and sclerosis (Mesfin et al., 1988; Bagley and 
Flanders, 1990; Endres et al., 1990; Grosse-Siestrup and Lajous-
Petter, 1990). Hence, a totally implantable catheter technique with 
titanium vascular access port was used in the haemodynamic study 
on sufentanil LA and sevoflurane combination (Chapter 6). The 
catheters were implanted in the femoral artery of the dogs, while the 
vascular access ports were secured on the lumbar region. This 
location was chosen to facilitate repeated port punctures. All catheters 
remained patent during the study. No problems concerning wound 
healing occurred. Blood sampling and blood pressure measurement 
were easy to perform requiring only minimal animal restraint. Four 
dogs showed an increased body temperature without signs of 
lameness or local infection at the incision sites. A contamination of the 
flush solution with Pseudomonas aeruginosa was the aetiology of this 
finding. The problem was solved after a few days of antibiotic 
treatment. Nevertheless, this problem showed the importance of 
aseptic preparation and storage of the flush solution. Furthermore, 
only some minor problems of little clinical importance occurred. In 
conclusion the described arterial catheterisation technique with 
vascular access ports was suitable and technically feasible for 
experimental haemodynamic protocols. 
 
The cardiopulmonary effects during and following clinically 
conducted sevoflurane anaesthesia in sufentanil LA premedicated 
dogs were evaluated (Chapter 7). Opioids are often included into the 
premedication protocol because of their analgesic properties. In order 
to overcome the problems associated with intermittent administration 
of short acting opioids, it was postulated that a single intramuscular 
administration of a potent opioid (sufentanil) in a long acting 
formulation could be used as premedication, providing effective pre-
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emptive analgesia over an extended period of time. The goal of this 
study was to evaluate potential deterioration of cardiopulmonary 
influences of sufentanil LA administered at different time points in 
combination with sevoflurane anaesthesia in dogs. During 
anaesthesia the expected bradycardia was masked by thiopental and 
sevoflurane (sympathetic and baroreceptor-reflex stimulation), while a 
long lasting, but clinically not relevant bradycardia persisted for 24 
hours after anaesthesia (Mutoh et al., 1997; Polis et al., 2001). In all 
anaesthesia groups MAP showed a similar pattern while MAP values 
were lower compared to the sufentanil group. An initial transient 
period of panting occurred after sufentanil LA administration. This 
panting was probably related to alterations in the thermoregulatory 
centre induced by the opioid (Lukasik, 1999; Lascelles, 2000; Nolan, 
2000). Respiratory depression was observed in the sufentanil-
sevoflurane groups during anaesthesia. This was probably clinically 
irrelevant since high PaO2 and SaO2 values occurred during 
anaesthesia. However, temporary support of ventilation with IPPV 
however might be occasionally indicated. Therefore, clinical 
observation and/or respiratory function monitoring with spirometry or 
capnography would be helpful. Thirty minutes between sufentanil LA 
premedication and induction of anaesthesia might be preferable, since 
less respiratory depression occurred in this group. Obviously, in 
clinically adjusted sevoflurane anaesthesia the addition of sufentanil 
LA as premedication moderately enhanced the occurring 
cardiopulmonary side effects during anaesthesia. No marked 
differences were observed between the different sufentanil LA-
sevoflurane groups. 
  
In the second part of this study, the antinociceptive and 
sedative effects of sufentanil LA were emphasised together with other 
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potential side effects (hypothermia, lateral recumbency, ataxia, noise-
sensitivity, defaecation, salivation, excitation,…) (Chapter 8). In 
addition, the potential dosage reducing effect of sufentanil LA on 
thiopental induction dosage and sevoflurane end-tidal concentration 
were evaluated and an optimal time interval between the IM 
administration of sufentanil LA and the beginning of sevoflurane 
anaesthesia induced by thiopental was determined.  
A similar sedation and analgesia pattern was observed in all 
sufentanil groups. Signs of sedation and analgesia occurred 15 
minutes after sufentanil LA administration and were long lasting. This 
was indicative for a fast systemic resorption from sufentanil LA and a 
slow decrease in plasma concentration afterwards (Verbeeck et al., 
1998; Hoeben et al., 1999). In the postanaesthetic period pain scores 
were lower and sedation scores higher in the sufentanil-treated 
groups. In many dogs diminished pain and elevated sedation scores 
persisted during 24 hours. The present study showed that the 
combination of sufentanil LA and clinically directed sevoflurane 
anaesthesia was associated with a significant reduction in end-tidal 
sevoflurane concentrations necessary to avoid reaction to a 
standardized pain stimulus. This effect was most pronounced when 
sufentanil LA was administered 15 minutes before induction of 
anaesthesia. This dose dependent MAC reducing effect was 
previously reported for other opioids (Valverde et al., 1989; Sebel et 
al., 1992; McEwan et al., 1993; Brunner et al., 1994; Michelsen et al., 
1996; Ilkiw et al., 1997). Severe hypothermia was observed in all 
sufentanil groups even after 24 hours. Hypothermia could be expected 
because it is a common and potentially serious complication of 
general anaesthesia and opioid administration in particular 
(Bissonnette, 1991). The persistence of hypothermia was probably 
due to the long acting effect of sufentanil LA causing cessation of 
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shivering and of metabolic heat production (Okada et al., 1998). 
Furthermore, some minor side effects as lateral recumbency and 
ataxia were observed illustrating the sedative effects of sufentanil LA. 
The presence of defaecation, excitation, salivation, and arousal on 
auditory stimulation in some dogs was of little clinical importance. It 
could be concluded that sufentanil LA in addition to sevoflurane 
anaesthesia offered beneficial dosage reducing analgesic effects. 
Because cardiopulmonary depression induced by sevoflurane was 
marked at higher concentrations, its combination with an opioid is 
advisable to lower anaesthetic concentration needed for surgical 
interventions. 
 
  
CONCLUSIONS 
 
1/ Little difference in emergence times between halothane, isoflurane 
and sevoflurane in premedicated dogs after 1 hour of inhalation 
anaesthesia occurred (chapter 3). 
 
2/ Sevoflurane anaesthesia at 1.5 MAC in premedicated healthy dogs 
induced a relatively moderate cardiopulmonary depression during 
spontaneous and controlled ventilation and can be used safely. 
Increasing the anaesthetic concentration from 1.5 to 2 MAC caused a 
marked cardiopulmonary depression. Higher concentrations of 
sevoflurane are better avoided during all ventilation modes in dogs. 
 
3/ Thoracoscopic procedures in sevoflurane (1.5 MAC) anaesthetized 
dogs with low pressure (2 mm Hg) CO2-insufflation into one 
hemithorax allowed an optimal visualization of the intrathoracic 
structures for short periods. However, the thoracoscopic procedure 
should be accomplished in one short episode since additional 
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insufflation periods could lead to more rapidly occurring and more 
pronounced cardiopulmonary depression. 
 
4/ Femoral artery catheterisation with vascular access ports was 
considered  suitable and technically feasible for experimental 
haemodynamic protocols in dogs. 
 
5/ The addition of sufentanil LA as premedication before clinically 
adjusted sevoflurane anaesthesia moderately enhanced the occurring 
cardiopulmonary depression. 
 
6/ Sufentanil LA in addition to sevoflurane anaesthesia offered 
beneficial dosage reducing effects. Long lasting hypothermia was a 
major side effect. An optimal time period of 15 minutes should be 
respected between sufentanil LA administration and induction of 
sevoflurane anaesthesia to benefit from the reduction in sevoflurane. 
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The use of inhalation anaesthesia in veterinary small animal 
practice is quickly gaining ground under the impulse of recent 
developments in human anaesthesia. Until now, halothane and to a 
lesser extent isoflurane are commonly used as inhalant anaesthetic 
agents for veterinary anaesthesia. Recently, sevoflurane has been 
developed and is nowadays routinely used in human anaesthesia. 
Physico-chemical characteristics of sevoflurane, its influences on 
body systems and economic considerations of sevoflurane in clinical 
anaesthesia practice are described and summarised in chapters 1 and 
2 of this work. The major objectives of this thesis were to examine the 
clinical use of sevoflurane in veterinary anaesthesia and the potential 
application of sevoflurane in some specific anaesthesia protocols. 
 
In the first part of this work the influences of sevoflurane on 
recovery times and on cardiopulmonary parameters with different 
ventilation patterns and at 2 MAC multiples (1.5 and 2 MAC) were 
determined (chapter 3 and 4). The influence of 3 volatile agents (Halo, 
Iso and Sevo) at 2 concentrations (1.5 and 2 MAC) on non-invasive 
cardio-respiratory parameters and recovery times (first eyelid reflex, 
emergence time) following clinical anaesthesia was studied. After 
premedication with fentanyl-droperidol (5 mg/kg and 0.25 mg/kg IM) 
and induction with propofol (5 mg/kg IV) six dogs were randomly 
anaesthetised for one hour for a standard neurologic stimulation test. 
A wide individual variation in respiration rate (induced by an initial 
hyperpnea) was observed in the 1.5 MAC protocols. Heart rate was 
significantly lower during 1.5 and 2 MAC halothane when compared to 
isoflurane and sevoflurane. An increase from 1.5 to 2 MAC induced 
significant decreases in diastolic and mean arterial blood pressure in 
all groups without significant changes in the systolic arterial pressures. 
Time for a first eyelid reflex was significantly longer after 2 MAC 
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compared to the 1.5 MAC protocol. There was no significant 
difference between the 3 anaesthetic agents. Although emergence 
time was longest for halothane at both anaesthetic concentrations, no 
significant difference in emergence time was observed for the 3 
volatile agents. Clinically there was little difference in emergence 
times between halothane, isoflurane, and sevoflurane in premedicated 
dogs after 1 hour of inhalation anaesthesia. 
 
Furthermore, the effects of sevoflurane on cardiopulmonary 
parameters were emphasized. Three types of ventilation (SpV, IPPV 
and PEEP) were compared at 2 anaesthetic concentrations (1.5 and 2 
MAC). Increasing the MAC value during sevoflurane anaesthesia with 
spontaneous ventilation induced a marked cardiopulmonary 
depression; on the other hand, HR increased significantly, but this 
was clinically not relevant. The influences of artificial respiration on 
cardiopulmonary parameters during 1.5 MAC sevoflurane anaesthesia 
were moderate and clinically acceptable. In contrast, PEEP ventilation 
during 2 MAC concentration had very pronounced depressant 
influences, especially on right cardiac parameters. In conclusion, at 
1.5 MAC, a surgical anaesthesia level, sevoflurane could be used 
safely in healthy dogs during spontaneous and controlled ventilation 
(IPPV and PEEP of 5 cm H²O). Higher concentrations of sevoflurane 
should better be avoided during all ventilation modes in dogs, 
because of marked cardiopulmonary depression. 
 
In the second part of the thesis, the application of sevoflurane 
in different anaesthesia protocols was studied. First, the 
cardiopulmonary influences of different levels of carbon dioxide 
insufflation (3, 5 and 2 mm Hg) during two-lung ventilation were 
studied in 6 sevoflurane (1.5 MAC) anaesthetized dogs for left sided 
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thoracoscopy (chapter 5). Although carbon dioxide insufflation into the 
left hemithorax with an intrapleural pressure of 2 to 5 mm Hg 
compromised cardiac functioning in 1.5 MAC sevoflurane 
anaesthetized dogs, it could be an efficacious adjunct for 
thoracoscopic procedures. Intrathoracic view was satisfactory with an 
intrapleural pressure of 2 mm Hg. Therefore, the intrathoracic 
pressure rise during thoracoscopy with two-lung ventilation should be 
kept as low as possible. Additional insufflation periods should be 
avoided, since a more rapid and more severe cardiopulmonary 
depression would occur. 
 
Secondly, the cardiopulmonary effects of sufentanil LA in 
sevoflurane anaesthetized dogs was evaluated together with the 
occurrence of antinociceptive and sedative effects and other opioid 
side effects. An optimal time interval between the administration of 
sufentanil LA and the induction of sevoflurane anaesthesia was 
examined in addition to the possible dosage reducing effects of 
sufentanil LA on thiopental and sevoflurane (chapter 7 and 8). The 
combination of sufentanil LA followed by clinically adjusted 
sevoflurane anaesthesia induced a moderate cardiopulmonary 
depression. The combination of sufentanil LA and clinically directed 
sevoflurane anaesthesia was associated with a significant reduction in 
the sevoflurane end-tidal concentration necessary to avoid reaction to 
a standardized pain stimulus. This effect was most pronounced when 
sufentanil LA was administered 15 minutes before induction of 
anaesthesia. In the post-anaesthetic period pain scores were lower 
and sedation scores higher in the sufentanil-treated groups. In many 
dogs diminished pain and elevated sedation scores persisted during 
24 hours. In conclusion, sufentanil LA in addition to sevoflurane 
anaesthesia offered beneficial dosage reducing analgesic effects; 
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although some minor side effects (hypothermia, lateral recumbency, 
ataxia, arousal on auditory stimulation, defaecation, salivation and 
excitation occurred. To achieve this advantageous dosage reducing 
effect 15 minutes should be respected between sufentanil LA 
administration and induction of sevoflurane anaesthesia. 
 
For this hemodynamic study repetitive arterial blood samples 
and blood pressure measurement were required. Therefore, a method 
using coated polyurethane catheters and titanium vascular access 
ports (VAP) with a silicone membrane providing arterial access for a 
longer period was described in forty dogs (chapter 6). This technique 
allowed repeated arterial blood pressure measurement and blood 
sampling in unrestrained conscious and anaesthetised dogs. Catheter 
extraction caused by the dogs did not occur. On the other hand, 
infection with Pseudomonas aeruginosa due to a contaminated 
heparinised flush solution was diagnosed in 4 dogs. The dogs healed 
rapidly after an appropriate antibiotic therapy. It could be concluded 
that the described arterial catheterisation technique with vascular 
access port over a two weeks period was suitable and technically 
feasible for experimental protocols in dogs.
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Onder invloed van recente ontwikkelingen in de humane 
anesthesie neemt het gebruik van inhalatie anesthesie in de kleine 
huisdierenpraktijk snel toe. Tot op heden werd als inhalatie 
anestheticum meestal gebruik gemaakt van halothaan of in iets 
mindere mate van isofluraan. Sevofluraan dat recent op de markt 
kwam, wordt tegenwoordig al veel aangewend in de humane 
anesthesie. In hoofdstuk 1 en 2 van dit proefschrift wordt als inleiding 
eerst ingegaan op de fysisch-chemische eigenschappen, de invloed 
op de verschillende orgaansystemen en enkele economische 
aspecten van sevofluraan gebruik tijdens de klinische anesthesie 
voornamelijk bij de mens. Hoofdstukken 3 - 5 en 7 – 8 zijn gewijd aan 
onderzoek over het gebruik van sevofluraan bij de hond. Evaluatie 
van de klinische aanwending van sevofluraan in de kleine 
huisdierenpraktijk enerzijds en evaluatie van enkele mogelijke 
toepassingen in specifieke anesthesie protocols vormden de 
belangrijkste doelstellingen van dit proefschrift. 
 
 In het eerste deel van het proefschrift werd de invloed van een 
eind-expiratorische concentratie van 1.5 en 2 MAC sevofluraan, 
isofluraan en halothaan op de ontwaaktijd (ooglid reflex en 
extubatietijd) en op enkele hemodynamische parameters tijdens een 
klinische anesthesie bij de hond onderzocht (hoofdstuk 3). De honden 
werden gepremediceerd met fentanyl-droperidol (5 µg/kg en 0.25 
mg/kg IM) en vervolgens werd de anesthesie geïnduceerd met 
propofol (5 mg/kg IV). Tijdens de één uur durende anesthesie werd 
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een standaard neurologische stimulatietest uitgevoerd. De 
hartfrequentie was significant lager gedurende halothaan anesthesie 
dan tijdens isofluraan en sevofluraan anesthesie en dit bij beide MAC 
waarden. Bij concentratie toename van 1.5 naar 2 MAC ontstond een 
significante daling van de diastolische en gemiddelde arteriële 
bloeddruk in alle anesthesiegroepen. Dit ging echter niet gepaard met 
significante veranderingen in de systolische arteriële bloeddruk. Een 
positieve ooglid reflex was significant vlugger aanwezig na toepassen 
van het 1.5 MAC protocol in vergelijking met het 2 MAC protocol. Er 
was echter geen significant verschil in terugkeren van de ooglidreflex 
tussen de 3 inhalatie anesthetica onderling. De extubatietijd was het 
langst na halothaan anesthesie voor beide anesthesie concentraties, 
maar toch waren er geen significante verschillen merkbaar tussen de 
3 anesthetica. Er werd besloten dat er na een klinische anesthesie 
van 1 uur bij gepremediceerde honden geen verschil was in ontwaak 
tijden tussen halothaan, isofluraan en sevofluraan. 
 
 Vervolgens werd de mogelijke invloed van sevofluraan op 
verschillende cardiopulmonaire parameters bij de hond onderzocht. 
Drie ventilatie technieken (spontane ventilatie, intermittent positive 
pressure ventilation (IPPV) en positive end expiratory pressure 
ventilation (PEEP)) werden vergeleken bij gebruik van 2 
anesthetische concentraties (1.5 en 2 MAC). Verhogen van de eind 
expiratorische concentratie tot 2 MAC tijdens spontane ventilatie 
veroorzaakte een duidelijke cardiopulmonaire depressie, en 
anderzijds een significante, maar klinisch irrelevante stijging van de  
hartfrequentie. Tijdens IPPV waren de cardiorespiratoire invloeden 
met gebruik van 1.5 MAC eerder gematigd en zeker klinisch 
aanvaardbaar. Bij 2 MAC daarentegen waren de cardiopulmonaire 
invloeden van PEEP uitgesproken nefast voornamelijk op rechter hart 
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parameters. Er werd besloten dat een concentratie van 1.5 MAC 
sevofluraan (meestal gepaard gaande met een chirurgisch anesthesie 
niveau), veilig kon gebruikt worden bij de gezonde hond en dit zowel 
bij spontane als artificiële respiratie (IPPV en PEEP van 5 cm H2O). 
Hogere sevofluraan concentraties daarentegen zouden beter 
vermeden worden voor anesthesie van de hond ongeacht de ventilatie 
methode. 
 
 In het tweede deel van het proefschrift werd de mogelijke 
toepassing van sevofluraan bij verschillende anesthesie protocols bij 
de hond onderzocht. Een eerste toepassing was de anesthesie voor 
thoracoscopie waar Two Lung Ventilation, TLV, met CO2-insufflatie 
gebruikt wordt. Een tweede toepassing was de combinatie van een 
sevofluraan anesthesie met een premedicatie met een langwerkend 
opiaat, sufentanil LA.  
 
Bij de thoracoscopie werden in eerste instantie 
cardiopulmonaire invloeden van CO2-insufflatie (3, 5 en 2 mm Hg) 
gedurende TLV tijdens sevofluraan anesthesie bestudeerd (hoofdstuk 
5). CO2-insufflatie in de linker thorax helft met een intrapleurale druk 
van 2 tot 5 mm Hg onderdrukte de hartwerking tijdens 1.5 MAC 
sevofluraan anesthesie. Desondanks werd deze techniek als een 
efficiënte hulpmiddel beschouwd voor thoracoscopische ingrepen. 
Gezien de cardiopulmonaire onderdrukking wordt de intrathoracale 
druktoename tijdens thoracoscopie met TLV best zo laag mogelijk 
gehouden. Een intrapleurale druk van slechts 2 mm Hg gaf reeds een 
goede zichtbaarheid in de thorax. Hierbij is het wel aan te bevelen dat 
het thoracoscopisch onderzoek tijdens één enkele insufflatieperiode 
kan uitgevoerd worden, daar een sneller optredende en meer 
uitgesproken cardiopulmonaire depressie optreedt bij herinsufflatie. 
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 Om de kombinatie van een sevofluraan anesthesie met 
sufentanil LA te evalueren werden de hemodynamische invloeden van 
een premedicatie met sufentanil LA tijdens en na sevofluraan 
anesthesie bij de hond onderzocht. Daarnaast werden eveneens de 
sedatieve, antinociceptieve en eventuele andere opiaat effecten onder 
de loep genomen. Het dosis reducerend effect van sufentanil LA op 
thiopental inductie en sevofluraan anesthesie werd bestudeerd. Er 
werd een optimaal tijdsinterval tussen de toediening van sufentanil LA 
en de inductie van sevofluraan anesthesie bepaald (hoofdstuk 7 en 8). 
De combinatie van sufentanil LA premedicatie en sevofluraan 
anesthesie induceerde een matige cardiopulmonaire onderdrukking. 
Door sufentanil LA premedicatie was er een lagere eind expiratoire 
concentratie van sevofluraan nodig om een vergelijkbare analgesie/ 
anesthesie te bekomen. Dit effect was meest uitgesproken wanneer 
sufentanil LA 15 minuten voor de inductie werd toegediend. Na de 
anesthesie bleven de pijnscores lager en de sedatiescores hoger in 
de sufentanil LA groepen. Dit analgetisch en sedatief effect van 
sufentanil LA bleef bij vele honden aanwezig gedurende 24 uur. Een 
gedurende 24 uur persisterende hypothermie was een klinisch 
belangrijke nevenwerking opgemerkt na sufentanil LA premedicatie.  
 
 Voor de beoordeling van de gasuitwisseling en het meten van 
de bloeddruk tijdens en na de sufentanil LA/ sevofluraan anesthesie 
was herhaalde arteriële bloedmonstername voor bloed-gas analyse 
en een arteriële toegang voor bloeddrukmeting noodzakelijk. De 
arteriële katheterisatie techniek die bij deze honden (n=40) gebruikt 
werd wordt beschreven (hoofdstuk 6).  Deze techniek maakt gebruik 
van polyurethaan katheders en een titanium “vascular access port”. 
Herhaalde arteriële bloeddrukmetingen en bloedafnames waren 
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hierdoor mogelijk bij geänesthesieerde en niet geänesthesieerde 
honden. De honden ondervonden weinig hinder van deze techniek en 
deden geen pogingen om de katheter te verwijderen. Bij 4 honden 
werd er wel een infectie (koorts en arthritis) vastgesteld. Dit bleek te 
wijten aan het gebruik van gecontamineerde heparine spoelvloeistof 
(Pseudomonas aeruginosa). Verwijderen van het implantatiemateriaal 
en een aangepaste antibioticatherapie brachten volledige en snelle 
genezing.
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